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Classic murine models of experimental asthma based on intraperitoneal sensitization followed 
by airway challenge do not reflect the way in which humans acquire allergic disease to airborne 
allergens. The interaction of the airway mucosa with the allergens may be essential for the 
triggering of the subsequent immune response. In the present work, we developed a murine model 
of allergic disease based on primary airway exposure to antigen followed by continuous airway 
challenge. Following sensitization and after only three intranasal challenges, a classical 
intraperitoneal model developed airway hyperresponsiveness to MCh, increased airway contractile 
tissue mass, eosinophilic inflammation and mucous hypersecretion in the upper and lower airways. 
We detected in this model a high number of Foxp3 mRNA+ cells in the lung inflammatory 
infiltrates. Conversely, murine models based on primary airway allergen exposure and continuing 
challenge showed attenuated asthma features, including borderline airway hyperresponsiveness, a 
modest increase in airway contractile tissue mass and mucous production, and an attenuation of the 
eosinophilic inflammatory infiltrates with a drift towards a lymphocytic profile. In such models 
based on primary airway exposure, mucous overproduction was found as an early response prior to 
the development of any adaptive immune response, which suggests the participation of and innate 
immune response prior to the onset of chronic airway inflammation. Subepithelial collagen 
deposition behaved differently from the airway contractile tissue mass, and increased progressively 
over time. Contrary to the intraperitoneal model, moderate numbers of Foxp3 mRNA-expressing 
cells were found in the pulmonary inflammatory infiltrates upon primary airway antigen exposure. 
However, such Foxp3 mRNA+ cells increased over time proportionally to the duration of the 
allergen instillations, and their numbers were proportionally balanced with Il10 and Tgfb mRNA 
expression. These findings suggest a role of Tregs in the attenuation of the asthma features in the 
primary airway exposure models, whereas most Foxp3+ cells in the intraperitoneal sensitization 
model may have been non-functional. In all, these results suggest that classic animal models of 
experimental asthma based on intraperitoneal sensitization represent the effector arm of the adaptive 
immune response, but fail to reflect the regulatory arm, which is likely operated by Treg 
subpopulations. The data are also consistent with the hypothesis that primary contact of the antigen 
with the respiratory mucosa is crucial to determine the profile of the subsequent immune response in 
terms of attack versus tolerance, and that the innate immune system plays a central role in such 
decisions.  
To demonstrate that FOXP3-expressing T cells may drive immune regulation in an 
experimental asthma setting, versus the induction of asthma features by effector CD4+ T cells, we 
performed two series of adoptive transfer experiments employing genetically modified T cells, by 
Role of the effector and regulatory arms of the adaptive immune reseponse in the pathophysiology of experimental asthma 
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means of retroviral gene transduction. Adoptive transfer of 100,000 antigen-specific, effector, GFP-
expressing, CD4+ T cells was sufficient, upon antigen airway exposure, to elicit migration of GFP+ 
cells to the airways and induce airway hyperresponsiveness and inflammation. On the contrary, 
antigen-specific Treg cells generated by forced FOXP3 expression, of which 75,000 were 
adoptively transferred to recipients with established experimental asthma, led to an attenuation of 
asthma features.  
Finally, to find translational evidence on a role of Treg cells in human asthma, we studied the 
presence of FOXP3+ cells in bronchial biopsies from severe asthmatics versus control subjects. 
FOXP3+ cells were virtually absent in the control subjects, whereas the specimens from asthmatics 
revealed a significant influx of FOXP3+ lymphocytic cells in subepithelial location. Further work is 
warranted to better define the phenotype and Treg function of such FOXP3+ cells. 
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AD: anno domini (in the year of our Lord) 
ADAM: A disintegrin and metalloproteinase domain 
ANOVA: analysis of variance 
aTreg: adaptive T regulatory cell 
BAL: bronchoalveolar lavage 
BALT: bronchial associated lymphoid tissue 
BDP: beclomethasone dipropionate 
BC: before Christ 
BCR: B cell receptor 
bFGF: basic fibroblast growth factor 
Breg: B regulatory lymphocyte 
cDNA: complementary deoxyribonucleic acid to mRNA 
CS: calf serum 
CT: cytotoxic 
CTLA-4: cytotoxic T-lymphocyte antigen 4 
DAPI: 4',6-diamidino-2-phenylindole (fluorescent stain) 
DN: double negative 
DNA: deoxyribonucleic acid 
DP: double positive 
EMTU: epithelial-mesenchymal thropic unit 
FBS: foetal bovine serum 
FC: flow cytometry 
FEV1: forced expiratory volume in the first second of forced expiration 
FISH: fluorescent in situ hybridization 
FOT: forced oscillation technique 
FOXP3/Foxp3: forkhead box P3 protein / gene 
FRC: functional residual capacity 
GALT: gut associated lymphoid tissue 
G-CSF: granulocyte-colony stimulating factor 
GFP: green fluorescent protein 
GINA: Global Initiative for Asthma 
GITR: glucocorticoid-induced TNFR-related protein 
H-E: haematoxylin eosin 
HDM: house dust mite 
HGF: hepatocyte growth factor 
HRP: horseradish peroxidase 
IFNG: interferon gamma 
i.e.: id est 
Ig: immunoglobulin 
IL: interleukin 
IL7R: interleukin 7 receptor 
i.n.: intranasal 
i.p.: intraperitoneal/intraperitoneally 
IRES: internal ribosome entry site 
IRF4: interferon regulatory factor 4 
iTreg: induced T regulatory cell 
i.v.: intravenous/intravenously 
LABA: long-acting beta-agonist 
LB: Luria Bertani (culture medium for prokaryotes) 
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LBA: Luria Bertani medium with ampiciclin 
MCh: Acetyl-β-methylcholine chloride 
MCS: multicloning site 
MHC: major hystocompatibility complex 
MLCK: myosin light chain kinase 
MLI: mean linear intercept 
MOI: multiplicity of infection 
mRNA: messenger ribonucleic acid 
NFKB: nuclear factor kappa-light-chain-enhancer of activated B cells 
NK: natural killer 
NKT: natural killer T cell 
NMWL: nominal molecular weight limit 
nTreg: natural T regulatory cell 
OVA: ovalbumin 
PAMP: pathogen-associated molecular patterns 
PAS: periodic acid Schiff 
PBM: perimeter of the basal membrane 
PBS: phosphate buffer saline 
PCR: polymerase chain reaction 
PE: phycoerythrin 
PEEP: positive end expiratory pressure 
PBS: phosphate buffer saline 
PCR: polymerase chain reaction 
PDGF: platelet-derived endothelial growth factor 
pMDI: pressurized metered-dose inhaler 
PSG: Penicillin-Streptomycin-Glutamine 
RAG: recombination activating gene 
RNA: ribonucleic acid 
Raw: airway resistance 
RL: lung resistance 
Rti: tissue resistance 
RT: room temperature 
SABA: short-acting beta-agonist 
SCG: sodium cromoglycate 
SEM: standard error of the mean 
SMA: smooth muscle actin 
STAT: signal transducer and activator of transcription 
TCR: T cell receptor 
TGFB: transforming growth factor beta 
Th1/2/3: type 1/2/3 helper T lymphocyte 
Tm: melting temperature 
TLC: total lung capacity 
TLR: Toll-like receptor 
TNFA: tumor necrosis factor alpha 
TNFR: tumor necrosis factor receptor 
TSDR: T regulatory specific demethylated region 
Tr1: type 1 regulatory T cells 
VEGF: vascular endothelial growth factor 
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Note about gene/protein nomenclature following consensus guidelines1 
 
Guidelines for the human species 
- Full gene names are not italicized, Greek symbols are never used and hyphens are almost never 
used (eg: transforming growth factor beta). 
- Gene symbols are italicized with all letters are in upper case and no hyphens. Greek symbols are 
never used (eg: TGFB). 
- mRNA use the gene symbol and formatting conventions (italics) (eg: TGFB mRNA levels). 
- Proteins designations use the same as the gene symbol, but not italized (eg: TGFB). 
 
Guidelines for mouse/rat species 
- Full gene names are not italicized, Greek symbols are never used and hyphens are almost never 
used (eg: transforming growth factor beta). 
- Gene symbols are italicized with first letter upper case and all the rest lower case and no hyphens. 
- Greek symbols are never used (eg: Tgfb). 
mRNA and cDNA use the gene symbol and formatting conventions (italics) (eg: Tgfb  mRNA 
level). 
- Proteins designations use the same as the gene symbol, but not italicized and all upper case (eg: 
TGFB). 
 
                                                 
1 HUGO Gene Nomenclature Comitee (HGNC) guidelines (avaliable in http://www.genenames.org) 
Mouse Genome Informatics guidelines (available in http://www.genenames.org) 
Instrucitons to authors in the journal Genetics and Molecular Biology 
(http://www.gmb.org.br/nomenclature.html) 
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1. ASTHMA 
1.1. General aspects 
Asthma is a complex disease characterized mainly by airway inflammation (1). The word 
“asthma” comes from the Greek verb aazein, meaning to pant, to exhale with the open mouth. We 
have evidence in Egyptian hieroglyphics that asthma preceded the Greeks. Indeed, the first attempt 
to clinically describe asthma is documented in a Chinese medical book, approximately in the year 
2600 BC (2, 3). However, the earliest text where the word asthma was coined as a medical term is 
The Corpus Hippocraticum, by Hippocrates (460-360 BC), where asthma was associated with 
spasms that more likely occurred among anglers, tailors, and metalworkers. Aretaeus of Cappadocia 
and Galen of Pergamo corroborated Hippocrates’ texts in the 1st and 2nd centuries AD respectively, 
and described asthma as bronchial obstruction. This first perspective of asthmatic disease remained 
almost intact until past the Middle Age. During this period, a hospital facility was built in Damascus 
in 706 by Al-walid, the Ummayad Caliph. This hospital may be considered the most ancient 
precedent of modern hospitals.  
In the 17th century, Jean Baptiste Van Helmont (1579 – 1644), a Belgian physician, chemist and 
physiologist who suffered from asthma, said that asthma originated in the “pipes” of the lungs and 
pointed out that the contraction of the lungs is a pathophysiological mechanism of asthma (2). Later 
in the same century, Bernardino Ramazzini (1633 – 1714) detected a link between asthma and 
organic dust and also recognized exercise-induced asthma. By the same time, English physician Sir 
John Floyer, who developed asthma following a respiratory infection, provided detailed accounts of 
signs and symptoms of asthma and described a hereditary component. In 1684 Thomas Willis 
proposed that asthma was caused by defaults in the nerves and nervous fibers pertaining to the 
breathing parts. From this we can conclude that asthma was first depicted as a disease rather than a 
symptom by Thomas Willis and John Floyer in the 17th century. 
The asthma concept was refined in the later part of the 19th century with the publication of a 
treatise by Henry Hyde Salter, where he wrote a detailed description of asthma symptoms, helped 
by suffering asthma himself (4). At that time, allergic diseases like asthma or hay fever were 
considered as an “aristocratic disease” due to asthma being more prevalent in England in aristocratic 
people than in farm workers. This was later interpreted as a sign of superiority in the British 
population by the British physician Morell Mackenzie (1837 – 1892). Also, the French writer 
Marcel Proust (1871 – 1922) described in detail his asthmatic disease in letters to his mother, where 
he wrote about symptoms and feelings he felt during his asthma attacks.  
Asthma 
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Advances in Medicine at the beginning of the 20th century were to a great extent contributed by 
Sir William Osler, who described asthma as a condition producing spasms of bronchial muscles, 
swelling of the bronchial mucous membrane and a special form of inflammation of the smaller 
bronchioles (5). Osler was first in connecting clinical observation with physiology and pathology. In 
1903, Brodie and Dixon experimentally documented the physiological process of bronchial 
narrowing from constriction of airway smooth muscle (6). In 1906, experimental exposure to 
purified allergens was found to reproduce the symptoms of hay fever (7), which led to the 
characterization of asthma as an allergic hypersensitivity to foreign antigens. In 1921 the discovery 
of a serum substance that could passively transfer “allergy” to a specific allergen (8) led to the 
identification of IgE (9) and provided a crucial link to characterize asthma as an allergic disorder. In 
the first part of 20th century, Paul Ehrlich described aniline stains for eosinophils (eosin) and mast 
cells (toluidine blue) (10, 11), which favoured the histopathological study of different diseases, 
mainly allergic diseases including asthma. These advances, together with technical advances in 
optical microscopy, led to a clearer understanding of how allergen exposure triggers the release of 
chemical mediators from airway mast cells (early reaction), and this in turn leads to the recruitment 
of eosinophils, basophils and mononuclear cells (late reaction) (12, 13). The late response in asthma 
was also linked with enhanced airway reactivity to irritant stimuli. In the 1970’s and early 80’s, the 
mast cell was attributed a central role in triggering IgE-dependent inflammation in asthma (14), and 
a wide range of pro-inflammatory products (histamine, prostaglandin D2, cysteinyl leukotrienes, 
tryptase, chymase, heparin…) were identified as mast cell products participating in the asthmatic 
reaction. Also at that time, there was increasing interest in the role of T lymphocytes in allergic 
responses (15), which led to the identification of a special subset of T cells capable of secreting 
cytokines (IL4, IL5, IL13) that selectively interact with mast cells, basophils and eosinophils, and 
were responsible for the recruitment, priming and survival of the primary effector cells of the 
allergic cascade (16).  
In addition to airway inflammation, structural changes occurring in asthmatic airways became 
an important hallmark of asthma in the early 1990’s. Such changes are especially prominent as the 
disease takes on a more severe and chronic phenotype (17, 18) and are described in detail below. In 
the early 2000’s, the interplay between the bronchial epithelium and the subjacent mesenchymal 
elements, involved in processes such as lung development, repair and inflammation (local 
production of cytokines and growth factors), led to coin the term epithelial-mesenchymal trophic 
unit (EMTU). The EMTU was suggested to release growth factors involved in the airway structural 
changes of asthmatic subjects (19). Also, recent genetics research has shown that particular gene 
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polymorphisms (ADAM33, DDP10, SPINK5, MUC8…) may determine or influence asthma or 
atopy susceptibility (20-22). In the last decade, there have also been considerable advances in the 
knowledge of dendritic cell biology and function that have highlighted the importance of these cells 
in asthmatic disease (23).  
Significant improvements in asthma care have been achieved from the early 90’s upon the 
introduction of the Global Initiative for Asthma (GINA), which issued reference guidelines for 
asthma management. GINA defines asthma as a “chronic inflammatory disorder of the airways in 
which many cells and cellular elements play a role. The chronic inflammation causes an associated 
increase in airway hyper-responsiveness that leads to recurrent episodes of wheezing, 
breathlessness, chest tightness and coughing, particularly at night or in the early morning. These 
episodes are usually associated with widespread but variable airflow obstruction that is often 
reversible either spontaneously or with treatment” (24).  
The main clinical asthma features are wheezing, cough, chest tightness, dyspnea, 
bronchoconstriction and airway hyperresponsiveness. Such features are variable in the asthmatic 
subjects, with different clinical-epidemiological “phenotypes” being defined according to the 
disease history, clinical manifestations, inflammatory profile and response to therapy. Airflow 
obstruction is variable in asthma, and can be episodic (in association with triggers such as 
infections, allergens, inflammatory bursts), or rather persistent (associated to airway structural 
changes), leading in the latter case to an irreversible deterioration of lung function (25). Recently, 
the understanding on asthma disease mechanisms evolved to consider that airway remodeling, 
defined as structural alterations that develop in association with chronic inflammation, plays a 
central role in the clinical manifestations of the disease and causes the clinical signs (26, 27). 
Chronic airway inflammation may lead to airway remodeling, and the reversible episodes of airflow 
obstruction may evolve towards chronic obstruction and the aforementioned progressive, ireversible 
deterioration of lung function. A variety of factors, from respiratory infections to pollution, 
allergens and meteorological conditions (humidity, cold, wind…), may trigger acute asthma 
episodes, and the overlay of asthma exacerbations may alsoinfluence the progression towards a 
chronic decline in lung function (28). Although the basic and clinical knowledge on asthma has 
considerably evolved in the recent years, a greater complexity of the disease is also being perceived. 
There is no current explanation for the increasing prevalence of asthma as per the data presented on 
the next section. Furthermore, a relevant proportion of the asthmatics suffer from severe disease 
refractory to maximum available therapy, and the disease mechanisms and their variability are far 
from being understood. 
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1.2. The asthma burden  
Asthma affects approximately 300 million people worlwide, causing about 180,000 deaths each 
year, and is estimated to account for 1 every 250 deaths (24, 29). Many of these deaths, otherwise 
preventable, are due to suboptimal long-term medical care and slow emergency response on life-
threatening asthma attacks in developing countries with poor health resources. From another 
standpoint, industrialized countries have seen a sustained increase in asthma prevalence since the 
60’s, and have taken a lead in asthma research as a priority in the health systems of the European 
Union and North America. It is unclear whether the increasing prevalence in these areas is currently 
slowing down or inverting (30). Nevertheless, the prevalence of asthma appears to increase with 
industrialization and Occidental lifestyle (31), and this trend is paralleled by an also growing 
prevalence of autoimmune diseases and allergies. It is estimated that the overall asthma prevalence 
is increasing by 50% per decade in the world, and has doubled within a decade in the European 
Union (29, 32). Another reason to establish asthma as a research priority is the fact that, despite 
current treatments and their positive impact in the management of most asthmatics, about 10% of 
asthmatics still develop severe, refractory disease (33) and, in a percentage of the latter, asthma may 
turn fatal (34). 
In Spain, the prevalence of asthma ranges from 5.1 to 7.5% in the general population, (24, 32) 
and 9 to 13% in children aged 13-14 (35). Acute asthma attacks are a frequent cause of 
hospitalization, since approximately 20% of asthmatics have acute episodes requiring emergency 
room visits (28, 36). Indeed, acute asthma is the most common cause of hospital admissions among 
children of all ages (37). Noteworthily, patients that suffer asthma exacerbations cost three times 
more, in terms of health care resources, than those who do not exacerbat (36). Therefore, asthma 
exacerbations imply a great cost for the health systems in all countries. Additionally, the 
productivity losses caused by poor asthma control are estimated to account for €9.8 billion per year 
in Europe (29).  
 
1.3. Asthma pathophysiology 
1.3.1. Airway structure 
Anatomically, the intrathoracic airways start with the trachea, which bifurcates into the left and 
right main bronchi. From this point, the intrapulmonary airways continue to branch into successive 
generations of bronchi, then bronchioles (which lack supportive cartilage in their wall), terminal 
bronchioles and respiratory bronchioles (where the respiratory epithelium alternates with alveolar 
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openings). This tree-like structure of conducting airways ends into the lung parenchyma, which is 
the area of gas exchange, made of respiratory bronchioles, alveolar ducts, sacs and alveoli. 
At the histological level, the airways consist of several tissue layers that differ in composition 
from the trachea to small bronchioles. The function of this branching is to carry inspired air to the 
alveoli, and expired air to the outside. In this route, the air passes through three levels of conducting 
airways: trachea, bronchi and bronchioles. The inner layer of the airway wall is the so-called 
respiratory epithelium, a pseudo-stratified ciliated cylindrical epithelium, in which all cells are 
anchored to the basal membrane, but not all of them reach the lumen. This epithelium is composed 
by several cellular types including: basal cells with a regenerative function; ciliated cylindrical cells, 
whose cilia are joined by dynein arms, a protein that gives consistency and promotes cilia 
movement; and goblet cells that contain mucus granules. Next layer, underlying the respiratory 
epithelium basal membrane, is the lamina propia, a layer of conjunctive tissue rich in elastin fibers, 
which provides a space for the distribution of blood and lymphatic vessels and nervous fibers. Both 
layers, the respiratory eptithelium and the lamina propia, are called mucosa. Immediately beneath 
the mucosa, and depending on the level of the airways, we can find a layer called submucosa. The 
tracheal submucosa is a layer of dense connective tissue containing mucous, serous or mixed glands 
that secrete mucin and polipeptidic substances to airway lumen. Also in the trachea and beneath the 
submucosa, we find the tracheal cartilage, the tracheal muscle and the adventicia, a layer of loose 
connective tissue and adipose cells that surrounds the trachea. 
From the standpoint of neurophysiology, the lungs are mainly innervated by the sympathetic 
and parasympathetic systems, which determine the bronchial airway tone by sustaining a balance 
between bronchodilation and bronchoconstricition stimuli. Although the sympathetic system 
comprises less direct innervation of the airways than the parasympathetic, the bronchial smooth 
muscle cells express β2-adrenergic receptors that can be stimulated by circulating catacholamines to 
produce smooth muscle relaxation and bronchodilatation. By contrast, the parasympathetic system 
innervates the airways directly, inducing bronchoconstriction through cholinergic stimuli.  
1.3.2. Pathophysiological changes in asthma: airway remodeling 
The term “airway remodeling” in asthma can be defined as a process occurring in response to 
chronic airway inflammation that results in permanent structural abnormalities in the airway wall 
(27, 38). Airway remodeling is believed to provide a pathophysiological basis for airway 
hyperresponsiveness and airflow obstruction (39), and may start in an early phase of the disease 
prior to the onset of symptoms (Figure 1). The changes described as part of airway remodeling are: 
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 Thickening of the respiratory epithelium. The respiratory epithelium is particularly 
thickened in asthmatic subjects. Epithelium desquamation has also been described in asthma (40), 
Figure 1. Airway histopathological changes in asthma. (A) The normal airway wall. In the respiratory 
epithelium, ciliated cells are predominant, and goblet and basal cells and goblet cells intercalate. The 
lamina propria, rich in elastine fibers that give consistence to the airway structure, underlies the 
epithelium, followed by the airway smooth muscle layer and the adventitia. (B) Asthmatic airway, goblet 
cell hyperplasia and hypertrophy, together with increased mucous and serous glands, lead to mucous 
overproduction. Excessive deposition of extracellular matrix causes subepithelial fibrosis, and the airway 
smooth muscle undergoes hyperplasia and hypertrophy. All such changes lead to an overall thickened 
airway wall and facilitate airway narrowing.  
B 
A 
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although some consider this phenomenon as an artifact resulting from tissue processing (41). A 
role for the airway epithelium in the pathogenesis of asthma has been proposed by studies 
highlighting the presence of epithelial dysfunction and a breakdown of the epithelial tight junction 
integrity (42-44). Evans et al. introduced the term EMTU, referring to the involvement of airway 
structural cells in controlling the airway microenvironment during processes such as lung 
development, repair, and regulation of inflammatory responses (45). Airway epithelium 
abnormalities in asthma may lead to a deregulated interaction between the epithelium and 
subjacent mesenchymal elements such as fibroblasts, altering EMTU function. Fibroblasts have 
the ability to differentiate into myofibroblasts that secrete extracellular matrix proteins and pro-
inflammatory mediators. Also, increased epithelium fragility and damage during chronic 
inflammation may led to epithelial cell activation and the release of a wide range of pro-
inflammatory mediators (cytokines, eotaxin, growth factors, extracellular matrix proteins, and 
metalloproteases), which may contribute to chronic inflammation and airway remodeling (46). 
Another reason for the thickening of the respiratory epithelium is globet cell hypertrophy and 
mucous hypersecretion. 
 Increase in the size and number of mucous glands. Mucous glands in asthma are present in 
peripheral bronchioles, where they are normally absent, and can make up a higher proportion of 
the submucosa in fatal asthma compared with normal subjects (47). These glands may have 
dilated secretory ducts and eventually leak air, causing interstitial emphysema in complicated 
asthma (48). An increased mucous viscosity can significantly reduce mucociliary clearance (49), 
plugging the small airways and causing a poor response to inhaled bronchodilators (50). Mucous 
overproduction can also cause mucous plugs in airways of all sizes, from second generation 
airways to bronchioles (51), and lead to atelectases. As such, it has been reported that over 50% 
of the airways can be occluded by mucous during a fatal asthma attack (52).  
 Goblet cell hyperplasia. The increase in goblet cell number is associated with mucous 
hypersecretion. Goblet cell hyperplasia and the consequent secretory hyperactivity are attributed 
to inflammatory mediators such as IL9 (53) and IL13 (53-55). Mucous production by the 
increased mucous glands also contributes to excessive mucous in the airways.  
 Subepithelial fibrosis. The basement membrane of the airway epithelium is formed by the 
basal lamina (the “true” basement membrane as defined by electron microscopy) and the lamina 
reticularis (a net of reticular fibrils, of type VII collagen mainly, and  microfibrils of fibrilin), 
both synthesized by conjunctive tissue cells. The thickening of the lamina reticularis, a feature of 
subepithelial fibrosis in asthmatic bronchi, is caused by excessive deposition of extracellular 
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matrix and alterations in its turnover (56). The appearance of such thickening under regular 
bright-field microscopy led to the term “thickening of the basal membrane”, an inaccurate 
interpretation from early observations. The excessive deposit of extracellular matrix is actually 
located in the subepithelial region and is mainly constituted by type I and III collagen fibers, 
fibronectin and proteoglycans (26, 57, 58). Subepithelial fibrosis may result from airway 
epithelium dysfunction and loss of integrity, which may resul in an impaired repair response to 
injury (44). It has been also speculated that subepithelial fibrosis may oppose airway smooth 
muscle contraction and limit its effect on airway narrowing (59). 
 Bronchial angiogenesis. A network of capillaries of the systemic circulation runs in the lamina 
propria and plays a role in the inflammatory process. Also, there is angiogenesis leading to 
neovascularization with altered permeability, which may facilitate edema and contribute to airway 
narrowing and airflow obstruction (52, 60). Several endothelial growth factors may be implicated 
in angiogenesis, such as the vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor (bFGF), platelet-derived endothelial cell growth factor (PDGF) and hepatocyte growth 
factor (HGF) (26). 
 Increased airway smooth muscle mass. The term airway smooth muscle mass refers to the 
amount of airway smooth muscle, relative to airway size. Airway smooth muscle mass is 
characteristically increased in asthma, probably due to a combination of cellular hyperplasia and 
hypertrophy. Clinical and experimental data suggest that the increased smooth muscle mass plays 
a central role in the mechanism of airway hyperresponsiveness, a cardinal asthma feature. 
Furthermore, the airway smooth muscle may play a pro-inflammatory role through the secretion 
of several mediators (61). 
 
The increase in airway smooth muscle mass occurs through a combination of mechanisms that 
include the action of mitogenic and pro-inflammatory molecules, alterations of extracellular matrix 
components, and direct actions of immune cells such as mast cells (62) and T cells (38, 63, 64), 
which will be described further on. The increased airway smooth muscle may play several roles in 
the pathophysiology of the disease. Airway smooth muscle cells are able to secrete mediators that 
can alter tissue homeostasis and thus modify the function of other cell types. In fact, airway smooth 
muscle cells in asthma may induce myofibroblast migration and recruitment to the lamina propria, 
which has been observed in asthmatic patients and may play a relevant role in the disease (57, 65). 
Also, Ma et al. observed in vitro an increase in myosin light chain kinase (MLCK) activity in 
smooth muscle cells obtained from pulmonary biopsies of asthmatic patients, compared with 
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healthy controls. Airway smooth muscle may therefore have a greater contractile capacity in asthma 
(66). However, these results remain controversial, because Woodruff et al, in a similar study, found 
no difference in MLCK expression levels between smooth muscle cells from asthmatics versus 
controls (67).  
Apart from the properties of the airway smooth muscle itself, other studies showed alterations 
in the airway cartilage and fibronectine volume and integrity in asthma, which may result in 
increased bronchocostriction upon smooth muscle contraction (27, 57). 
1.3.3. Response to airway provocation 
Airway hyperresponsiveness, (also termed airway hyperreactivity or bronchial 
hyperresponsiveness or hyperreactivity) is a cardinal asthma feature, defined as exaggerated 
bronchoconstriction in response to a variety of nonspecific stimuli. Airway hyperresponsiveness is 
most usually determined by measuring the forced expiratory volume in the first second of forced 
expiration (FEV1) in response to increasing concentrations of an inhaled, nebulized cholinergic 
agonist such as β-methacholine (MCh). MCh works as an acetylcholine analogue (68) inducing 
direct constriction on airway smooth muscle cells. The test output is the MCh concentration that 
causes a 20% or greater fall in FEV1 (provocative concentration 20 or PC20), and the test is 
generally considered positive if such value is <8 mg/mL. The test is aimed at reflecting the airway 
responsiveness to nonspecific bronchoconstrictive stimuli such as cold air, ozone, infections, etc. 
The MCh challenge test is very sensitive and has a high negative predictor value (69).  
The relation between airway hyperresponsiveness and asthma symptoms is variable. 
Approximately 50% of subjects with airway hyperresponsiveness are asymptomatic. Also, airway 
hyperresponsiveness can present subclinically and may precede asthma symptoms. Airway 
hyperresponsiveness is considered a risk factor for the development of asthma in children (70). 
Recently, associations between genetic polymorphisms and airway hyperresponsiveness have also 
been reported. A polymorphic alelle of the A disintegrin and metalloproteinase domain 33 
(ADAM33) gene has been associated with the onset of childhood asthma and airway 
hyperresponsiveness, impaired lung function in infancy and the accelerated decline in lung function 
that occurs in severe asthma (71). ADAM33 encodes a membrane-associated protein that can be 
cleaved into a soluble catalytic fragment, which is a powerful angiogenesis factor involved in 
smooth muscle development (72). 
The airways can also be challenged with specific allergens. During allergen exposure in atopic 
asthmatics, the inhaled allergen binds to IgE on the surface of mast cells, leading to the immediate 
release of histamine, which causes an early bronchoconstrictor response within 10 minutes and 
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lasting approximatelly 90 minutes. IgE has been linked to allergic responses in humans for almost 
50 years (73, 74). Histamine acts on H1 receptors of the airway smooth muscle, sharing signalling 
pathways with M3 muscarinic receptors. Both are G-protein-coupled receptors that, upon activation, 
allow the increase of intracellular Ca+2 concentration in the muscular cell, which in turn stimulates 
myosin light chain kinase activation, inducing smooth muscle cell contration. This IgE-dependent 
bronchoconstriction, termed early airway allergic reaction, can be followed by a subsequent, 
sustained bronchoconstriction starting 3-8 hours later and lasting several hours or days. This latter 
response, termed late airway allergic reaction, involves CD4+ effector T cells and is mediated by a 
complex array of mediators including cytokines and leukotrienes (75). 
1.3.4. Asthma treatment 
From ancient literature, it is inferred that asthma existed priorly to the times of the Egyptian 
Empire, 3000 years BC, although the disease has only been identified as an entity termed asthma 
since the 17th century. The George Ebers Papyrus, found in Egypt in the 1870s, contains 
prescriptions written in hieroglyphics for more than 700 remedies, including asthma (a mixture of 
herbs heated on a brick so that the sufferer could inhale their fumes). In the 2nd century, Roman 
physician Galen treated asthma symptoms with owl’s blood in wine. In the Middle Age, Moses 
Maimonides (1135-1204 AD), a physician in the court of Sultan Saladin of Egypt and Syria, 
diagnosed asthma in the Prince Al-Afdal. He related asthma episodes with wet months when the 
disease would begin as a common cold. He also noted that the dry months of Egypt helped asthma 
sufferers and suggested avoidance of strong medication, plenty of sleep, fluids, moderation of 
sexual activity, and chicken soup. At the end of the 19th century, although seemingly 
counterintuitive given the potential for exercise-induced brochospasm, exercise was proposed to 
improve subjective and objective asthma indices (4); but the proposed regimens were unrealistic 
(76). One hundred years ago in China, it was common to give a person with asthma herbs 
containing ephedrine, which may have had a bronchodilator effect mediated through β2-adrenergic 
receptors. Also, earlier treatments of asthma included tobacco, Indian hemp, sedation (using 
chloroform, ether, or opium), coffee or tea among others. Some of such agents block cholinergic 
signalling to some extent and favor the sympathetic tone and airway smooth muscle relaxation (77). 
The first pharmacological aim for the treatment of asthma, before the relevance of chronic 
airway inflammation was understood, was to achieve bronchodilation. After the first studies on the 
use of nebulizers to produce a fine spray in the 1870’s, James Burnett, an Edinburgh physician, 
reported in 1903 the benefits of inhaled adrenaline as a bronchodilator therapy for asthma (78). 
However, it was not until the 1950’s when inhalation therapy was revolutionized with the invention 
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of the first pressurized metered-dose inhaler (pMDI) (79). By the early 1960s, the rapid response to 
inhaled aerosols of non-selective adrenergic agonists such as adrenaline and isoprenaline was 
extensively exploited with pMDIs, but the association between isoprenaline and an increase in 
asthma deaths defeated its usefulness (80, 81). Further development led to safer bronchodilators, β2-
adrenergic agonists, to be administered with pMDI inhaler devices. Salbutamol a short-acting β2-
adrenergic agonist (SABA), was marketed as a substitute for isoprenaline and is still widely used, 
nowadays as rescue medication, due to its quick and more selective action on airway smooth muscle 
and minimal side effects (82). The use of salbutamol and the introduction of systemic steroids for 
the management of life-threatening asthma made a large reduction of asthma deaths possible in the 
late 1970s (79). 
The isolation of cortisone by Tadeus Reichstein in 1936, and its posterior identification by 
Kendall and Hench (79), favoured its first application in asthma in 1950 (83), which in turn led to 
the confirmation of its beneficial effects by clinical trials a few years later (84). In subsequent years, 
prednisone and hydrocortisone were developed and introduced in the clinical practice. However, the 
association of long term systemic steroid therapy with serious adverse effects, such as hypertension, 
osteoporosis, diabetes and obesity, led to the need of researching on a safer administration of 
steroids. Clinical trials in the 1970s stablished that the inhaled administration of beclomethasone 
dipropionate (BDP) or other steroids is an effective treatment to control asthma (85, 86). The studies 
reported that BDP reduces airway eosinophilic, mast cell and mononuclear cell inflammation and 
decreases the late asthmatic reaction and airway hyperresponsiveness (87, 88). The characterization 
of asthma as an airway inflammatory disease and the identification of the role of mast cells (12, 13) 
led to the finding that chromone mast cell-stabilising agents such as sodium chromoglycate (SCG) 
attenuate both the allergen-induced early and late bronchoconstrictor responses (89). Although the 
efficacy of SCG resulted equal to or inferior to low-dose inhaled steroid therapy, chromones are 
nowadays used rarely (79).  
Inhaled corticosteroids revolutionized the management of asthma in the 1980s. In the late 
1980s, inhaled long-acting β2-adrenergic agonists (LABAs), first salmeterol and then formoterol, 
were introduced in the clinical practice (90-93). LABAs have a bronchodilator action for up to 
twelve hours, and appear to also have a side anti-inflammatory effect. Clinical trials (94, 95) 
reported benefits from adding LABAs to the therapy of patients with poorly controlled asthma, 
which led to treatments combining LABAs with inhaled steroids as a current standard therapy for 
moderate persistent asthma and beyond (96, 97). 
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The evidence that allergen exposure in specific settings was a key step in the pathophysiology 
of asthma, led in the 1990s to the idea of blocking the primary mast cells signaling cascade by 
directing a monoclonal antibody to the IgE site that binds its high affinity receptor (FcεR1) on the 
mast cell. This approach was successful in mouse models of allergy (98) and subsequently tried in 
humans with omalizumab, an engineered, humanized anti-IgE monoclonal antibody (99). The 
omalizumab has inaugurated a new are of therapeutics based on genetically engineered monoclonal 
antibodies to block specific mediators or their receptors, with a growing development pipeline and 
important hopes for severe asthma and other diseases. In the case of omalizumab, still the only 
approved therapy of this type for asthma, the treatment effectiveness is variable and concerns on its 
cost and potential side effects have been raised (100-107). 
Presently there is no cure for asthma. Asthma treatment is currently intended to control 
inflammation, mainly by means of inhaled corticosteroids. However, there is no evidence of 
attenuation or reversal of airway remodeling through pharmacological therapy. Recently a new 
therapeutic approach has been introduced to ameliorate symptoms in patients with severe asthma, 
which is bronchial thermoplasty. This consists in delivering a radio frequency energy to the airways 
by flexible bronchoscopy with the aim of reducing airway smooth muscle mass and responsiveness 
(108-111). However, there is not enough evidence that this technique ameliorates all asthma types 
(112) and its high complexity and cost make this approach not valid for routine treatment. In all, we 
can conclude that current asthma treatment is suboptimum and not sufficient to control severe 
asthma (38). Also, the pathogenesis of asthma is far from well understood, which makes further 
basic and clinical research necessary for the development of new therapeutic targets and treatments. 
 
1.4. Animal models of experimental asthma 
Animal models have contributed significant knowledge to the pathogenic mechanisms of 
asthma and continue evolving to better delve into airway remodeling and the asthmatic 
immunological response.  
It is probable that the first recording of bronchoconstriction in an animal model of allergic 
disease was reported by Auer et al. in 1910 using guinea pigs during anaphylactic shock (113). In 
this work, guinea pigs were subcutaneously sensitized to horse serum and challenged intravenously 
(i.v.), which resulted in anaphylactic death caused by asphyxia. The cause of asphyxia was defined 
by the authors as “a titanic contraction of the smooth muscles of the bronchioles; which occludes 
their lumen gradually, so that finally no air enters or leaves the lung […] the animal was 
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strangulated”. Since this first animal model in which a bronchoconstriction was described, extensive 
effort has been done to achieve an animal model that mimics human asthma.  
1.4.1. Different animal models of experimental asthma 
No laboratory animal is known to spontaneously develop a disease resembling asthma. 
However, some outbread animal species do naturally develop asthma-like diseases. Cats can 
develop a bronchial disease similar to human asthma, with lung inflammation and 
bronchoconstriction (114, 115). Current research work in cats is being conducted to elucidate 
mechanisms that may help discover new therapeutic targets for human asthma (116). 
Horses can get sensitized to hay molds and develop an allergic airway obstructive disease, 
called “heaves”, with neutrophilic airway inflammation and airway smooth muscle remodeling 
(117). 
Dogs has been used to model allergic disease due to their natural predisposition to develop 
allergic responses to antigens that are clinically significant to atopic humans (118), but this allergy 
normally manifests as dermatitis or conjunctivitis rather that airway inflammation. However, several 
works have developed dog models that achieve asthma hallmarks, such as increased IgE, airway 
hyperresponsiveness (119), lung eosinophilia and acute physiological constriction in response to 
allergen inhalation (120). These models may result useful to study physiological and clinical 
implication of asthmatic disease. Some of such models have been achieved through selectively 
breeding dogs with high IgE levels at baseline (119). The high IgE levels seem to correlate with the 
predisposition to develop allergic reactions by the dogs, which matches with human allergic disease.  
Sheep can develop natural allergic sensitization to Ascaris suum (a parasitic nematode worm), 
which is accompanied by elevated IgE levels and airway hyperresponsiveness (121) (122). This fact 
has made sheep a potential and attractive model for asthma, progressively developed to date (123). 
However, initial studies where drugs showed to be effective in moderating lung allergic responses in 
sheep (124, 125), did not translate to humans (126). This highlights the care that must be taken 
when comparing animal models with human disease. In the case of sheep, one also has to take into 
account the high costs for housing and manipulation that these large animals require. 
 Guinea-pigs have been used as animal models for pulmonary hypersensitivity for more than 80 
years (127). In these animals, the major benefit is the lung as the target organ for the 
hypersensitivity response, which allows for intranasal (i.n.) sensitization against allergens and the 
subsequent development of neutrophilic/eosinophilic pulmonary inflammation and airway 
hyperresponsiveness after i.n. challenge (128). These animals are also relatively inexpensive, easy 
to handle, and mimic physiological abnormalities of human asthmatics, developing a well-
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characterized early and late phase response to allergen challenge following sensitization (129, 130). 
However, the existence of few inbred strains and species-specific reagents, together with a 
discrepancy in the response to leukotrienes with humans (131), must be taken into account when 
employing the guinea pig for experimental purposes beyond the histological study of the lungs, and 
airway hyperresponsiveness (132). 
Rats are widely used to develop animal models for human diseases (133-140) as they are 
relatively cheap, large in size, and stable under anaesthesia. In the respiratory field, the rat eases 
particular measurements such as airway markers of inflammation in bronchoalveolar lavage (BAL) 
fluid. Also, the rat can be easily sensitized to a broad range of antigens (133, 141-143) and 
sensitization and challenge typically result in a Th2 dominant response, characterized by 
eosinophilia and antigen-specific IgE (144), although is dependent on the strain used (145). The rat 
represents a useful asthma model that has allowed us to better understand allergic airway diseases, 
but the expansion of genetic technologies, mainly applied to the mouse, have displaced the rat as a 
“second option” for asthma models. However, the availability of rat-specific reagents has increased 
in recent years together with the advent of transgenic technology, which is balancing the usage of 
rats with mice. 
1.4.2. Murine models of experimental asthma 
Murine models of experimental asthma have become widely used to study allergic airway 
disease. Mice are broadly used to model most diseases because of the detailed understanding 
regarding their genetics (146), the ease to manipulate outcomes using transgenic technology (147), 
and the broad amount of commercially available mouse-specific probes and antibodies. In fact, 
actual therapeutic targets have been developed from studies in mice (148), which reflects the 
importance of murine models to study human diseases. Thus, murine models are considered an 
important basic research tool to understand the molecular and cellular bases of asthma (149-151).  
However, some differences must be taken into account when working with disease animal 
models, and the mouse is not an exception. Differences in the tracheo-brochial tree between humans 
and mice must be considered (152), such us: the size, where total lung capacity in humans is about 5 
L and only 1 mL in the mouse; the alveoli of the murine lung are smaller (80 μm mean linear 
intercept (MLI)) than those of humans (MLI of 210 μm); the thickness of the blood-gas barrier is 
about 0,38 μm in the mouse and 0,62 μm in humans; the murine lungs have fewer airway 
generations (13-17) than do human lungs (17-21 generations), and no respiratory bronchioles. Also, 
mice only have pulmonary circulation in the lungs, lacking bronchial systemic circulation. Despite 
all such differences, animal models have produced extensive knowledge applicable to human 
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disease and, in fact, provided the essential link between inflammation, airway hyperresponsiveness 
and asthma more than 20 years ago (153). Experimentally induced asthma in mice shows an 
immunological profile analogue to human asthma, with Th2 allergic response and eosinophils as 
one of the main cellular components of the inflammatory infiltrates in the lung (154, 155). Mice 
also have other advantages compared with other animal models (rat, horse, sheep…): they are 
cheap, small, and have a rapid biological cycle, with a gestational period of approximately 20 days, 
a lactation period about 4 weeks, and they reach sexual maturity at 5 weeks. Pros and cons in the 
usage of mice as models for human asthma have been widely reviewed (156-163). 
An important issue to take into account in the development of mouse asthma models is the 
choice of mouse strain, because the effects of allergic sensitization and the experimental asthma 
outcomes vary significantly depending on the strain used (164). The most commonly used strain for 
asthma modeling is the Balb/c, because of its Th2-biased immune response.   
1.4.3. Allergen nature 
A wide diversity of allergens were used to sensitize animals in asthma models, from the most 
traditionally used ovalbumin (OVA) to a number of actual human allergens such as house dust mite 
(HDM), cockroach antigens, Aspergillus fumigatus and ragweed extracts. Early experiments in 
animals on toxicity were performed more than 100 years ago on dogs, guinea-pigs, and rabbits, 
where violent or fatal reactions to repeated injections of foreign proteins were described (165). The 
toxicity of serum xeno-infusion was attributed to so-called “toxalbumins” (166). Already in the 20th 
century, the first animal models of experimental asthma were described in guinea pig (1926) (167), 
dog (1970) (168) and even the monkey (1972) (169, 170). These models were based on sensitizing 
animals to an allergen followed by subsequent challenges, which induced lung inflammation and 
airway disease. In 1960´s Mota reported the induction of an anaphylactic reaction through the 
induction of “mast cells sensitizing antibody” using sensitization to egg albumin plus Bordetella 
pertussis bacilli (171), and suggested a role for mast cells in airway allergic diseases. OVA is not an 
air-borne allergen causing human asthma, and immunological tolerance is normally developed 
through bowel exposure from the diet. This immunoregulatory mechanism is called “oral 
tolerance”. In the case of laboratory rodents, the diet has an OVA-free controlled composition, 
therefore leaving the antigen with the capacity to induce allergic Th2 responses in these animals.  
In the 1970s, Church reported a rat model of “anaphylactic bronchoconstriciton” and the 
inhibitory effects of dexamethasone, SCG, and other drugs (172). Church used a nematode 
(Nippostrongylus brasiliensis) infection to sensitize rats and the challenge was done i.v. Two years 
later, Stotland et al. immunized rats with OVA plus aluminium hydroxide gel as a coadjuvant with 
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or without B. pertussis vaccine, and reported “anaphylactic bronchoconstriciton” 14 days after 
sensitization (173). At the same time, Chang et al. established a mouse model of sensitization to 
ragweed pollen, a real human air-borne allergen, achieving anaphylactic reaction to intravenous 
challenges (174). In 1976, Gerbrandy et al. studied the kinetics and localization of IgE production in 
a F1/J mouse model of allergic sensitization to tetanus toxoid and B. pertussis, where they compared 
several sensitization approaches (175). They reported that intratracheal and intraperitoneal (i.p.) 
sensitization result in higher IgE production than subcutaneous immunization. They showed that the 
site for IgE production is the bronchial lymph nodes in both cases and that the effect of i.p. 
sensitization is attributable to peritoneal draining into bronchial lymph nodes. This work 
demonstrated lung involvement in the allergic response and the correlation with serum IgE levels. In 
1978, Carswell et al. established an experimental asthma model that became “classical”, in which 
Lister rats were subcutaneously sensitized with OVA and aluminum or B. pertussis as coadjuvants, 
followed by aerosol airway challenge (176). They reported an increase in serum IgE levels and its 
relationship with the respiratory response. A year later, Piechuta et al. varied Carswell’s model with 
i.p. sensitization and also reproduced the correlation of IgE levels with the respiratory response 
(177).  
In the 80s, approximately 10% of the U.K. population suffered from allergies to HDM (178) 
and the association between HDM and asthma became an intense focus of research. Dust mites are 
organisms classified inside an arachnid subclass (Acari) of less than 1mm in length. They feed on 
organic detritus such as flakes or human skin shedding and grow in the environment of dwellings. 
The mite’s gut contains potent digestive enzymes (mainly proteases) that persist in their feces and 
become major allergens (179). HDM extracts contain a complex array of allergens (180), although 
their major mite component is Dermatophagoides spp (D. pteronyssinus in Europe and D. farinae in 
America). The major allergen from D. pteronyssinus, especially for asthma, is a 25 kDa molecule 
present in the mite faecal particles. This allergen, called Der p 1 has been first isolated by Chapman 
et al. in 1980 (181) and molecularly characterized by Simpson et al. (182). In the following years, a 
wide range of allergens with similar patterns was described in HDM extracts and their relationship 
with human atopic diseases was studied (183). These advances awakened the interest in applying 
actual allergens to animal models of allergic diseases, including asthma, with the aim of 
reproducing the human disease as closely as possible. This led in the early 90s to encompass clinical 
experimental research with HDM in atopic people (184-186) with animal models (187, 188). Since 
then, HDM has become an extensively used allergen to develop animal models of allergic airway 
disease (189, 190). 
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Nowadays, the most used allergens are HDM extract and OVA. HDM contains antigens 
implicated in allergic rhinitis and asthma in humans, and its use in animal models is an advantage in 
these terms (191-193). However, an inconvenience of this approach is that HDM is a complex 
mixture of antigens and it is difficult to standardize for experimental purposes. Taking all this 
together, the allergen choice must be in agreement with the aims of each study, taking into account 
the advantages and limitations and searching for a balance in each case. 
1.4.4. Sensitization and challenge protocol 
Since the first murine asthma model over 40 years ago (172), a broad range of protocols have been 
used to induce experimental allergic disease in animal models. The majority of murine asthma 
models have been based on i.p. sensitization, achieved by injecting an antigen mixed with an 
adjuvant, either as a single dose or followed by a booster dose. Once sensitization is attained, 
subsequent airway allergen challenges trigger an allergic cascade in the lungs, eliciting mast cell 
degranulation, recruitment of inflammatory cells (especially eosinophils), activation of T and B 
cells, and the release of a myriad of mediators, which results in the manifestatios of allergic disease 
in the upper and lower airways. These models reproduce the efferent/effector stage of the disease 
efficiently (airway inflammation and remodeling, airway hyperresponsiveness), but do not represent 
the afferent phase, i.e. allergic sensitization, in the way it occurs in human disease. The division 
between the sensitization and challenge phases is artificial in these models, and sensitization is 
induced by a parenteral antigen "vaccine" administered with an adjuvant. 
Probably, the first experiment of primary airway exposure leading to IgE production was performed 
by van Hout et al. (194), who used aerosolized OVA to challenge rats, which led to IgE synthesis. 
In the 80s, Holt et al. highlighted the “need of models which more closely approximate the 
triggering of IgE responses under natural conditions, i.e. wherein the antigenic stimulus is not 
accompanied by adjuvant, and the portal of entry of the antigen is normal” (195). Despite the 
obvious importance of the respiratory tract as a portal of entry for antigens which act as allergens, 
the interest in antigen inhalation as a mode of induction for specific IgE responses has not been 
reflected by the classical i.p. sensitization models. This line was followed by others. McCaskill et 
al. developed an animal model of grass pollen hypersensitivity using primary airway exposure to the 
antigen, although an injected B. pertussis vaccine was still used as an adjuvant (196). Also, 
Sedgwick et al. reported in 1984 that repeated exposure of rats to aerosolized OVA induced 
tolerance to subsequent injection of the same antigen (197). In this model, spleen and respiratory 
tract lymph node cells, but not serum from aerosol-challenged animals, were responsible for the 
antigen tolerization (198). 
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In human asthma, allergic sensitization is due to primary airway exposure to antigen, through a not 
well known time course and natural disease history. However, there are few works on allergic 
airway disease that do not distinguish between sensitization and challenge periods (192, 193). 
Animal models of allergic disease where the first exposure to antigen was not in respiratory tract, 
depended on IL10 to limit the immune response. Conversely, animal models of asthma with first 
antigen exposure in the respiratory tract did not show dependence on IL10 to generate tolerance 
(199). Moreover, the first exposure to antigen in the airways seems to enrich local lymph nodes in 
FOXP3+ regulatory T (Treg) cells that mediate tolerance through membrane-bound TGFB. These 
observations highlighted the fact that the sensitization route determines different immune responses. 
In this context, the contribution of Treg cells to the development or attenuation of allergic disease 
may depend on the nature of the allergen and the local microenvironment in which the allergen is 
delivered. 
There are also different ways to challenge animals with an allergen. McCusker et al have 
reported that the route and site of challenge influence the final result of the model (200). Allergen 
administration can be done via intra-tracheal instillation, a route used in rat asthma models, but 
difficult in the mouse due to the small size of the animal. Another method is to challenge the 
animals with aerosols or nebulilzed antigen in a closed box (201-206). Although this approach has 
been widely used, the amount of inhaled antigen is not controlled and the antigen can be deposited 
on the skin and hair of the animals, and reach the intestine after grooming themselves. Finally, i.n. 
instillation is the most used method for airway challenge and resembles the allergen-specific nasal 
provocation test in humans (207). I.n. performed on alert animals has been reported to achieve 90% 
antigen deposition in the nasal cavity and less than 3% in the digestive tract (55, 200, 208). 
Alternatively, i.n. challenge can be done under light anesthesia (e.g. with inhaled sevoflurane), 
which is less traumatic and may involve less risk of swallowing the allergen by the animal, either 
directly or by licking the nose during instillation (209). 
1.4.5. Pulmonary function  in small laboratory animals: the FlexiVent  
The widespread use of rodents as animal models for lung diseases demanded the development 
of techniques and equipment for pulmonary function testing in mice and rats. The small size of the 
airways was an important challenge to overcome from early studies on pulmonary resistance in 
mouse, in the late 1980s (210). Two main options exist for pulmoanry function testing in rodents: 
invasive and noninvasive approaches (211). Each type of technique has its own pros and cons, and 
factors such as and reliability for each particular experimental purpose must be considered (212). 
Invasive procedures requiring intubation yield the most sensitive, specific and accurate data on 
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pulmonary mechanics, and are applicable to the assessment of both obstructive and restrictive lung 
disorders. Because of the tracheal intubation, invasive approaches by-pass upper airway resistance 
and the measurements are therefore more specific for the lungs. Moreover, invasive pulmonary 
function testing under mechanical ventilation can determine central and peripheral pulmonary 
mechanics parameters through complex ventilator-driven pressure waves (“perturbations”) and 
mathematical modeling. However, invasive approaches have some inconveniences. One such 
inconvenience is the requirement of complex animal instrumentation involving anesthesia and 
tracheostomy, althought the major disadvantage is that invasive pulmonary function techniques are 
usually terminal experiments, not allowing repetitive measurements in the same animals. 
Noninvasive pulmonary function testing is quick and simple in terms of animal instrumentation, 
since no anesthesia nor intubation are required, and, as a major advantage, it allows repetitive 
measurements. However, noninvasive measurements are not based on a direct assessment of 
pulmonary mechanics, and their reliability has been questioned.  
For invasive pulmonary function testing, the animals must be anaesthetized with agents such as 
sevoflurane (fluoromethyl hexafluoroisopropyl ether), a general anesthetic also used in humans for 
the induction and maintenance of general anaesthesia. It produces denso-dependent central nervous 
system, cardiovascular, and respiratory depressant effects (213) and is one of the preferred agents 
for mask induction due to its lesser irritation on mucous membranes (214). Following anesthesia 
and intubation, neuromuscular blockade is necessary to put the animal under mechanical ventilation. 
For this purpose, a paralyzing agent is used such as rocuronium bromide, a competitive 
acetylcholine blocking agent that also exerts a stabilizing effect on the postsynaptic membrane and 
prevents action potentials on the skeletal muscle fibers. The paralysis induced by rocuronium first 
affects highly irrigated fast muscles and then the diaphragm. Once paralysed, the animal is 
subjected to mechanical ventilation that is usually set at 150-250 breaths/min and 6-10 mL/Kg for 
the mouse (211, 215). This is achieved by means of a rodent mechanical ventilator such as the 
FlexiVent® (SciReq, Montreal Canadá) (216). The Flexivent is fitted for inhaled anesthesia and has 
a positive end-expiratory pressure (PEEP) module in its expiratory arm, which also serves as a 
washer trap to cleanse the gas output. Since rats and mice have small airways and the functional 
residual capacity (FRC) is largely maintained by inspiratory muscle tone, which is minimal or null 
in the anesthetized animals, it is important to use PEEP to avoid small airway collapse at the end of 
expiration. The inspiratory and expiratory arms of the ventilator are connected to the tracheal 
cannule through a Y-tube adapter provided with two air valves that work together in each 
respiratory cycle, and pressure transducers. The main component of the apparatus is a piston pump 
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driven by a high-precision linear motor. The exact position of the piston at any given time and its 
movements, as well as the ventilation settings and pressure waves, are software-controlled 
(FlexiVent 5.2). Following a pressure/volume calibration protocol, the ventilator is able to infer the 
inspiratory volume and flow from the movements of the piston and proper corrections for gas 
compression. Pulmonary function measurements are obtained using the so-called “forced oscillation 
technique” (FOT). For this purpose, the ventilator software briefly interrupts tidal breathing support 
and forces simple or complex sinusoidal pressure waves, called perturbations, on the animal’s 
airway opening. During the perturbations, the ventilator correlates the differential pressure 
measured at the transducers with the inferred volumes introduced. From these data sets, the software 
then calculates pulmonary function variables by applying mathematical models. The models are: (i) 
the linear first-order single compartment model, which considers all airways and pulmonary 
structures as a unique compartment; and (ii) the complex constant-phase model, which differentiates 
pulmonary mechanics parameters from peripheral and central structures (217, 218). The single 
compartment model, based on a simple-wave perturbation called “snap-shot”, is the one commonly 
used for general pulmonary function purposes. The main variable obtained is lung resistance (RL), 
which reflects the global lung resistance comprising airway (Raw) and tissue (Rti) resistance (210, 
219). RL measurements upon airway challenge with increasing MCh doses, allows us to evaluate 
airway hyperresponsiveness in these rodent models. Airway hyperresponsiveness to MCh is 
reflected as a peak-like progressive increase in RL.  
 
2. ALLERGIC RHINITIS 
2.1. General aspects 
Allergic rhinitis is an inflammatory disease that affects the nasal mucosa and is caused by an 
IgE-mediated hypersensitivity, which is triggered by sensitization and subsequent allergen exposure 
(220). After allergen exposure, a transient episode of itching and sneezing begins within seconds 
and wanes 5 to 30 minutes later (221). This early phase is driven by basophils and mast cells that 
release pre-formed mediators (such us histamine, tryptase, leukotrienes, and platelet activating 
factor). A secondary phase of rhinorrhea and obstruction begins minutes later and can last for hours. 
This late phase is mainly driven by prostaglandins, interleukins and chemoattractants that elicit the 
recruitment of eosinophils and neutrophils into the nasal tissue. The diagnosis of allergic rhinitis is 
based on its clinical manifestations. Symptoms include pruritus, nasal congestion and irritation, 
rhinorrea and sneezing, and can be accompanied by tearing. The diagnosis is further supported by a 
positive skin prick test, or by the detection of serum specific IgE antibody to aeroallergens 
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(radioallergosorbent test, RAST). Rhinitic symptoms are variable and all these symptoms are not 
necessarily present in the same patient. The immune system response in allergic rhinitis represents a 
Th2 pattern like asthma. Concerning prevalence, it is estimated that approximately 20% of the 
European population has allergic rhinitis, although the data may be underestimated as many patients 
do not recognize rhinitis as a disease, and therefore do not consult with a physician. Currently, 
allergic rhinitis is considered the most prevalent atopic disease in the world (30). It has increased 
more rapidly than asthma in the last 20 years. Although allergic rhinitis is not a severe disease, it 
alters the social life of the patient (222, 223) and affects work productivity (224). The direct cost of 
treatments plus indirect costs derived from loss of productivity (225) result in a considerable socio-
economic impact.  A study on the prevalence of allergic rhinitis in Western Europe showed that 
approximately 45% of allergic rhinitis patients are not diagnosed (226). Allergen-specific nasal 
provocation testing allows to evaluate the degree of allergen-specific nasal responses in patients 
with rhinoconjunctivitis (207). Like in asthma, eosinophils may traffic through regional lymph 
nodes after antigen exposure (227, 228). Once allergens reach the nasal mucosa of allergic rhinitis 
patients, local antigen presenting cells become activated and migrate to the regional lymph nodes, 
where they activate naive T lymphocytes upon antigen presentation. The antigen-specific T cells 
acquire a Th2 pattern of activation, which drives the allergic response through cytokines such as 
IL9, IL4, IL13 and IL5, specific IgE production by activated B cells, mast cell degranulation and 
further pathways (229, 230).  
2.1.1. Relationship between allergic rhinitis and asthma 
A number of studies highlighted a link between allergic rhinitis and asthma (231), and 
suggested that the airways of asthmatics and allergic rhinitis patients respond to allergens with a 
similar inflammatory pattern (232). Moreover, subepithelial fibrosis was found in the nasal mucosa 
of patients with perennial rhinitis (233, 234), therefore suggesting that pathological tissue 
remodeling occurs in association with chronic inflammation in allergic rhinitis, such as in asthmatic 
bronchi (235, 236). 
Allergic rhinitis and asthma often coexist in the same patient (235) and share similar 
inflammatory patterns (237). Rhinitis and asthma have been suggested to be two manifestation of 
one syndrome within two sections of the respiratory tract, an idea that has led to an ongoing debate 
on an “airway system integration” theory (220, 238-241). Whether such airway unity concept is an 
acceptable model or not from a physiopathology standpoint, epidemiological data have shown an 
association between allergic rhinitis and asthma. Approximately 80% of asthmatics have allergic 
rhinitis (235, 239, 242), whereas 15-40% of allergic rhinitis patients have, or eventually develop, 
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asthma (241). The clinical, pathological and epidemiological evidence of a close relationship 
between allergic rhinitis and asthma led to the development of a series of workshops on Allergic 
Rhinitis and its Impact on Asthma (ARIA) for joint diagnostic and therapeutic strategies (243). 
2.1.2. Relationship between the upper and intrapulmonary airways 
There are several physiologic and anatomical communication systems between the upper and 
lower airways (235, 238): 
-Naso-bronchial interaction. An allergen deposited in the nares can induce bronchospasm. It has 
been proposed that this phenomenon is driven by a nervous network between the nasal cavity and 
the lower airways, in which the trigeminal nerve (cranial par V that collects the sensitivity of the 
nasal mucosa) is the afferent pathway, and the pneumogastric nerve (cranial par X that provides 
cholinergic innervation to the tracheobronchial tree) is the efferent arm (235). 
-Respiratory tract pathway. Inflammatory mediators from nasal secretions may be aspirated into 
the lower airways, especially during the night or patients with depressed consciousness and 
impaired cough reflex (such as mechanically ventilated patients). In this context, IL13 has been 
identified as a “communicator” between the upper and lower airways (54, 55). 
-Circulatory pathway. Systemic dissemination of inflammatory mediators seems the most 
plausible mechanism for the propagation of inflammation between the upper and lower airways. It 
has been proposed that allergic inflammatory responses initiated in the nasal mucosa tend to spread 
systemically. Eosinophilia and leukocyte activation in peripheral blood induced by nasal challenges 
have been described (244-246). 
 
2.2. Rhinitis animal models 
Mizuno et al. established in 1991 one of the first animal models of experimental allergic rhinitis 
in guinea pigs (247). They studied the role of antihistaminic drugs in guinea pigs with induced 
allergic rhinitis. For this purpose, they systemically sensitized animals against OVA and performed 
subsequent challenges to induce a nasal response. They also developed a method to measure 
increases in i.n. pressure during induced allergic rhinitis episodes. Later, Yamasaki et al. established 
a guinea pig allergic rhinitis model using i.n. sensitization and challenge with aerosolized OVA 
(248) to study chemical mediators involved in allergic rhinitis, and Zhao et al. studied in this model 
its similarities with human symptoms (249). Although the model did not reproduce all human 
allergic rhinitis symptoms, it achieved considerable similarities such us early and late responses, 
including late-phase nasal blockage, increased levels of IgE, and eosinophilic infiltration.  These 
authors also introduced the measurement of a respiratory rate as an index to reflect nasal blockage. 
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Recently, Suleimani et al. studied the relationship between nasal airway pressure and lung inflation 
pressure in OVA sensitized and challenged guinea pigs and found no correlation (250), although 
this negative finding may have been due to an excessively short duration of the model.  
Studies on dogs have also been performed. The anatomy and physiology of the canine nasal 
cavity was well characterized (251-253), and several canine models of experimental allergic rhinitis 
have been established (254-257). Models in large animals such as dogs may better represent the 
human disease and have an advantage as the size of the animal allows for invasive techniques that 
are not necessarily terminal, which facilitates re-testing for therapeutic studies. However, the size of 
the animal implies a high cost of maintenance and breeding, and the long life cycle is a 
disadvantage as compared to rodents.  
Rodents represent a valid and useful experimental tool for the study of allergic diseases, 
including allergic rhinitis (221). Compared with rodent asthma models, allergic rhinitis modeling is 
less developed. Few reports are available, which mainly focused on acute inflammation (nasal 
obstruction and inflammatory mediators) and less on airway remodeling and upper-lower airway 
correlation (221, 258, 259).  
 
2.3. The murine nasal cavity  
There are some studies of the nasal cavity in murine models of allergic rhinitis (260-262). 
However, despite the frequent coexistence of allergic rhinitis and asthma in humans, few studies 
analyzed the nasal cavity in murine asthma models (55, 150, 200, 263). Sampling procedures in the 
murine nasal cavity, such as nasal lavage or quantitative morphometry, are technically difficult 
(151), but some data sets have been achieved. In asthma murine models based on i.n. instillation, 
90% antigen deposition in the nasal mucosa has been reported (151, 200). In asthmatics, 
eosinophilic inflammation and basal membrane thickening were observed in the nasal mucosa, 
concomitant with analogue alterations found in bronchial biopsies (233). These data encourage the 
analysis of the upper airway in murine models of experimental asthma. However, there are few 
allergic rhinitis murine models (221, 261, 262, 264, 265), and the even less studies that have 
considered the upper and lower airways together (200, 263). 
In the 1980s, John T. Young established a protocol for the histopathological study of the nasal 
cavity in the rat (266), where four frontal sections were studied, from the upper incisor teeth to the 
last molar (Figure 2). Meticulous anatomical diagrams of the rat and mouse nasal cavity were also 
done (267) to serve as a guide for comparative studies. Based on the similarities between the rat and 
mouse nasal cavity (268), Farraj et al. adapted the study of the rat nasal cavity to a mouse model of 
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allergic airway disease (263). In this work, 
only three sections were set for analysis 
because of the smaller size of the mouse 
skull: a proximal section (just posterior to the 
incisor teeth, comprising the nasal turbinates); 
a middle section (at the level of the incisive 
papilla in the hard palate, comprising the 
paranasal sinuses); and a distal section (at the 
level of the second palatal ridge, comprising 
the etmoidal sinus and nasopharynx). 
The rodent and human nose cavities have 
similar types of epithelia, but with different 
thickness and distribution (221). Interspecies 
variability in the gross anatomy also exist 
(269). The human nose has three 
nasoturbinates (superior, middle and inferior), 
wheras in rodents, evolutionary pressure 
related to olfactory function and dentition 
defined the shape of the turbinates differently. 
Rodents have maxiloturbinates, 
nasoturbinates, and ethmothurbinates, the 
latter forming the ethmoidal sinuses. Also, 
although similar types of epithelium cover the 
nasal cavity in rodents and humans (Figure 3), their distribution is quite different. Approximately 
50% of the nasal cavity is covered by olfactory epithelium in rodents, as opposed to only 3% in 
humans (268). In the mouse, as for humans, an important function of the nasal cavity is to condition 
the air, as it is inspired before entering the lower airways. Such conditioning is mainly aimed at 
humidity and temperature. To hydrate the incoming air, the epithelium of the nasal cavity abounds 
in mucous and serous glands, and goblet cells, which all secrete mucous substances that wet the air 
as it passes through. Regarding temperature control, the nasal cavity is profusely irrigated by 
superficial blood vessels which, together with abundant venous sinuses, draw a large blood flow in 
the proximity of the nasal epithelium and work as a heating system. Similarly to humans, the murine 
nasal cavity is provided with two airflow conducts with protuberances called nasoturbinates and 
Figure 2. Histopathology of the nasal cavity in 
the rat. Ventral view of the rat hard palate, with 
the lower jaw removed. The distribution of four 
tissue sampling blocks (I-IV, stippled areas) to 
be processed for analysis is indicated. The 
numbers on the right indicate the location of the 
seven cuts necessary to produce the four slices. 
A, upper incisor teeth; B, incisive papilla; C, first 
palatal ridge; D, second palatal ridge; E, first 
upper molar tooth; F, nasopharynx. Reproduced 
from Young J.T. Fundam Appl Toxicol 1981; 
1:309-12) 
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maxiloturbinates, which break and slowdown the 
laminar airflow, allowing time to condition the 
air before it enters the lower airways. 
An anterior section section of the nose 
(Figure 4-A) shows the fibro-cartilaginous nasal 
septum, sagittally oriented to separate the main 
nare conducts. The incisor teeth roots, which are 
curved backwards in the mouse, are 
symmetrically placed besides the nasal cavity and 
can be seen as compact dentin matrix structures. 
Laterally, there are two pairs of turbinates, the 
naso-turbinates and maxilo-turbinates, from top 
to bottom respectively. Near the bottom of the 
cavity, adjacent to both sides of the septum, there 
is the vomeronasal organ, typical of vertebrates 
but not developed in humans.   The vomeronasal 
organ is covered by a specialized tissue 
connected to sensorial neurons where particular 
molecules are detected, mainly pheromones. The 
epithelium covering the proximal section of the 
nasal cavity varies depending on the area. At the 
bottom there is non-stratified, non-keratinized 
squamous epithelium (Figure 3-A). Upper in the 
cavity there is a transition to pseudo-stratified, 
ciliated cylindrical respiratory epithelium (Figure 
3-B), provided with a broadly irrigated lamina 
propria. 
In the mid section of the nasal cavity (Figure 
4-B) a narrowing of the air ducts can be 
appreciated. In this section, the maxillary 
paranasal sinuses can be observed as lateral 
cavities communicating with the nares. 
Figure 3. The nasal epithelium in the mouse. 
Different types of epithelium can be found in the 
murine nose depending on its location. In the 
anterior zone, there is non-stratified, not 
keratinized squamous epithelium (A). Deeper 
inside the nares, there are areas with pseudo-
stratified, ciliated cylindrical respiratory 
epithelium (B), comprising basal cells (white 
arrows), goblet cells (black arrows) and 
cylindrical ciliated cells (hollow arrows). Finally, 
the most abundant epithelium, covering the nasal 
cavity is the columnar olfactory epithelium (C). 
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Surrounding the paranasal sinuses, there is a mixed glandular tissue formed by serous and mucous 
glands. In this mid region of the nasal cavity, there is respiratory epithelium covering the bottom 
and middle part of the cavity and sinuses. In the upper part there is a specialized columnar 
epithelium (Figure 3-C), the olfactory epithelium, also profusely irrigated across its lamina propria. 
 
Figure 4. Frontal histological sections of the murine nasal cavity, HE stained. Anterior (A), mid (B) 
and posterior (C) sections are shown. The panels show the dorsal surface of the nose (d), hard palate (p), 
nasal septum (t), maxiloturbinates (m), nasoturbinates (n), dental roots (r), vomeronasal organ (v), 
maxilar (s) and ethmoidal (e) sinuses, and the epipharynx (f). 
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A posterior section of the nasal cavity (Figure 4-C) shows the airway as a restricted opening 
behind the septum, covered by respiratory epithelium, which corresponds to the proximal pharynx 
(homolog to the nasopharynx in humans). The upper part of the posterior nasal section is composed 
of a labyrinth of cavities that form the ethmoidal sinus. The ethmoidal sinus is covered by olfactory 
epithelium. Since this is an area of slow airflow, this provides enough time to allow for olfactory 
particle deposition over the epithelium of the sinusal structure. 
 
3. THE IMMUNE SYSTEM 
The human immune system is a complex and fascinating network of cells, tissues, and organs 
that work in coordination to maintain a “health status” in the body, despite its continuous interaction 
with potentially hazardous particles and microorganisms. As such, the immune system can 
distinguish between self and non-self components (such as molecules, viruses, bacteria, or cells). 
Also, the immune system can identify and eliminate tumor cells by recognising surface antigens 
expressed by uncontrolled proliferating cells (270-273). All such functions have been acquired and 
improved for over millions of years of evolution and have made the immune system essential for the 
survival of individuals and populations. 
 
3.1. Immune cells 
Virtually all external particles that reach any part of the body interact with some component of 
the immune system. First of all, the innate immune system includes all surface, mechanical, and 
mucosal barriers that cover all the surfaces that are in contact with the external environment. Such 
barriers also comprise resident cells with phagocytic capacity, which mainly belong to the myeloid 
lineage (Figure 5). These cells are monocytes, granulocytes, mast cells and dendritic cells. 
Monocytes originate in bone marrow from monoblasts (which in turn derive from a myeloid 
progenitor) and circulate in the bloodstream throughout the body. After 24h, monocytes migrate 
from the bloodstream to tissues where they will differentiate into resident macrophages. The main 
monocyte/macrophage function is phagocytosis, by which they engulf and destroy pathogens (such 
as microorganisms), whole cells or cell detritus (from self or non-self origin), and other substances. 
For instance, alveolar macrophages perform an intense cleaning job inside the pulmonary alveoli, 
where they attempt to phagocyte and destroy all external particulate substances that are inhaled 
from the outside and are potentially harmful. Macrophages also play an important role in 
inflammation, where they can trigger inflammatory responses by secreting cytokines upon the initial 
contact with pathogens. Conversely, macrophages can also modulate or switch off inflammation and 
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induce reparation (274-277). Another important function of macrophages is that they can also act as 
antigen presenting cells, and participate in hemostasis through the production of substances that 
participate in coagulation (278) and fibrinolysis (279). 
The granulocytes are leukocytes characterized by densely stained granules in their cytoplasm. 
The granules store different substances depending on the type of granulocyte. Neutrophilic granules, 
which define the neutrophils, serve as a reservoir for digestive and hydrolytic enzymes, prior to their 
delivery into the phagosome (274). The main role of neutrophils in immunity is to take up 
microorganisms by phagocytosis and destroy them via intracellular vesicles using hydrolytic 
enzymes contained within the granules. Neutrophils are abundant in the blood but not normally in 
healthy tissues. They are short lived and usually die soon after phagocytosis.  Eosinophils and 
basophils, containing eosinophilic and basophilic granules respectively, are involved in the response 
against parasites, which are too large to be ingested by macrophages or neutrophils. Eosinophils 
contain a range of toxic proteins and inflammatory mediators in their granules. They have two 
effector functions. First, upon activation they release granules containing highly toxic substances to 
kill microorganisms and parasites. Second, their activation induces the synthesis of chemical 
mediators that amplify the inflammatory response by recruiting and activating more eosinophils and 
other leukocytes (280). Upon activation, basophils release histamine contained in the basophilic 
granules. They are also present at the site of inflammation, require growth factors similar to 
eosinophils, and exert similar functions. In fact, eosinophil degranulation triggers in turn basophil 
and mast cell degranulation (281). 
Mast cells protect the internal body surfaces against pathogens and are involved in the response 
against parasitic worms. They underlay the body surfaces and alert the immune system of local 
invasion by microorganisms. Once activated, mast cells release prostaglandins, leukotrienes, and 
cytokines contained in their basophilic granules, initiating an immune response against parasitic 
worms and triggering an inflammatory cascade that is amplified by the recruitment of several cell 
types, including eosinophils, basophils and Th2 lymphocytes (282). When a response is 
inappropriately triggered, mast cells get directly implicated in the early and late-phase allergic 
reactions. Even in this context, mast cells can exert a dual role depending of the level of stimulation. 
Low allergen concentration results in low receptor occupancy, providing a strong signal that leads to 
allergic inflammation. On the contrary, a high allergen concentration can induce the production of 
immunoregulatory cytokines (283). 
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In vertebrates, when a novel antigen or pathogen interacts with the body, an adaptive immune 
response follows the innate immune response. The adaptive immune response is much more 
complex since it provides specific antigen recognition and memory, and therefore takes a longer 
time to be achieved. However, once developed, the immune response to subsequent challenges by 
the same antigen will be much faster and effective. The adaptive immune response is an 
evolutionary improvement only met by vertebrates, involves most lymphoid cells, and requires the 
cooperation of myeloid cells.  
Dendritic cells, discovered and initially described in 1973 by Nobel Price awardee Ralph M. 
Steinman (284), represent the link between the innate and adaptive responses of the immune system 
(285, 286). For this reason, dendritic cells are a current research hot topic. Functionally, two types 
of dendritic cells have been described. Plasmacitoid dendritic cells are characterized by specific 
receptors like Gr-1 and B220, are present in the lungs and seem pivotal in the maintenance of 
tolerance to innocuous inhaled antigens. The other subtype is myeloid dendritic cells, which appear 
to participate in allergic sensitization (287). From the standpoint of their differentiation and 
localization in tissues, dendritic cells comprise a wide variety of cells from different haematopoietic 
origins (288, 289), with the common characteristic of working as antigen presenting cells. They 
home blood, lymphoid, and non-lymphoid tissues and recognize pathogen-associated molecular 
patterns of microbial products (Toll-like receptors, mannose-like receptors, inflammatory 
compounds released by damaged tissues, etc.). Upon phagocytosis of a pathogen, the dendritic cell 
acquires a mature phenotype, activates its antigen-presenting machinery, loses the phagocytic 
capacity, and increases the expression of class-II major hystocompatibility complex (MHC-II). 
Mature dendritic cells migrate through the afferent lymphatic vessels to the T-cell area of local 
draining lymph nodes. There, they select antigen-specific T cells and induce their activation and 
differentiation into effector T cells (primary immune response). Dendritic cells can even transfer 
their MHC-II receptors with bound peptide to effector immune cells through a process called 
trogocytosis, which may be a mechanism of amplification of the immune response (290). 
The common bone marrow lymphoid progenitor gives rise to two lineages: natural killer (NK) 
cells and lymphocytes. The NK cells circulate in the blood and have cytoplasmic granules and 
invariant membrane receptors (which make NK cells be considered part of the innate immune 
response). The invariant membrane receptors allow NK cells to recognise molecular patterns present 
on microorganisms and harmful cells (such as cells infected by viruses or intracellular pathogens, 
tumour cells) as well as to distinguish self versus non-self antigens and cells (291). When a NK cell 
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recognizes a cell as infected or harmful, the cytotoxic granules are released onto the surface of the 
target cell, where certain granule proteins induce apoptosis. 
Lymphocytes are divided into B and T lineages. Both are antigen specific responders, and are 
the core of the adaptive immune response. B cells originate in bone marrow, where they begin their 
maturation process with the production of specific antigen receptors. During development, each B 
cell undergoes a process of somatic DNA recombination called gene rearrangement (292-294), 
which results in the expression of a B cell receptor (BCR) onto the cell surface. All the BCRs of a 
particular B cell clone are identical and recognize a specific antigen epitope. Once gene 
rearrangement is successfully achieved, B cells are released into the blood as immature B cells and 
are recruited by secondary lymphoid organs. The production of antigen receptors is then completed 
and the cells become mature naive B cells. When a naive B cells meets its specific antigen through 
the BCR, it interacts with a helper T cell and becomes an activated B cell. Clonal expansion and 
immunoglobulin class switch ensue, which then leads to the development of plasma cells that 
produce a particular immunoglobulin class and the resulting soluble antibodies (295, 296).  
Since the research work presented in this thesis was mostly focused on T cells, a more in-depth 
account of T cell development and function is presented on the following section. 
3.1.1. Development of T cells in the thymus 
The bone marrow microenvironment provides all the necessary signals for lymphocyte survival 
and differentiation into B and T cell lineages from the common lymphoid progenitor. These signals 
are mainly provided by stromal cells, which is a network of specialized non-lymphoid connective 
tissues that form specific contacts with immature lymphocytes by interacting through cell adhesion 
molecules and their ligands. Stromal cells also provide soluble and membrane-bound cytokines and 
chemokines that control the proliferation and maturation of B lymphocytes. The most important 
factor for T cell survival and development in the bone marrow is the IL7 cytokine, produced by the 
stromal cells (297). IL7 induces upregulation of IL7 receptor (IL7R) on early lymphoid progenitors, 
promoting the rearrangement of immunoglobulin heavy chain genes in B-cell progenitors (298) and 
favouring the survival of T-cell precursors that migrate to the thymus (Figure 6). 
In the thymus, there are also early T cell populations, named Pro-T cells, which neither express 
the specific T-cell receptor (TCR, analogue to the BCR) nor other markers of T cell maturation (like 
CD4 or CD8) (299). These Pro-T cell populations, also named double negative (DN) thymocytes, 
are specifically triggered to proliferate and become thymocytes committed with the T cell lineage 
through interactions with the thymic stroma. DN cells are divided into four stages depending on the 
expression of Kit (stem-cell factor receptor, essential for B-lineage differentiation), CD25 (the IL2 
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receptor α-chain), CD44 (a general leucocyte and erythrocyte marker) (300-302), and also other 
markers such as CD3, CD4 and CD8. At DN1 stage, thymocytes still express Kit and CD44. In 
these early maturation steps, as for B cell development and early T cell stages in the bone marrow, 
IL7 is essential for T cell survival. Kit signalling is also important for the achievement of DN 
lymphocytes. As soon as thymocytes mature and evolve to the DN2 stage, they express CD25, and 
rearrangement of the T-cell receptor β-chain locus occurs. As the cells progress into the DN3 stage, 
they reduce CD44 and Kit expression. If the gene rearrangement is successful, DN3 thymocytes 
express a surrogate pre-T-cell receptor called pTα, which attaches to CD3 on the cell membrane to 
form the pre-T-cell receptor (pre-TCR). These cells lose their CD25 expression and begin 
Figure 6. Development of T cells.T lymphocytes originate in the the bone marrow from a common 
lymphoid progenitor. They subsequently migrate to the thymus, where they undergo positive and 
negative selection and commit to CD4 or CD8 lineages, becoming mature but inactive. Mature naive T 
lymphocytes are then released to the bloodstream and recruited to lymph nodes, where they check for 
specific antigens presented by antigen presenting cells. Once a naive T cells find its specific antigen, it 
becomes activated, proliferates, and migrates to the site of inflammation. 
Immature T 
lymphocyte
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marrow
Thymus
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stream
Naive CD4 T 
lymphocyte 
Naive CD8 T 
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proliferation in the DN4 stage. The formation of pre-TCR is a check point in thymocyte 
development that prevents further rearrangements on the β-chain locus and allows next maturation 
steps to occur. The pre-TCR:CD3 assembly leads to the expression of both CD4 and CD8 on the 
thymocyte membrane. These double positive (DP) thymocytes make up the majority of thymocytes. 
Once DP cells cease proliferation, the α-light chain begins its rearrangement, leading to a TCR and 
DP thymocyte maturation progress. 
3.1.2. CD4/CD8 lineage choice 
CD4 and CD8 are transmembrane proteins with extracellular domains, which work as co-
receptors for invariant MHC-II and MHC-I sites, respectively (Figure 7) (303, 304). As such 
interaction promotes and stabilizes the TCR:MHC engagement. The CD4 and CD8 intracellular 
domains associate with tyrosine kinases and initiate the TCR signal transduction when enzimatically 
activated (305). DP thymocytes have a lifespan of approximately 3 days, and are unique among T-
lineage cells in that they do not express IL7R (they are refractory to IL7) nor most receptors for 
other pro-survival cytokines (306). As a result, DP thymocytes only survive if rescued from 
apoptosis through the recognition and engagement to self-peptide:self-MHC complexes born by 
thymus stromal cells, by a process known as “positive selection”. After the positive selection, such 
thymocytes will again express IL7R and other survival receptors (306).  
CD4/CD8 lineage selection is presently explained by the kinetic signalling model (307). In this 
model, DP thymocytes terminate Cd8 but not Cd4 transcription during positive selection (308), 
expressing steadily diminishing amounts of cell-surface CD8. These intermediate thymocytes 
appear phenotypically as CD4+CD8low cells, yet remain as lineage-uncommitted cells (308). If TCR-
mediated positive selection signals persist in the presence of the progressive absence of membrane 
CD8, thymocytes differentiate into CD4+T cells. If TCR-mediated positive selection signalling 
ceases in the absence of Cd8 transcription, then thymocytes differentiate into CD8+T cells (309), 
with the subsequent loss of CD4 expression and re-expression of CD8. In summary, CD4+T cell 
differentiation is TCR signal dependent, whereas, if TCR signalling is disrupted, IL7R signals 
initiate Cd8 transcriptiption leading to CD8+T cell differentiation (307). In fact, in vitro blockade of 
IL7R selectively abrogates the generation of CD8+T cells (310), and the deletion of GF11 (a 
negative regulator of IL7R expression) selectively increases CD8+T cell differentiation (311). 
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 Negative selection 
Parallel to the positive selection process in the thymus, there is a lymphocyte maturation stage 
involving the depletion of those thymocytes that strongly recognize self-peptide:self-MHC (312). 
Although the exact mechanism of the distinction between self versus foreign antigens is not 
completely understood, it seems that the signaling weakness and/or the strength of the 
TCR:antigen:MHC complex account for turning the thymocyte into an apoptosis or survival fate 
(313). Therefore, while a strong TCR affinity of immature T cells for ligands presented in the 
thymus results in apoptosis, the weak interaction between TCR and self-peptide:self-MHC can 
induce survival and maturation. A similar process also occurs in the bone marrow through antigen 
presenting cells (313). Negative selection taking place in the bone marrow or thymus is termed 
central self tolerance, whereas if the selection occurs in secondary lymphoid organs, it is known as 
secondary self tolerance. During TCR and BCR gene rearrangement, immature lymphocyes bearing 
receptors that bind to self antigens are induced to die or become anergic, a process known as “clonal 
CELL
CD8+ Tcell
CD8
TCR
CD3 CD3
MHCI
APC
CD4+ Tcell
CD4
TCR
CD3 CD3
MHCII
Figure 7. TCR:MHC interaction. A naive CD4+ T cell interacts with an antigen presenting cell, 
through a MHC-II  dimer loaded with a peptide from the processed antigen (A). The MHC-II receptor 
interacts with the TCR, and the CD4 extracellular domain stabilizes the interaction, promoting 
activation of cytoplasmic kinase signalling in the T cell. All cells in tissues are susceptible to be killed 
by cytotoxic CD8+ T cells, which recognize antigens presented on MHC-I molecules (B). In this case, 
the CD8 extracellular domain stabilizes the interaction in a similar way as the antigen presenting 
cell:CD4+T cell interaction. 
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deletion”, aimed at making lymphocytes unable to respond against self antigens. Such selection 
processes maintain a tolerance status against self antigens, and were demonstrated in the 1980s and 
1990s (314-316). However, a question arises on how thymus stromal cells, or other cells in 
secondary lymphoid organs, express antigens from the whole body including tissue-specific 
antigens. This seems controlled by a gene called autoimmune regulator (AIRE) (317), involved in 
enabling the thymus to own a “self antigen database” to test interactions between TCRs of immature 
thymocytes and self-antigens. 
3.1.3. Minority lymphocyte subsets 
TCRs are dimers formed by pairing α, β, γ or δ chains. Although the vast majority of T cells 
bear α:β TCRs, there is a minor population of T cells bearing γ:δ TCRs that differ in the types of 
antigens that are able to recognize, and in the pattern of receptors expressed. Such TCRγδ T cells 
are delivered to the periphery and usually reside within epithelia. T cells with γ:δ or α:β TCRs share 
a common progenitor; in fact, TCRγδ T cells diverge from TCRαβ T cells at the DN1 stage. The 
compromise between both subsets is not yet fully understood, but it seems that the strength of the 
TCR signal, together with Notch signaling, is critical in the following steps of T cell maturation 
(318). The Notch signaling pathway is a cell signaling system present in most pluricellular 
organisms (319) and implicated in lymphocyte development (320, 321). In fact, in humans, an early 
decrease in NOTCH activation results in TCRγδ T cell lineage differentiation, while sustained 
signalling from the DN1 stage results in a TCRαβ phenotype (322). In contrast with TCRαβ T cells, 
TCRγδ T cells display a TCR repertoire of limited diversity (γ:δ TCRs result from few DNA 
rearrangements) and recognize antigens through CD1 receptors (a subtype of MHC-I that mainly 
recognizes lipids) (323). Because their TCRs are relatively invariant, and respond effectively 
without clonal expansion, TCRγδ T cells belong to a subclass of lymphocytes called innate-like 
lymphocytes (ILLs). However, recombination activating gene (RAG)-1 and RAG-2 recombinases 
are necessary for the gene rearrangements that lead to γ:δ TCRs, and therefore TCRγδ T cells are 
considered cells of the adaptive immune system by definition. 
Another subset of ILLs is the NKT cells (324). These cells derive from immature DN 
thymocytes (325), bear α:β TCRs of limited diversity, and usually express an NK1.1 receptor (326), 
commonly found on NK cells (327). There is a subset of NKT cells that also express the CD4 
receptor (328). The NKT cells play an important role in both innate and adaptive immune responses 
by recognizing specific glycolipid antigens, presented by CD1, and by their rapid secretion of 
cytokines like IL4, IL10 and IFNG (329). NKT cells are believed to be involved in inflammation, 
and in polarizing Th1/Th2 and antitumour responses. 
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3.1.4. How naive T cells become activated effector T cells 
The activation of a naive T cell by an antigen is a complex process that needs the participation 
of the innate immune system. Antigens reach the body through a mucosal surface or a cut in an 
epithelium. Microorganisms and other pathogens typically bear a repetitive molecular structure 
pattern on their surface proteins. These structures are known as pathogen-associated molecular 
patterns (PAMPs), which signify the presence of non-self for the immune system. Innate immune 
cells recognize PAMPs through receptor families such as macrophage mannose receptors (330), 
scavenger receptors (331), Toll-like receptors (TLRs) (332, 333) and mannal-binding lectins (334). 
The innate immune system cells phagocytize and destroy pathogens that pass trough natural 
barriers, and also produce large amounts of co-stimulatory molecules and cytokines. These in turn 
stimulate the activation of T cells and induce their differentiation into different types of effector 
cells. Antigens or pathogens that pass trough mucosal surfaces are ingested and processed by 
antigen presenting cells, which are mainly tissue-resident dendritic cells that take up antigens and 
became activated. This induces their migration to local lymphoid tissues attracted by chemokines, 
which are produced by the lymph node stroma and high endothelial venules (CCL19, CCL20 and 
CCL21). In the secondary lymphoid tissues, the antigens are presented to naive T cells by the 
antigen presenting cells (335). Alternatively, if antigens reach the blood, antigen processing and 
presentation by antigen presenting cells is carried out in the spleen. 
After T cell maturation occurs in the thymus, naive T cells are released into the blood stream 
and enter the peripheral lymphoid tissues (spleen, lymph nodes, mucosal associated lymphoid 
tissue) through specific adhesion receptors such as selectins, integrins, members of the 
immunoglobulin superfamily, and mucin-like molecules (336, 337). The T cells move through the 
secondary lymphoid organs, scanning, with their specific TCRs, antigen:MHC complexes presented 
by antigen presenting cells. If no recognition occurs, T cells leave the lymphoid tissues and go back 
into the bloodstream to the next organ. Each naive T cell bearing a specific TCR samples thousands 
of antigen:MHC complexes a day on the surface of antigen presenting cells. When a naive T cell 
recognizes its specific antigen on the surface of an antigen presenting cell, it stops migrating and T 
cell activation ensues. A unique, activated naive T cell generates a clone of effector T cells with 
identical antigen specificity, by a process called clonal expansion. Apart from the 
TCR:peptide:MHC interaction, co-stimulatory signals are also required to induce T cell activation 
and clonal expansion (338). B7 is a dimeric, trans-membrane, co-stimulator protein, belonging to 
the immunoglobulin superfamily, and is expressed on activated dendritic cells in the lymph nodes. 
Naive T cells express the B7 counter receptor on their membrane, which is CD28 (also an 
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immunoglobulin superfamily molecule). CD28:B7 ligation provides a survival signal to the T cell, 
necessary to initiate clonal expansion (339), IL2 secretion, and IL2R expression (340). Furthermore, 
cytokines are required to differentiate proliferating T cells towards different types of effector T 
cells, as discussed later. Once proliferation occurred, T cells differentiate into effector T cells and 
do not require any other co-stimulatory signal to act (341). Activated effector T cells leave the 
lymph nodes via the efferent lymph vessels and reach the bloodstream, ready to exit at sites of 
inflammation. If there is a point of infection, the innate immune cells secrete TNFA that induces 
local inflammation. Furthermore, on the surface of the local endothelium, the adhesion molecules 
VCAM1 (CD106) and ICAM1 (CD54) are expressed and recognized by VLA-4 and LFA-1 
respectively on the effector T lymphocytes (342), resulting in effector T cell recruitment. 
3.1.5. Main and minor T cell subsets 
As mentioned above, naive T cells fall into two large groups. The first bears CD8 co-receptor 
on their surface and the other CD4. Almost all CD8 T cells differentiate into CD8 cytotoxic (CT) T 
cells. CT cells recognize foreign antigens attached to MHC-I molecules and kill cells that present 
such antigens, by direct contact or by releasing cytokines (343) like IFNG, which can block viral 
replication or even lead to the elimination of viruses from infected cells without killing them (344). 
When effector CT cells recognize an antigen on the surface of a target cell, cytotoxic granules 
contained in the cytoplasm are released into the cytoplasm of the target cell by a calcium dependent 
mechanism (345). These cytotoxic granules contain enzymes and proteins such as perforin, 
granzymes and granulysin (346), that trigger apoptosis of target cells (343). 
CD4 T cells differentiate into helper T cells and regulatory T cells, depending on the co-
stimulatory signals that accompany the activation process. Helper and Treg cells differ in function, 
membrane receptors and cytokine secretion patterns. Helper T cells provide essential signals for the 
adaptive immune responses. The T helper (Th)-1 cells activate macrophages to enhance their 
efficiency at killing engulfed pathogens, and stimulate  the production of antibodies against 
extracellular pathogens by producing co-stimulatory signals for antigen-activated B lymphocytes. 
The Th2 cells activate antigen-stimulated B cells to differentiate and produce antibodies, 
particularly of the IgE class, which is involved in the response against parasites. A more recently 
defined subset, the Th17 cells, is involved in the immune response against extracellular bacteria and 
some parasitic worms by inducing a neutrophilic response. There is also a recently described subset, 
Th9 (347, 348), which seems to originate from “reprogrammed” Th2 cells under TGFB influence 
(348) and may be implicated in asthma pathogenesis through IL9 production (349). 
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Treg cells are a heterogeneous group of cells with different developmental origins but with a 
common immunosuppressor role. They act through cell contact and secrete immunoregulatoty 
cytokines to modulate the responses against innocuous antigens that do not warrant a defensive 
immunological response. As such, the main goal of Treg cells is immunological tolerance. There are 
different types of Treg cells depending on their origin. Natural Tregs (nTregs) are generated in the 
thymus and play an essential role in balancing the immune system, and preventing autoimmune 
reactions mediated by self-reactive effector T cells that escape negative selection in the thymus 
(350). Another type, adaptive Tregs (aTregs), appear to develop in the periphery from uncommitted 
naive CD4+ T cells. Adaptive Tregs are a heterogeneous population comprising different subsets, 
defined by their origin and their pattern of secreted cytokines. Examples of aTregs are the so-called 
TR1, TH3 and others. 
3.1.6. Helper T cells 
The differentiation of naive CD4+ T cells into different subsets of effector T cells occurs during 
the progression of an adaptive response, and depends on the stimulatory signals delivered by antigen 
presenting cells and the inflammatory milieu (351) (Figure 8). 
Th1 response 
The differentiation of effector CD4+ T cells into the Th1 and Th2 subsets was first described by 
Mosmann et al. in the 1980’s (352). The Th1/Th2 differentiation is accompanied by extensive 
modifications of the chromatin structure at the loci encoding Th1 and Th2 cytokines (353, 354). The 
Th1 subset is involved in the response against prolonged or chronic infections, when an effector 
response is necessary to eliminate pathogens that can survive inside the phagocitic cells. The Th1 
response activates macrophages and CT T cells, to respond against viruses and other intracellular 
pathogens (such as mycobacteria and some other bacterial and protozoa genera), and also activate B 
cells to produce IgG, to opsonize pathogens and infected cells (355). 
During chronic infection, activated cells such as macrophages, endothelial cells or dendritic 
cells, produce chemokines (CCL3, CCL4 and CCL5) that bind to CCR5 and CCR1 receptors on 
dendritic cells and, along with antigen TCR recognition, stimulate the production of IL12 and IFNG 
(356). IL12 and IFNG (357, 358) stimulate naive T cell differentiation (359) through the JAK-STAT 
intracellular signalling pathway, which in turn induces activation of transducer and activator of 
transcription (STAT)-4 and STAT1 (360). These signal-transducing activators of transcription 
induce Tbet expression, which leads to Th1 cell activation, inhibits Th2 differentiation (361), and 
stimulates the production of IL2 and IFNG (362). 
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There is research interest in the regulation of Th1/Th2 differentiation signals because this was 
the first diversion of the CD4+ T cell-driven immune response to be defined, and and its regulation 
is not yet fully understood.  
 
Th2 response 
The Th2 immune response leads the defense against extracellular pathogens and parasitic 
worms, and is also involved in allergic diseases. Mature CD4+ T cells committed with Th2 effector 
function secrete a cytokine pattern that defines this T cell subset, which includes IL4, IL5, and IL13. 
IL4 is a key cytokine promoting Th2 differentiation from naive T cells and, together with IL13, 
induces B cells to switch to IgE production (363, 364). IL5 is a potent chemoattractant for 
eosinophils (365). 
Pathogen-driven Th2 development is less understood than the Th1 response. The pathways 
linking the innate immunity to the induction of Th2 adaptive responses are under current research, 
and the exact mechanism that initiates Th2 cytokine production is unknown, although some 
Figure 8. Differentiation of CD4 T cells depending on stimulatory signals. After leave thymus, 
CD4+ T cells can differentiate into several phenotypes in peripheral lymphoid organs depending on 
the inflammatory microenvironment. This include effector phenotypes that coordinate an adaptive 
inflammatory response pattern through cytokine secretion; but also several regulatory phenotypes 
that limit and control the immune response triggered by effector phenotypes. 
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investigations have pointed to Notch signalling in this role (366-369). As an alternative explanation 
has been proposed that, if an infection is caused by pathogens that do not trigger Th1 cytokine 
release (IL12, TNFA), small amounts of IL4 produced by some cells in the immune response can 
dominate and induce Th2 differentiation by default. TCR stimulation upon IL4 signalling induces 
expression of the trans-acting T-cell-specific transcription factor GATA3, which plays a central role 
in compromising naive T cells with the Th2 lineage (370, 371). In fact, GATA3 expression is key to 
induce Th2 differentiation (370), and inhibits Th1 activation (372), through a STAT4 inhibition 
mechanism (373). GATA3 can also change the phenotype of committed Th1 cells by a chromatin 
remodeling mechanism (371), and has been shown to be essential for thymocyte maturation at DN3 
(374) and SP (375) stages. GATA3 promotes the opening of chromatin at the IL4 locus during early 
Th2 differentiation (376) and controls the expression of IL5 (377) and IL13 (378) in committed Th2 
cells, but it is not essential for IL4 expression (375). Despite the central role known for GATA3 in 
Th2 activation, another pathway involving STAT5 has been described, which can act in a GATA3-
independent manner (376, 379). STAT5 expression is dependent on IL2 signalling, which can 
induce Th2 differentiation through this mechanism (380, 381). GATA3 and STAT5 may therefore 
collaborate to induce IL4 production, because both transcription factors bind directly to different 
sites of the Il4 locus and modulate its expression in naive CD4 T cells (376). 
Once effector CD4+ T cells are committed towards a Th2 phenotype, clonal expansion is driven 
by an IL4 dependent mechanism. When a TCR of a mature CD4+ T cell recognizes a specific 
antigen in the presence of IL4, it induces proliferation of mature Th2 cells by growth factor 
independent 1 (Gfi1) activation through STAT6 (382). In fact, activation of Stat6 transcription 
upstream of Gfi1 is sufficient to induce proliferation on mature Th2 cells (383). STAT6 can in 
parallel induce GATA3 expression by an unknown mechanism and therefore IL4 secretion (376). 
Thus, the sustained presence of a pathogen may produce an IL4 rich milieu that activates Stat6 
transcription. STAT6 may activate Gfi1 transcription and Th2 prolifferation, and may also induce a 
positive feedback on Gata3 expression, both resulting in a maintained Th2 response in the tissue. 
Th17 response 
Upon encountering a pathogen, dendritic cells usually respond by synthesizing IL6 and TGFB. 
These cytokines together, in the absence of other cytokines such as IL4, IFNG or IL12, induce naive 
CD4+ T cell differentiation into Th17 cells (384, 385), and inhibit Th1 and Th2 differentiation.  
In the mid 1990s, Yao et al. described and characterized IL17 as a novel cytokine produced by 
T cells in response to particular pathogens (386, 387). IL6 and TGFB activate a transcription factor 
called signal Stat3 in mice, which in turn induces the expression of orphan nuclear receptor RORγτ 
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in developing Th17 cells (388, 389). RORγτ induces the transcription of the gene encoding IL17, 
and is a key transcription factor for the differentiation of naive CD4+ T cells into effector Th17 cells 
(390, 391). This effector subset is mainly implicated in the defence of mucosal surfaces, especially 
in the lung, against extracellular pathogens such as Klebsiella pneumoniae (392), Borrelia 
burgdorferi, Mycobacerium tuberculosis (393) or even helminth parasites (394). During infection 
by such pathogens in the lung, Th17 cells produce IL17, which induces granulocyte colony 
stimulating factor (GCSF) expression and granulocyte recruitment to the lung parenchyma (395). 
IL17 stimulates stromal cells in vitro to produce proinflammatory and hematopoietic cytokines (like 
IL6 and IL8), chemokines, and prostaglandin E2 (396), which may play a role in the recruitment of 
neutrophils, and the differentiation of local monocytes into macrophages. GCSF is drawn back to 
the bone marrow to increase the production of neutrophils and macrophages. Work done with 
knock-out animal models, and research on human immunological disorders, has allowed to link the 
failure of the Th-17 response with autoimmune disorders such as encephalitis and arthritis (397), 
and allergic diseases like asthma (398). 
3.1.7. Regulatory T cells 
Already in the 1970s, Gershon et al. realised that there were T cell populations able to confer 
tolerance to recipient animals when transferred from antigen-tolerant donors (399). Immunologists 
described then a cell type with immunomodulatory activity, which mediated tolerance in skin 
allograft experiments, and named this cell type “suppressor T cells” (400). However, the lack of 
specific markers to identify and isolate this subset prevented a clear definition and hampered the 
study of suppressor T cells until more than two decades later. Nevertheless, during that interim 
period some investigators pursued work on the “suppressor T cells”, reporting implication in several 
pathologies and defining in vitro and in vivo characteristics (401-404). Scattered and inconsistent 
results from the latter led to a confusing stage about this cell type, and the term “suppressor T cells” 
consequently dissipated (405). Despite the controversies on immune regulation and the “suppressor 
T cells”, some investigators continued working on poorly defined cell subsets that seemed to 
exerted tolerant properties, but the term “suppressor” was in general avoided (406). In the early 
1990s Sakaguchi et al. demonstrated a T cell subset responsible for restoring thymus-ablated mice 
to a healthy tolerant state (407, 408). In their work, mice suffering from a severe autoimmune 
syndrome after thymectomy could be rescued by adoptive transfer of a CD4+CD25+ T cell 
subpopulation from healthy animals. Subsequent experiments by Thorton et al. demonstrated the 
inhibitory properties of CD4+CD25+ cells on effector T cell activation in vitro (409). Further work 
to characterize this immunoregulatory CD4+CD25+ cell subset followed and, in the 21st century, 
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Hori et al., Fontenot et al. and Khattri et al. demonstrated by independent work (410-412) that the 
forkhead box P3 (FOXP3) transcription factor controled the development of immunoregulatory 
CD4+CD25+ T cells able to inhibit T effector responses against self-antigens. These cells appeared 
to maintain a tolerogenic state of the body to self-antigens. In fact, defects in the FOXP3 gene, 
located in X chromosome, underlie the human syndrome called X-linked neonatal diabetes mellitus, 
enteropathy, and endocrinopathy (IPEX) (413), an autoimmune inflammatory disease caused by an 
uncontrolled activation and expansion of CD4+ T cells (414). Furthermore, a defect in the Foxp3 
locus is also linked with a fatal lymphoproliferative disorder in mice ("Scurfy" phenotype) (415). 
Experiments in mice revealed that glucocorticoid-induced tumour necrosis factor receptor family-
related gene (GITR) is necessary, at least in vitro, for Treg mediated suppression of effector T cells 
(416). However, although FOXP3 is considered a good Treg cell marker in mice, this seems less 
clear in humans (417). Cells without FOXP3 expression that exert regulatory functions (418-420), 
and non-regulatory cells with transient FOXP3 expression, have been recently described (421-423). 
In fact, it has been reported that TCR activation slightly upregulates FOXP3 expression without 
leading to any immunoregulatory functions (424). Although some FOXP3-associated markers such 
as low IL7 receptor expression (CD127LOW) (425) and tumor necrosis factor receptor 2 (TNFR2) 
(426) have been recently described to identify human Treg cells, a key marker remains missing in 
humans. 
Treg cell development and suppression mechanisms 
Treg cells can be described as a heterogeneous group stemming from diverse developmental 
origins that maintains immune homeostasis, prevents autoimmunity and moderates inflammation. 
There are different Treg phenotypes, including a regulatory effector-memory phenotype, 
caracterized by CCR6 expression, which seems to function as a counterbalance to common effector-
memory T cells (427). Also, depending on different MHC-II expression, a spectrum of suppressor 
capacities can be found among the Treg population (428). Therefore, defects in the Treg 
development or function may result in different autoimmune diseases (351, 429, 430).  
The transcription factor FOXP3 seems to be central to immune regulation, and it is expected 
that complex transcription machinery controlling its expression exists. Recent experiments have 
shown epigenetic regulatory mechanisms acting at the Foxp3 locus (431). Upstream the Foxp3 
locus there is an evolutionarily conserved CpG-rich element that works as a Foxp3 expression 
enhancer, and whose demethylation status correlates with the FOXP3 expression level. This T 
regulatory specific demethylated region (TSDR) is demethylated in nTreg cells with stable FOXP3 
expression but remains methylated in FOXP3- T cells (350). However, FOXP3 expression can be 
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achieved independently from the TSDR methylation status. Thereby, TGFB can induce Foxp3 
expression in CD4+CD25- cells in peripheral tissues, but no epigenetic changes are induced in TSDR 
after TGFB stimulation (350). Indeed, it seems that regulatory T cell function, but not lineage 
commitment, requires Foxp3 expression (432). Also, several immunological cell subsets without 
Foxp3 expression have shown regulatory properties in immune responses (433). Nowadays, 40 
years after the first attempts to describe “suppressor” cells, there is still a lack of a molecular marker 
to identify immunoregulatory cells. In fact, it is presently know from experimental approaches that 
immunoregulatory cell subsets do exist, and this field has proven to be more complicated than just a 
regulatory/non-regulatory phenotype issue. Possibly, regulatory properties are not a characteristic of 
just one defined cell type, but an atribute of various cell subsets that can exert a regulatory function 
in a particular tissue environment. Moreover, Treg cells seem to be involved, not only in the 
tolerance to self-antigens or the attenuation of late immune responses, but also in early immune 
responses to local viral infections (434). Conversely, the involvement of Treg cells in the 
maintenance of chronic infection has also been proposed (435). Defects in Treg cells have been 
related to failure in the suppression of anti-tumour responses, contributing to disease progression in 
several types of tumors (435).  
FOXP3+ Treg cells are linked to the immunomodulatory cytokines IL10 and TGFB (436-439). 
Several signals seem to be important for Treg phenotype commitment in nTregs. First, IL2 is 
necessary for T cell growth in the thymus and acts through the IL2 receptor (CD25), also expressed 
in nTregs, which are entirely dependent on paracrine IL2 for survival and growth (440, 441). 
However, IL2 it is not necessary for the regulatory function (442). Second, the interaction between 
B7 and CD28, important as well for lymphocyte survival in the thymus, seems also important for 
controlling autoimmune diseases through a mechanism requiring the expression of cytotoxic T-
Lymphocyte Antigen 4 (CTLA4) (443). CTLA4 is a member of the immunoglobulin superfamily 
that binds to B7, acting as a CD28 homologue, but transmits instead an inhibitory signal on T cell 
activation (444). TCR stimulation in naive T cells stimulates transient expression of CTLA4 (445), 
which may prevent self-reactive pathogenic T cell from acting (446). Foxp3 upregulates CTLA4 
expression (447), which is in turn constitutively expressed on the surface of nTregs (411, 448). 
CTLA4 expression allows nTreg cells to interact with B7 expressed on antigen presenting cells and 
downregulate their ability to activate effector T cells (449) (Figure 9). A third factor that seems 
important for nTreg development is the nature of the interaction between the TCR on lymphocytes 
and the MHC on antigen presenting cells (450), although the pathways inducing gene expression so 
as to confer immunoregulatory properties to Treg cells are still unknown. The Rel-NFKB 
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transduction pathway has been linked to the generation of nTreg cells (451, 452). Isomura et al. 
identified the NFKB pathway transcription factor c-Rel as critical to generate normal amounts of T 
reg cells (453), and this finding was further supported by Visekruna et al. and Deenick et al. (454, 
455). FOXP3 also associates with the nuclear factor of activated T cells (NFAT) to induce a Treg 
phenotype (447), and interacts as well with the transcription factor AML1/Runx1 to inhibit IL2 and 
IFNG production (456). It seems therefore logical that a transcription factor such as FOXP3 would 
stimulate not just one gene but several (457, 458), and thus would regulate parallel pathways, which 
alltogether determine the regulatory phenotype.  
 
Natural Treg cells may also act through contact-independent mechanism, via cytokines. 
Upregulation of Ebi3, a member of the IL12 family that may be a downstream target for FOXP3, 
has been recently observed in FOXP3+ T reg cells (459). EBI3 pairs with IL12alpha in the 
Figure 9. Dual antigen presenting cell:Tcell interaction. (A) Antigen presenting cells present antigen 
to naive T cells through MHCII:TCR interaction which, together with B7:CD28 coestimulation and IL6, 
IL12 and TGFB signalling, triggers T cell activation, differentiation and proliferation to achieve effector 
function. Conversely (B), when nTreg cells interact with antigen presenting cells presenting specific 
antigen, B7:CTLA4 interaction leads to antigen presenting cell inhibition. 
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cytoplasm to form IL35, a cytokine that contributes to the immunoregulatory role of nTreg cells 
(460). IL35 suppresses effector T cell proliferation in vitro (460), induces proliferation of Treg cells 
(461), and may attenuate effector T cells in acute and chronic infections and in autoimmune 
diseases. Treg cells also secrete IL10 and/or TGFB, probably depending on the nature of pathogens 
and tissue environment, to control infections or inflammatory diseases (462, 463). IL10 and TGFB 
are implicated in various disease settings involving Treg cells (463). IL35 is not expressed in all 
human nTreg cells (464), and the exact function and settings in which the suppressor cytokines 
IL35, IL10, and TGFB exert inhibitory roles in Treg cell-mediated regulation remains to be 
clarified.  
Granzymes are serine proteinases that enter target cells and mediate activation of intracellular 
caspases, leading to apoptosis. Granzyme-mediated cytolisis is typically induced by cytotoxic cells, 
such as NK cells and CT lymphocytes. Granzymes are contained in cytoplasmic granules that are 
released into the target cell cytoplasm through perforines. Surprisingly, activated human Treg cells 
express granzymes A and B (465), which would theoretically provide them with a cytotoxic 
potential. In the mouse, granzyme B expression is upregulated in Treg cells and makes them able to 
kill B cells, resulting in the suppression of B cell function (466). Mice deficient in granzyme B have 
reduced Treg suppressive activity in vitro (467). Treg cells can also release adenosine nucleotides 
(468-470), which bind to the adenosine A2A receptor on effector T cells. Activation of the A2A 
receptor inhibits effector T cell function and leads to the generation of adaptive or inducible Tregs 
(iTregs) from effector T cells (471). Another mechanism that the Treg cells use to modulate the 
immune response is to interact directly with dendritic cells. The differential expression of the 
transmembrane glycoprotein neuropilin 1 (NRP1) on Treg cells, which promotes prolonged 
interaction between Tregs and immature dendritic cells (472), provides Treg cells with an advantage 
over naive T cells. Subsequently, Treg cells express lymphocyte-activation gene 3 (LAG3), which is 
a CD4 homologue that binds MHC-II molecules with a very high affinity and blocks dendritic cell 
maturation (473). Treg cells can also interact with dendritic cells through CTLA4 and induce the 
production of immunosuppressive molecules that suppress effector T cells (474, 475). 
From the mechanisms by which Treg cell subsets can act, it is difficult to elucidate whether 
there is a key common pathway, or multiple redundant or non-redundant pathways, to initiate and 
maintain immunological tolerance. Vignali et al. proposed a mechanism of tolerance induction by 
integrating all such mechanisms into a model by which regulatory T cells use one or another 
inhibitory pathway depending on the environmental context (463). However, no experimental 
demonstration has been achieved for this theory to date, and further research is warranted.  
The immune system 
 68
Other regulatory cell subtypes 
The first immunoregulatory cells to be discovered and characterized were nTregs, the 
CD4+CD25+FOXP3+ T cells naturally arising from the thymus. In recent years, different subsets of 
iTregs were described, which differentiate in the secondary lymphoid organs under different 
cytokine and antigen exposure profiles. At present, a variety of FOXP3-expressing and non-
expressing Tregs, arising from different developing origins, have been described. However, 
independently on their origin and characteristics, iTreg cell subsets share common functions: to 
maintain tolerance by suppressing potential effector responses against innocuous antigens and to 
control the normal immune response against infections (Table 1).  
 
Table 1. Main Treg subpopulations and their defining markers 
Treg cells Markers Characteristic mediators 
nTreg CD4+ CD25+ CD103+ FOXP3+ GITR+ CTLA4+ IL10, IL2, IL35, TGFB, IFNG 
Tr1 CD4+ CD25- CD45+ IL10, TGFB 
Th3 CD4+ CD25- FOXP3+ TGFB 
DN Treg CD3+ CD4- CD8- CD25+ CD28- CD30+ CD44- IL4 
CD8+ Treg CD8+ ¿? IFNG, IL6, IL10, TGFB 
NKTreg CD25+ CD103+ CTLA4+ GITR+ NK1.1+ IL2, IL4 
γδTreg TCR γδ IL10, IL2, IFNG , ↑↑TGFB 
 
 
Type 1 regulatory T cells 
In 1994, Groux et al. described a CD4+ T cell subset, similar to Th1, which seemed to suppress 
experimental autoimmune encephalomyelitis in mice through the secretion of IL10 and TGFB 
(476). Latter, in 1997, they described from their findings a regulatory cell subset that was called 
Type 1 regulatory T cells (Tr1). This subset was able to suppress the proliferation of CD4+ T cells 
through the secretion of IL10 and TGFB, and prevented colitis induced in severe combined 
immunodeficiency mouse by pathogenic CD4+CD45+ splecnic T cells (477). The stimulation of 
CD4+T cells in the presence of IL10 generated Tr1 cells, which inhibited antigen-specific immune 
responses and prevented disease in the colitis model. IL10 dependent Tr1 cells have shown in vitro 
and in vivo inhibitory capacities over naive CD4+ T cells in both humans and rodents (478), and 
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share immunosuppressive activities with nTregs (479, 480). Contrary to nTregs, Tr1 cells are 
involved in the regulation of the immune response against foreign antigens. Since Tr1 cells work in 
the absence of FOXP3 expression (480, 481), it must be highlighted that, although FOXP3 plays an 
important and necessary role for nTreg regulatory functions, it is not currently considered a “master 
regulator” for all cells with immunoregulatory capacities. In fact, effector T cells transiently express 
FOXP3, although its role in this case is unknown (481). 
Th3 regulatory cells 
In 2003, contemporarily with the demonstration of the role of FOXP3 in nTregs, Chen et al. 
showed that peripheral CD4+CD25- T cells may become iTreg cells by costimulation through their 
TCR and TGFB (482). Moreover, such cells inhibit specific CD4+ T cell responses in vivo and 
prevent HDM-induced allergic reactions in the lung. This cell subset, which showed an nTreg-like 
immunoregulatory phenotype, was called Th3. Recent experiments have shown that TGFB induces 
transient FOXP3 expression in Th3 cells, but does not modify the methilation status of the TSDR 
upstream Foxp3 locus (350). A parallel mechanism to induce Foxp3 expression independent from 
TSDR methilation, may exist in Th3 cells. Like Tr1 cells, Th3 cells are mainly generated in the gut-
associated lymphoid tissues (GALT) by a process involving dendritic cells and intestinal epithelial 
cells (483, 484). Tolerance induction is the default immune pathway in the gut, and the Th3 and Tr1 
subsets seem responsible for oral tolerance to ingested antigens (485, 486). 
Double negative regulatory T cells 
Double negative regulatory T cells (DN Treg) were first described in 2000 by Zhang et al., who 
reported a novel murine cell subset of CD4-CD8- Treg cells that inhibited CD8+ T cell responses of 
the same TCR specificity (487). DN Treg cells express a characteristic set of surface markers (αβ-
TCR+CD3+CD4-CD8-CD25+CD28-CD30+CD44-) and, contrary to other regulatory subsets, do not 
produce IL10, IL2, IL4 or IL13 (487) nor FOXP3 (488). These cells induce apoptosis on CD8+ T 
cells of the same TCR specificity requiring direct intercellular contact (489, 490). DN T cells 
account for 1-5% of peripheral αβTCR+CD3+ T cells (491, 492). Contrary to nTregs and similar to 
iTregs, DN Treg cells have extrathymic development. Early thymectomy does not abrogate their 
development nor suppressive function in peripheral lymphoid tissues (491). DN Tregs can 
differentiate in vitro (493), where TCR stimulation plus exogenous IL2 and IL4 are required for 
their expansion (491). Therefore, DN Treg cells need TCR stimulation to exert their regulatory 
function (487, 488). During their activation, DN Treg cells uptake MHC-peptide complexes from 
antigen presenting cells, in an antigen-specific manner via their TCR. Then, the acquired MHC-
peptide complexes interact with the TCR of target CD8+ cells (487). 
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DN Treg cells are implicated in allo- and xenograft transplantation tolerance (494) and mediate 
the inhibition of graft-versus-host disease in mice (495). The analysis DN Treg cell homing 
receptors revealed that CXCR5 expression is important for their homing to transplanted heart grafts 
(496). DN Treg cells can also suppress syngeneic CD4+ T cells through inhibition of IL2 production 
(497), and have the ability to kill allogeneic lymphoma cells (498), inhibit autoimmune disease 
(499) and lyse B lymphocytes (490). There is therefore current interest on the potential use of DN 
Treg cells to inhibit clonal expansion of allo- and xenograft T cells after transplantation (500-502), 
and other potential applications in the field of immune-mediated diseases.  
CD8+ regulatory T cells 
In the early 1990s, several studies pointed to CD8+ T cells as mediators of tolerance in 
experimental allergic encephalomyelitis (503), and provided evidence that CD8+ T cell regulatory 
subsets (CD8+ Tregs) participate in the regulation of immune responses (504). CD8+ Treg cells are 
involved in oral (505) and neonatal tolerance (506-508), and have been implicated in diverse 
functions of peripheral tolerance and in immune-related diseases (508-510). CD8+ Treg depletion 
abrogates tolerance in vivo, whereas adoptive transfer of CD8+ Treg cells mediates tolerance in 
syngeneic naive rats. A subset of CD8+ T cells was found responsible for increased survival of 
transplanted mice that received repeated feeding with an oral alloantigen (511). The vast majority of 
CD8+ subsets with immunoregulatory activity is primed through the TCR during the immune 
response to foreign or self-antigens (512). 
The CD8+ Treg immunoregulatory mechanism is similar to that seen for nTregs. There is 
inhibition of Th1, Th2 and cytotoxic CD8+ T cells through paracrine IL4, IFNG and IL10 (512), and 
modulation of antigen presenting cells (513). For the latter, CD8+ Treg cells interfere with the CD40 
signalling pathway of the dendritic cells, and this abrogates NFKB activation and dendritic cells 
maturation, resulting in the generation of tolerogenic antigen presenting cells. Subsequently, naive 
CD4+ T cells that interact with tolerogenic dendritic cells became anergic (512). 
A wide spectrum of CD8+ Treg subsets has been reported (512), but their study is hampered by 
the lack of a specific marker. The existence of CD8+ Treg cells and their involvement in immune 
diseases is now undisputed (514), although they represent a minor subset of the CD8+ T cells. It is 
very difficult to isolate CD8+ Treg cells from total CD8+ T cells, and their suppressor abilities are 
masked by the non-Treg majority. Like CD4+ Treg cells, CD8+ Treg cells can be classified into 
naturally occurring or induced. Among the naturally occurring, CD8+CD122+ Treg cells in mice 
(515, 516) and CD8+CXCR3+ in humans (517) can secrete IL10 and inhibit IFNG production. These 
subsets were found work similarly to nTregs: they downregulate IL2Rα chain expression on target T 
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cells through CTLA4 and TGFB1, and make the target cells become unresponsive to IL2 (518). A 
subset of CD8+CD25+ Tregs with FOXP3 expression has been recently described too (519). Induced 
CD8+ Treg cells also exist, including CD8+CD130+ Tregs involved in allograft tolerance (520), 
CD8+CD130+FOXP3+ Tregs expressing GITR and CTLA-4 (521), and CD8+CD25- Tregs able to 
suppress antigen-specific and cytotoxic T cells (522, 523). Mathematical models applied to in vivo 
experiments (524, 525) suggested that CD4+CD25+FOXP3+ T cells depend on interacting with 
CD8+ Tregs to modulate the proliferation of effector T cells (525).  
NKT regulatory cells 
NKT cells have been regarded as effector cells in immune-related diseases such as asthma 
(526), but they have also been shown to provide protection from graft versus host disease via an IL4 
dependent mechanism (527). An interaction between donor Tregs and NKT cells to protect against 
graft versus host disease has been described (528), and a reciprocal regulation has been documented 
where NKT cells modulate Treg function through IL2, and Treg cells suppress NKT cell 
proliferation and activity through direct cell contact (529). A protective role of NKT cells in 
experimental autoimmune encephalomyelitis has also been noted (530, 531), and a novel 
FOXP3+iNKT cell population described (532), which derive from iNKT cells activated in the 
presence of TGFB. Such cells, also identified in humans, show mixed characteristics of nTregs and 
iNKT cells: they express markers from both (CD25, CTLA4, GITR and CD103) and mediate 
suppression of CD4+ effector T cells through GITR (532). Conversion of iNKT cells into 
FOXP3+iNKT cells, and their participation in oral tolerance, was also described in the TGFB-rich 
gut mucosa (532). All together these data lead to the thought that NKT regulatory cells participating 
in oral tolerance may have been misidentified as Th3 cells, in the absence of NKT cell marker 
verification (437, 477).  
γδ T regulatory cells 
γδ T cells have been linked to epithelial regeneration (533) and seem to exert a regulatory 
function (534). Depletion of, or deficiency in γδ T cells, aggravate inflammation in bowel 
inflammatory disease models (535, 536). Kühl et al. found γδ T cells with in vitro regulatory 
capacities similar to those of CD4+CD25+FOXP3+ T cells from human peripheral blood (537). This 
γδ T regulatory subset secretes IL10 and IFNG in amounts similar to nTreg cells, and produces 
greater amounts of TGFB, althought neither IL2 secretion nor FOXP3 expression were detected 
(537). The latter matched previous experiments that failed to upregulate Foxp3 expression in γδ T 
cells upon activation in the presence of TGFB (532). Therefore, γδ T regulatory cells may exert their 
regulatory function through an IL2 independent mechanism, where IL10 secretion may stimulate 
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other T cells to produce TGFB (538), which adds to the TGFB secreted by the γδ Tregs, and 
altogether generates a local immunomodulatory environment. A recent study attributed a regulatory 
role to γδ T cells in certain asthmatic phenotypes (539). However, a new FOXP3+ γδ T cell subset 
with immunomodulatory properties was recently found in mice and humans (540). In this case, their 
development seemed to be TGFB and IL2 dependent (541).  
B regulatory lymphocytes 
At least in mice there is a B cell subset, activated through BCR, CD40 and/or TLR9, that exerts 
a regulatory function similar to Treg cells and is involved in shaping effector T cell responses (542, 
543). The B regulatory (Breg) cells inhibit effector T cell responses through IL10, TGFB, or direct 
contact (544). Among Breg subsets, B10 lymphocytes (545, 546) and CD1dhiCD5+ lymphocytes 
(547) are able to produce IL10. Recently, cell Ig domain and mucin domain protein 1 (TIM1) 
expression has been reported as new marker for B10 lymphocytes (548). 
Bregs play beneficial roles in diseases such as rheumatoid arthritis, systemic lupus 
erythematosus, inflammatory Bowel disease and experimental allergic encephalomyelitis (549). 
However, other studies have pointed out that Breg cells may be a cause of deterioration in diseases 
such as type 1 diabetes, and rheumatoid and collagen-induced arthritis (550-552).  
Plasticity in T regulatory cell lineage 
Nowadays, regulatory activity is being regarded as a dynamic phenotype where the notion of 
regulatory T cells as static populations with a committed and stable regulatory activity is getting 
obsolete. Even nTregs are now seen as a dynamic population that depends on tissue environment for 
its regulatory function (430). Different Treg and T effector phenotypes can switch capacities in vivo 
and in vitro depending on the cytokine environment. Regulatory FOXP3+ T cells in an autoimmune 
environment can re-methylate TSDR, lose Foxp3 expression, and became autoagresive by turning 
into Th1 or Th17 effector phenotypes (429).  This is explained by the fact that Treg cells may 
express, together with FOXP3, transcription factors of different T effector phenotypes (IRF4, 
TBET). In a chronic inflammatory environment, these “dualistic” Tregs can lose FOXP3 expression 
and turn into highly aggressive effector T cells that produce inflammatory cytokines and contribute 
to disease progression (199). FOXP3+ Treg cells immersed in an inflammatory context may also 
evolve to memory phenotypes (351). Surprisingly, FOXP3+ regulatory T cells may, under certain 
conditions, produce IL17 while retaining a regulatory phenotype (553, 554), or alternatively evolve 
towards an effector Th17 phenotype depending on IL6 signalling (555). Follicular B-helper T cell 
differentiation from FOXP3+ T cells has also been reported (556). Peripheral naive CD4+CD25- T 
cells can be shifted towards a CD4+CD25+FOXP3+ phenotype through stimulation in the presence 
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of TGFB and absence of IL6 and IL21 (384), or in the presence of IL4 and IL13 (557). The best 
understood mechanism to achieve CD4+CD25+Foxp3+ T cells from peripheral naive CD4+CD25-T 
cells is the TGFB dependent pathway. Inhibitory SMAD7 protein is normally induced by TGFB and 
limits TGFB production. Stimulation of naive CD4+CD25- T cells through their TCR in a TGFB 
rich environment increases TGFB production, which in turn induces Foxp3 transcription. Then 
FOXP3 strongly downregulates Smad7, rendering the naive CD4+CD25- T cells highly susceptible 
to TGFB signalling via SMAD3/4 (558) (Figure 10). Vitamin A inhibits IL6 and induces TGFB 
production, favouring Treg differentiation and inhibiting the Th17 phenotype (559).  
 
3.2. Inflammatory infiltrates and response in asthma 
The lungs, as the organs for gas exchange, play a vital role in the maintenance of homeostatic 
balances. This includes the regulation of pH and CO2 partial pressure, and the supply of O2 for 
tissue oxygenation and aerobic metabolism. But the lungs are also organs with an intense 
immunologic activity, since they enclose our largest surface in contact with the outside (75 m2 
approximately) and ventilate about 15,000 L of air a daily. Moreover, it is estimated that they are 
exposed to more that 7 kg of pollution through the year.  
The study of asthma necessarily implicates a correlation with the immune response, which 
underlies airway chronic inflammation, cardinal in asthma pathogenesis. Among the inflammatory 
cells involved, CD4+ T cells play a central role in orchestrating chronic inflammation, and may be 
Figure 10. Conversion of naive 
CD4+CD25- T cells into iTreg 
cells in a TGFB rich 
environment. TCR stimulation 
induces TGFB expression, which 
in turn induces SMAD7, that 
limits TGFB production by 
negative feed-back. But in a 
TGFB rich environment, 
SMAD7 is not able to 
downregulate paracrine TGFB 
production, and the increase in 
the intracellular amount of 
TGFB induces Foxp3 
transcription. FOXP3 strongly 
downregulates Smad7 and 
renders the cell sensitive to 
TGFB signalling through the 
SMAD3/SMAD4 pathway.  
Smad7
TGFβ
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Smad4
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production
+
Antigen
TCR
The immune system 
 74
directly implicated in the mechanism of airway remodeling (133, 560, 561). To trigger an adaptive 
immune response, CD4+ T cell activation by antigen presenting cells is required. Dendritic cells, the 
main antigen presenting cells, form a network underlying the basement membrane of the respiratory 
epithelium, which is an optimal location to capture and scan inhaled airborne antigens. Dendritic 
cell density is higher in the upper airway (600-800 cells/mm2) and decreases towards the 
intrapulmonary airways, where it reaches approximately 75 cells/mm2 in most peripheral airways 
(562). Macromolecules that do not cross the tight-junction barrier formed by respiratory epithelial 
cells are captured and processed by dendritic cells. The dendritic cells then evolve to a mature 
phenotype and migrate to the peribronchial, hilar and mediastinal lymph nodes, and probably to 
non-encapsulated lymphoid tissue as well, called bronchial associated lymphoid tissue (BALT). In 
these locations, the dendritic cells present peptides from processed antigens to naive CD4+T cells, 
which in turn get activated with a Th2 phenotype (563). 
Innocuous antigens do not usually elicit a defensive immune response, but induce antigen-
specific tolerance instead. In asthma, conversely, CD4+ T cells are activated into a Th2 phenotype, 
secrete IL4, IL5, and IL13, and inducing IgE synthesis by activated B-cells, eosinophil recruitment 
and mucus production. Through IL9, Th2 cells also enhance mast-cell activity and further stimulate 
the Th2 response (564, 565). All these Th2 pro-inflammatory cytokines map to the long arm of 
chromosome 5 in humans (566), and polymorphisms in this region are linked to the development of 
atopy and airway hyperresponsiveness (567).  
Eosinophils are a major component of the inflammatory infiltrates in asthma (32, 154). 
Eosinophils are recruited by Th2 cells through secretion of IL4, IL5 and IL13, and are important 
producers of the fibrogenic cytokine IL13 (568). IL13 plays an important role in airway remodeling. 
Its expression is increased in the lungs of asthmatic individuals with airway remodeling (569) and in 
murine models of experimental asthma (570). This cytokine is also implicated in the development of 
pulmonary fibrosis (571) and mucus hypersecretion (572). 
Aside from typical Th2 driven inflammation, asthma may also present with neutrophilic 
inflammation, usually corticosteroid-refractory. In this context, Th1 and Th17 responses emerge and 
lead to IFNG and IL17 secretion respectively, and neutrophil recruitment to the airways. This form 
of asthma presentation may also combine with a Th2 response (573). Highly activated Th17 cells 
were found in bronchial biopsies of patients with asthma, and the increased levels of IL17 mRNA 
correlated with neutrophil numbers (574, 575). In turn, neutrophils may attract eosinophils to the 
focus of inflammation and cause their degranulation (576). Recently, a new helper T cell subtype 
called Th17/Th2 has been described, which secretes IL17, IL4, IL5 and IL13 (577). It has been 
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suggested, in mouse models of allergic asthma, that lung recruitment of Th1 cells is a prerequisite 
for Th2 cell recruitment (578). It is also known that, conversely, Th1 cells counteract Th2 cell-
mediated responses. Adoptive transfer of OVA specific Th1 cells reverses Th2-derived IL4 
production, BAL eosinophilia, and airway hyperresponsiveness in a mouse model of experimental 
asthma (579), although opposite results have also been reported (580). In fact, IFNG production has 
been shown to aggravate inflammatory events in asthma (581). Therefore, the role of Th1 cells in 
asthma is not clear overall. 
iNKT cells also play a role in asthma, thought to be relevant but still uncertain. iNKT cells were 
shown to be essential for the induction of Th2 allergic responses, airway inflammation and airway 
hyperresponsiveness in mouse models of experimental asthma (582-584). Moreover, infiltrating 
iNKT cells were also described in the bronchial mucosa of asthmatic patients (585, 586). 
After the identification of FOXP3 as the first Treg cell marker in 2003 (411), an involvement of 
Treg cells in immune mediated diseases, including asthma, has been suspected. IL6 receptor 
blockade leads to CD4+CD25+ T cell expansion and may impair Th17 differentiation (555), and 
suppress airway inflammation (587). Treg involvement in asthma was also suspected from the 
clinical standpoint because it was noted that glucocorticoids induce FOXP3 expression and 
suppressive effects in the BAL of treated patients (588). Also, mutations in the FOXP3 locus in 
humans and mice (Foxp3) leads to immunodysregulation polyendocrinopathy enteropathy X-linked 
syndrome (IPEX) and Scurfy syndromes, respectively (589). IPEX syndrome presents with 
increased serum IgE, eczema and eosinophilia, also present in allergic diseases, whereas the Scurfy 
phenotype is associated with a fatal lymphoproliferative disorder in mice. Studies in murine models 
showed that Treg cells are involved in the mechanisms of tolerance induction (590, 591) and, in 
experimental asthma, exogenous Treg cells appear to modulate asthma symptoms (592-594).  
Regardless the extensive knowledge gained during recent years on immunoregulatory pathways 
and Treg cells, little evidence has been built on their role in asthma. Asthma disease mechanisms 
have been largely studied on experimental asthma models induced by i.p. sensitization in the 
presence of adjuvants, followed by airway antigen challenges. Although this approach reproduces 
most asthma features, it does not reflect the way in which humans acquire allergic disease to 
airborne antigens, and related rhinitis or asthma. Since mucosal contact with the antigen may be 
essential for the innate immune system to operate, and interactions at this level may determine the 
subsequent immune response, i.p. sensitization-based models may skip steps relevant to asthma 
pathophysiology. Thus, animal models based on primary airway antigen exposure in the absence of 
"vaccine-like" sensitization may more closely reflect how allergic asthma develops, and may 
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involve immunoregulatory pathways othewise by-passed in the classical i.p. sensitization models. In 
addition, the upper airway has been largely ignored in asthma studies. According to the current 
airway system integration theory, the upper airway as the primary site of antigen exposure may play 
an important role in the development of lower airway disease and should be considered in the 
models. Therefore, in the work presented in this thesis we aimed at developing an integrated 
rhinitis/asthma model based on primary airway antigen exposure, and apply such model to the study 
of immunoregulatory mechanisms and the plausible involvement of Treg cells in the disease 
mechanisms. Furthermore, to attempt some translation of the experimental data to human asthma, 
we involved clinical research on bronchial biopsies. 
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Hypothesis 
The pathophysiology of asthma may involve both effector and regulatory arms of the immune 
response. Classical experimental asthma models based on i.p. sensitization followed by airway 
challenge may not fully reflect the immune response involved in actual asthma, where humans are 
sensitized to airborne allergens through primary exposure in the airways. The development of 
experimental models based on primary airway antigen exposure, and the integrated analysis of the 
upper and intrapulmonary airways in such models, may unveil immunoregulatory mechanisms 
relevant to the disease.  
 
Objectives 
1. To develop a murine asthma model induced by primary airway antigen exposure through i.n. 
instillation of antigen or control, referenced to a classical i.p. sensitization model. 
a. To analyze airway hyperresponsiveness as a primary in vivo outcome, and profile its 
development and evolution through a time series of experiments.  
b. To analyze other experimental asthma outcomes including airway inflammation, goblet 
cell hyperplasia, mucus production, subepithelial fibrosis and airway contractile tissue 
mass. 
c. To analyze the presence and function of Treg cells as per Foxp3, Il10 and Tgfb 
expression. 
d. To develop an allergic rhinitis model for the integrated analysis of events in the upper 
and intrapulmonary airways.  
2. To generate antigen-specific Treg cells, traceable in vivo, by means of retroviral transduction 
inducing co-expression of Foxp3 and gfp. 
a. To construct a gene transfer vector suitable for the retroviral transduction goal. 
b. To demonstrate the effects of adoptively transferred, antigen-specific Treg cells, versus 
effector CD4+ T cells, on experimental asthma. 
c. To titrate the minimum effective number of effector CD4+ T cells, to induce experimental 
asthma on adoptive transfer.  
3. To obtain evidence on the presence of Treg cells in the airway wall of human asthmatics, by 
means of bronchial biopsy analysis. 
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1. Animals 
All study protocols were approved by the Comité Ético de Experimentación Animal, Xunta de 
Galicia, in accordance with European Union Directive 86/609 and Royal Decree 1201/2005 of 
Spain. 
Female BALB/c mice (Mus musculus) were purchased from Harlan Interfauna Ibérica, S.L. 
(Barcelona, Spain) and maintained at the Unidad de Cirugía Experimental (UCEX) of the Instituto 
de Investigación Biomédica de A Coruña (INIBIC). Animals were transported in approved cages 
(JAX® Mice Shipping Container, The Jackson Laboratory) with available food, and water supply by 
means of gelatinous wet packs. Upon arrival, the animals were inspected and then distributed in 
groups of 2-3 animals into cages made of polycarbonate macrolon. The cages had a cleft for a 400-
mL water feeding bottle and had top covers provided with polycarbonate filters (Ebeco, E. Becker 
& Co. GmbH, Germany). The cages were placed in a ventilated stainless steel rack (MIKROS-AS-
D 48-2L), with a double positive/negative-pressure filtration system (Ebeco, E. Becker & Co. 
GmbH). The animals were housed under controlled conditions, including periodic air changes (15-
20 changes per hour), temperature and humidity within a constant range (21-24ºC and 40-55% 
respectively), and a 12/12-hour light/dark cycle. Following a 7-day adaptation period after arrival, 
the animals were redistributed into groups of 4 to 5 mice and were fed ad libitum with water and 
Teklad Global maintenance feed, egg protein-free (Harlan Interfauna Ibérica, S.L., Barcelona). The 
mice were aged 6 to 12 weeks when entered in the experiments. 
 
2. Study design 
We developed protocols based on i.p. sensitization or, alternatively, direct primary allergen 
exposure in the airways through i.n. challenge, with the aim of establishing experimental asthma 
models that would allow us to investigate inmunoregulatory pathways. These models stemmed from 
prior reports (150, 164, 200, 595) and previous own experiece on Brown Norway rats (133). 
OVA or HDM were employed as allergens. Each model consisted of two groups: a control 
group challenged with PBS and an active disease group challenged with allergen. The immune 
response was induced by active sensitization or by adoptive transfer of T cells from donor animals. 
Mouse batches were assigned to the experimental groups through consecutive random sampling.  
Four models of active sensitization, using OVA as an allergen, were developed with n=10 
animals per experimental condition (Figure 11). Three of these models were based on direct primary 
allergen exposure in the airways: (i) short IN model (referred to as 3IN model here forth) consisting 
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of 3 i.n. instillations; (ii) long IN model (10IN model) consisting of 10 i.n. instillations; and (iii) 
extended IN model (30IN model), with 30 i.n. instillations. The fourth model involved i.p. 
sensitization as per classical asthma modeling (IP model), where the animals were all i.p. sensitized 
to OVA and then challenged with PBS (control group) or OVA. In this latter model, sensitization 
was achieved by means of two i.p. injections separated by one week (days 0 and 7), and the animals 
were then submitted to i.n. challenge starting one week after the second i.p. injection (day 14). For 
all models, i.n. instillations (PBS or OVA) were administered three times per week (Monday, 
Wednesday, and Friday) for a period according to each specific model. 
 
For experiments on adoptive transfer of effector CD4+ T cells, OVA was used for donor 
sensitization, in vitro T cell stimulation prior to transfer, and airway challenge of the recipients. The 
following experimental groups were included: (i) adoptive transfer of naive CD4+T cells from 
unsensitized donors, followed by plus 3 i.n. OVA challenges (n=6); (ii) adoptive transfer of OVA-
Figure 11. OVA models. Four murine models of experimental asthma were developed, with their 
respective controls challenged with PBS. White arrows: i.p. sensitization. Black arrows: i.n. exposure to 
OVA (or PBS in control groups). 
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stimulated CD4+ T cells plus 3 PBS i.n. challenges (n=12); and (iii, iv, v) adoptive transfer of 
25,000 (n=6), 50,000 (n=8) or 100,000 (n=12) stimulated CD4+ T cells, respectively, plus 3 OVA 
i.n. challenges. For airway antigen pre-load and in order to facilitate recruitment of the transferred 
CD4+ T cells to the airways, two i.n. instillations were administered to the recipients prior to cell 
transfer, on the day before and just before cell injection (Figure 12).  
Adoptive transfer was also employed for a pilot experiment on Treg cells, on HDM-challenged 
animals. In this case, two groups of mice were submitted to i.n. instillations (28 instillations in total, 
daily administered Monday through Friday for a 37-day period), and adoptive cell transfer was 
performed on day 31. The groups consisted of HDM-challenged animals receiving 75,000 CD4+ T 
cells with forced expression of Foxp3 (n=4, see section 4 on genetic cell engineering below) or 
HDM- challenged animals receiving i.v. vehicle (n=4) (Figure 12).  
 
 
3. Sensitization and challenge 
For i.p. sensitization to OVA, the animals were lightly anesthetized with 2% sevofluorane 
(Sevorane®, Abbot Laboratories, Madrid, Spain), inhaled in a Plexiglas chamber. On days 0 and 7, 
10 μg of OVA (Sigma-Aldrich, Sant Louis, USA) adsorbed in 50 mg of aluminum hydroxide 
(Imject® Alum, Pierce Laboratories, Rockford, USA) were i.p. injected in a 100-μL PBS volume. 
For all experimets using HDM, the allergen was standardized by Der p 1 content as previously 
Figure 12. Adoptive transfer models. Two adoptive transfer models were designed, to evaluate the 
involvement of effector CD4+ T cells (Teff) and Foxp3+ regulatory T cells in experimental asthma. White 
arrows: i.n. OVA instillations. Black arrows: i.n. HDM instillations. Teff and Treg: time points for 
adoptive transfer of effector and regulatory T cells, respectively. 
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described by Fattouh et al. (596). For i.p. sensitization to HDM, the animals were lightly 
anesthetized as described above for OVA, and 0.12 μg of Der p 1 allergen (1.2 μL of HDM stok) 
adsorbed in 50 mg of aluminium hydroxide (Pierce Laboratories) was i.p. injected in a 100 μL PBS 
volume. 
Intranasal instillations were started on day 14 after first i.p. sensitization (day 0 in non i.p. 
sensitized models) and were administered under light anesthesia as described above. For each 
instillation, 12.5 μL of a 6.66 μg/mL OVA solution in PBS, or PBS alone for controls, was 
deposited per nostril using a micropipette. For HDM instillations, 12.5 μL of PBS containing 1 μg 
of HDM Der p 1 allergen (HDM extract, Greer Inc., Lenoir, USA) was administered per nare.  
 
4. Genetic cell engineering 
T cells for adoptive transfer were genetically modified to induce expression of FOXP3, and/or 
GFP for in vivo tracking, as appropriate. The choice of gene transfer vector was determined by the 
need of achieving strong and permanent transgene expression in antigen- activated T cells as target 
cells. Since activated T cells undergo very fast cell cycle, we expected simple plasmid transfection 
methods originating episomes to lead to a loss of transgene expression upon target cell proliferation, 
and we therefore deemed such methods as not valid for our purposes. Thus we chose commercially 
available, replication-incompetent retroviral vectors, derived from murine oncoretroviruses. Such 
vectors are devoid of the env, gag and pol genes encoding the viral envelope and capsid proteins, 
and the retro-transcriptase, but preserve the necessary sequences for viral RNA encapsidation and 
for retro-transcribed DNA integration into the host cell genome, and transgene expression. Such 
kept elements include the retroviral 5’ and 3’ long terminal repeats (LTRs), the packaging signal for 
RNA encapsidation and the tRNA binding site. These retrovectors are issued as DNA plasmids 
provided with a multiple cloning site (MCS) containing a variety of restriction sites, which allows 
the user to insert the complementary DNA sequence (cDNA) encoding the product of interest. The 
plasmids are also provided with: a ColE1 origin of replication for replication in prokaryote 
competent cells; an ampicillin resistance gene (encoding a β-lactamase) for the selection of 
transformed bacteria, for vector DNA amplification; and a puromycine resistance gene that allows 
to select transfected cells for the preparation of packaging cell lines in eukaryotes.  
To produce virion particles for transfer to the target cells, packaging cell lines expressing the 
env, gag and pol structural genes were generated. The separate introduction and integration of the 
structural genes into the packaging cell line minimizes the chances of producing replication-
competent viruses due to recombination events during cell proliferation. The resulting retroviruses 
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can infect target cells and induce permanent expression of the gene of interest, but they cannot 
replicate within these cells due to the absence of viral structural genes.  
The retroviruses employed are RNA viruses that require target cells to be under active 
proliferation in order to transduce the cells, that is, to integrate into the host cell genome leading to 
permanent transgene expression. Oncoretroviruses take advantage of the absence of nuclear 
envelope during target cell mitosis (metaphase and anaphase) to integrate the retro-transcribed viral 
DNA into the host DNA. This mechanism can be used to selectively transduce proliferating cells 
within a cell population. In our experiments, we used this retrovirus property to selectively 
transduce antigen-specific CD4+ T cells. Following i.p. sensitization of the donor animals, 
splenocytes comprising antigen-presenting cells and antigen-specific CD4+ T cells are stimulated 
with antigen in vitro, leading to proliferation of the antigen-specific CD4+ T cells. By coupling 
antigen stimulation in vitro with retrovirus infection, only the antigen-specific CD4+ T cells are 
transduced with high specificity.  
4.1. Expression Vectors 
A Murine Stem Cell Virus (pMSCV) retroviral expression vector (Clontech Inc., Saint-
Germain-en-Laye, France) was used to induce GFP expression on target CD4+ T cells. GFP, a 238-
aminoacid protein first extracted from jellyfish Aequorea victoria, exhibits bright green 
fluorescence when exposed to ultraviolet light. More efficient and spectrally shifted mutant 
isoforms have been designed or discovered, such as the AcGFP1 variant used in this work. The 
cDNA encoding GFP was amplified from a pAcGFP1 vector (Clontech Inc.) using sticky end 
primers (Table 2, primers 01 and 02) and subcloned into the MCS of pMSCV between XhoI and 
EcoRI restriction sites. For all experiments, primers were designed and checked using TibMol tools 
(available at www.tib-molbiol.com). Polymerase chain reactions (PCR)s were performed in a 
conventional thermocycler (Primus 96, Peqlab Biotechnologie GmbH, Erlangen, Germany) using 
Expand High Fidelity PLUS PCR System (Roche Diagnostics, Mannheim, Germany) (see 
appendix). Restriction sites were checked and designed using Saccharomyces Genome Database 
(SCG) and New England BioLabs tools (available at http://www.yeastgenome.org and 
http://www.neb.com/nebecomm/default.asp respectively). Ligation reactions were performed using 
T4 DNA Ligase (Invitrogen, Life Technologies, Madrid, Spain) according to manufacturer’s 
instructions. PCR products and plasmids were purified with QIAquick PCR Purification Kit (Qiagen 
GmbH, Hilden, Germany) according to manufacturer’s instructions. Reactions with restriction 
enzymes and alkaline phosphatase were performed as appropriate (enzymes purchased from Roche 
Diagnostics and used according to manufacturer’s instructions).  
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 Table 2. Primers 
Primer Name Sequence (5´ – 3’)  Sticky end 
01 AcGFP/F cgcctcgagGTCGCCACCATGGTGAGC XhoI 
02 AcGFP/R ggggaattcCGGCCGCTCACTTGTACAG EcoRI 
03 Dir ZsGreen gggctcgagGCGGCTTCGAGGATAAA XhoI 
04 Rev ZsGreen gggctcgagATTATCATCGTGTTTTTCAAAGG XhoI 
05 Upper AcGFP gggctcgagATGGTGAGCAAGG XhoI 
06 Lower Puromic gggctcgagTCAGGCACCGGGCTTG XhoI 
07 Forward CheqGFP CTGATCTGGGGCCTCGGTG – 
08 Rev CheqGFP TATCGGGCAGCAGCACAGG – 
09 Foxp3 F ggggcggccgcATGCCCAACCCTAGGCC NotI 
10 Foxp3 R gggatcgatTCAAGGGCAGGGATTGGA ClaI 
 
Transgenic, antigen-specific Treg cells with forced FOXP3 expression were generated 
according Hori et al. (411) with minor modifications. Antigen-specific effector CD4+T cells were 
transduced using a bicistronic construct containing Foxp3 cDNA plus gfp as a reporter, expressed 
under the same promoter by means of an internal ribosome entry site (IRES). Foxp3 cDNA was 
kindly provided by Dr. Shimon Sakaguchi (Kyoto University, Japan). We used commercial 
bicistronic vector pRetroX-IRES-ZsGreen1 (Clontech) to obtain the IRES sequence. In the final 
construct, Foxp3 was subcloned upstream the IRES, and its expression could be monitored from the 
GFP signal. ZsGreen fluorescent protein, a GFP variant present in the commercially available 
pRetroX-IRES-ZsGreen1, was not of interest for our purposes because we had previously optimized 
immunohistochemical GFP detection in tissues for the AcGFP1 variant (see section 8.6). To replace 
ZsGreen by AcGFP1 cDNA we performed inverse amplification of the pRetroX-IRES-ZsGreen 
vector using primers 03 and 04 in Table 2 (with sticky ends for XhoI). We called the resulting 
vector, provided with a MCS upstream the IRES and the XhoI restriction site in frame downstream, 
pRetroX-IRES-Y. The fragment encoding GFP and puromycin resistance, from the pMSCV-GFP 
vector, was amplified using primers with XhoI sticky ends (Table 2, primers 05 and 06), and 
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subcloned into the Y site. Correct insert orientation was checked by PCR (Table 2, primers 07 and 
08). Then, Foxp3 mRNA was amplified using primers with sticky ends for NotI and ClaI restriction 
enzimes (Table 2, primers 09 and 10), at the 3’ and 5’ ends respectively. These restriction sites were 
then used to insert the Foxp3 mRNA into the MCS, giving as a result the pRetroFOXP3-IRES-GFP 
vector. 
4.2. Virion particle production  
The pMSCV-GFP and pRetroFOXP3-IRES-GFP vectors were separately replicated in 
competent DH5αTM Escherichia coli (Invitrogen) that became ampicilin resistant due to the 
expression of the ampicilin resistance gene present at the vectors. Transformed bacteria were 
selected with ampicillin in Petri dishes (Corning, New York, USA) using Luria Bertani agar (LBA) 
medium (see appendix), and then cultured in liquid Luria Bertani (LB) medium (see appendix) at 
37ºC with gentle agitation. Plasmid DNA was extracted using QIAprep Spin Miniprep Kit (Qiagen) 
according to manufacturer’s instructions. A HEK293T "Phoenix" (φNX) ecotropic packaging cell 
line (Orbigen, San Diego, USA) was transfected with pMSCV-GFP using Lipofectamine 
(LipofectamineTM 2000, Invitrogen) according to manufacturer’s instructions. To generate a stable 
packaging cell line, transfected Phoenix cells carrying plasmid integration events were selected by 
puromycin resistance using 2 µg/mL puromycin (Sigma-Aldrich) (see appendix for a detailed 
protocol). Surviving puromycin resistant cells were checked in a FacsCalibur cytometer (BD 
Biosciences, Madrid, Spain) for GFP expression, and then cultured and expanded. Cellular stocks 
were frozen in culture media with 10% DMSO (Sigma-Aldrich), and stored in liquid nitrogen for 
later use. 
Retrovirus production was performed according to Phoenix cell provider’s instructions: 
transfected Phoenix cells were cultured and expanded using 60 mL of D-MEM culture medium with 
10% foetal bovine serum (FBS) and 1% penicillin-streptomycin-glutamine (PSG) (all from Gibco, 
Invitrogen) into 15 cm culture plates (Corning). Once cells reached 95% confluence, culture 
medium was changed by production medium, D-MEM plus 10% calf serum (Gibco, Invitrogen), 
and the cells were maintained for 24 hours. Cell culture supernatant was collected and filtered 
through 0.45 µm filter (Stericup, Millipore) and  maintained at 4ºC to maximize virion viability. 
Virion particles were concentrated by centrifuging the supernatants in Centricon© 100.000 NMWL 
membrane filters (Millipore) at 3500 g. Virion stocks were stored at -80ºC until use.  
Viral titers in the frozen stocks were estimated using a murine NIH3T3 cell line (ATCC-LGC 
Standards partnership, USA). For this purpose, flow cytometry assays were performed in NIH3T3 
cells after transduction with serial dilutions of the pMSCV-GFP and pRetroFOXP3-IRES-GFP 
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stocks. Additionally, a western blot assay was performed on pRetroFOXP3-IRES-GFP transduced 
NIH3T3 cells to check for Foxp3 expression. Antibodies against FOXP3, GFP, and α-tubulin were 
used, followed by a horseradish peroxidase-conjugated goat antibody (see appendix for a detailed 
protocol). 
4.3. Lymphocyte cell culture 
For CD4+ T cell transduction and adoptive transfer experiments, donor mice were i.p. sensitized 
to OVA or HDM as described (see section 3 on sensitization and challenge). One week after 
sensitization, the mice were euthanized and the spleens were removed in aseptic conditions and 
digested with collagenase IV (Sigma-Aldrich) during 60 minutes in a CO2 incubator (37ºC). Tissue 
was disrupted using a 5 mL pipet, and the resulting cell suspension was passed through a 70 μm cell 
strainer (Falcon, BD Biosciences) and collected into 50-mL centrifuge tubes. Red blood cells were 
lysed using Red Blood Cell Lysing Buffer (Sigma-Aldrich) according to manufacturer’s 
instructions. Splenocytes were cultured at 5x106 cells/mL in 6-well plates (Corning). To favor Th2 
differentiation, cultures were supplemented with 10 ng/mL recombinant IL4 (PeproTech, Rocky 
Hill, USA), 100 U/mL IL2 (BD Bioscience), 250 ng/mL anti-IL12 (eBioscience, Hatfield, UK), 2% 
non essential aminoacids (Invitrogen) and 100 μM β-mercaptoetanol  (Merck, Madrid, Spain). To 
stimulate antigen-specific CD4+ T  cells, 40 μg/mL OVA (for CD4+ effector T cell experiments) or 
8 ng/mL HDM extract derived Der p 1 (for CD4+Foxp3+ T cell experiments) were added as 
appropriate.  
4.4. T cell retroviral infection 
After 24 hours of stimulation with antigen in vitro, the cells were infected with pSCMV-GFP or 
pRetroFOXP3-IRES-GFP using a spin infection procedure. Viral supernatant was added to the 
splenocyte cultures with 6 µg/mL polybrene (Sigma-Aldrich), at a multiplicity of infection (MOI, 
ratio of infectious viral particles to cells) of 1. The cultures were then centrifuged at 455g for 1 hour 
at 37ºC. After centrifugation, the cells were returned to the cell culture incubator and maintained in 
stimulation medium for 7 days, and then sorted by FACS to separate the GFP-expressing cells for in 
vivo transfer. Cell sorting was done with BD Bioscience FacsAria equipment. 
Analytic flow cytometry was performed to check FOXP3, cell surface markers (CD4, CD25) 
and/or GFP expression in transduced cells, using a BD Bioscience FacsScan cytometer. For this 
purpose, cells were resuspended in flow cytometry buffer (see appendix). PE-Conjugated Rat Anti-
Mouse CD4, allophycocyanin(APC)-conjugated Rat Anti-Mouse CD4 and PE-Conjugated Rat Anti-
Mouse CD25 antibodies (all from BD Bioscience) were used for the staining of cell surface antigens 
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at 0.8 μg/106 cells. For FOXP3 staining, APC-anti-mouse/rat FOXP3 Staining Kit (eBioscience) 
was employed at 0.5μg/106 cells.  
 
5. T cell adoptive transfer experiments 
To study the role of effector CD4+ T cells in experimental asthma, adoptive transferred 
experiments were performed. Naive syngeneic recipient mice were transferred freshly harvested 
CD4+ T cells from unsensitized donors, or effector, antigen-specific CD4+T cells from sensitized 
donors, the latter antigen-activated in vitro and transduced for GFP expression. Recipient mice 
received two prior i.n. instillations as stated (see section 2, Study Design). The cells were i.v. 
injected in the tail of the recipients in 75 μL PBS vehicle. Sham challenged mice (PBS-instilled, 
n=5) received 105 stimulated GFP+/CD4+ T cells (control 1). One group of OVA-challenged animals 
(n=5) received 105 non-transduced, non-activated T cells (control 2). Lastly, three groups (n=5 
each) received 0.25 x105, 0.5x105 and 105 antigen-specific, activated, GFP+/CD4+ T cells and were 
subsequently challenged with OVA (Figure 13). 
 
To study the role of Treg cells in experimental asthma, two groups of mice (n=4 per group) 
were i.n.-challenged with HDM as depicted (Section 2, Study Design). One group of animals 
Figure 13. Adoptive 
transfer of T cells. 
CTRL1 group was 
instilled with PBS and 
received 1x105 activated 
GFP+ T cells. CTRL2 
group was instilled with 
OVA and received 1x105 
non-activated, non-
trasduced fresh T cells. 
The three experimental 
groups (EXP 0.25X105; 
EXP 0.5x105; and 1x105) 
were instilled with OVA 
and received 2.5X104, 
5x104, and 1x105 
activated, GFP+ T cells, 
respectively. Adoptive 
cell transfer was 
performed i.v. on day 2 
after the first i.n. 
instillation. Animals were 
euthanized on day 10 
after first instillation. 
A 
B 
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received 75,000 antigen-specific CD4+FOXP3+ T cells. The cells were i.v. injected in the tail as 
described for effector T cells (Figure 14). 
 
 
6. Lung function 
Invasive lung function measurements were performed by forced oscillation technique under 
mechanical ventilation, using FlexiVent equipment (SciReq, Montreal, Canada; purchased from 
EMMS, London, UK).  
6.1. Measurement of airway hyperresponsiveness 
Increasing MCh (Acethyl-β-Methyl-Choline Cholride, Sigma-Aldrich) concentrations (Table 3) 
in filtered PBS were administered to mechanically ventilated animals by means of an Aeroneb®Lab 
ultrasonic nebulizer (Aerogen, Galway, Ireland) coupled to the FlexiVent inspiratory line.  
6.2. Preparation of animals for mechanical ventilation 
Figure 15 depicts the setup for mouse mechanical ventilation and lung function testing. 
6.2.1. Anaesthesia  
Mice were weighed before sedation and this value was introduced into the FlexiVent software 
for automatic adjustment of total lung capacity (TLC) and tidal volume.  
 
 
Figure 14. Adoptive tranfer of Treg cells. A group of mice received 28 i.n. instillations with HDM to 
stablish an experimental asthma model driven by primary HDM airway exposure in the absence of 
previous sensitization. An alternative HDM-instilled group was i.v.-injected with 7.5x104 GFP+ Treg 
cells on the day of instillation 24, to evaluate the immunoregulatory properties of these cells on 
established disease in vivo.  
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Table 3. MCh concentrations for airway reactivity testing. 
Dose 
 
MCh concentration 
(mg/mL) 
Average MCh dose per Kg body weight 
(mg/Kg) 
D0 0 0 
D1 1.25 1.56 
D2 2.5 3.13 
D3 5 6,25 
D4 10 12.5 
(D5)* 20 25 
*: Dose D5 was administered in limited experiments where indicated. 
 
For induction of anaesthesia, 2% sevoflurane was first administered into a plexiglass chamber 
as described for i.n. instillations, and then delivered through a nasal mask, leaving the neck of the 
mouse exposed. Deep anaesthesia was reached by increasing sevoflurane to 3%, and verified by the 
loss of the palpebral and toe-pinch reflexes.  
6.2.2. Tracheostomy 
The trachea was surgically exposed, and an incision between two upper-third tracheal rings was 
made to insert the cannula (FTC100 Tracheal Cannula, Ø 0.2 mm, EMMS). The cannula was then 
fixed with surgical silk to the trachea to avoid decannulation during animal manipulation.  
6.2.3. Neuromuscular blockade and connection to the mechanical ventilator 
A 0.15 mL volume of 0.5 mg/mL rocuronium (Esmeron®, Organon, Holland) was i.p. injected 
to abrogate spontaneous breathing. The animal was then quickly connected to the FlexiVent through 
the tracheal cannula and was kept anaesthetized by continuous sevoflurane inhalation through the 
ventilator inspiratory line. Ventilator settins used were 200-250 breaths/min respiratory rate, a tidal 
volume of approximately 0,14 mL (body weight-adjusted for each individual animal) and a PEEP of 
2 cm H2O. Optimal settings for mouse mechanical ventilation are shown in Table 4. 
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The mouse mechanical ventilation module of 
the FlexiVent is provided with a piston (a) 
controlled by a high-precision linear motor (b). 
The piston drives preset air volumes through 
the inspiratory arm (c) and to the tracheal 
cannula (d). Increasing MCh doses are 
administrated through an ultrasonic nebulizer 
(e). Expired air is drawn through the expiratory 
arrm, provided with a PEEP water trap (f), and 
then released through the exhaut. 
The FlexiVent equipment 
comprises a computer with 
proprietary software (a) that 
controls the mechanical 
ventilation module (b), collects 
the signals from the pressure 
transducers and calculates values 
for pulmonary function 
variables. Interchangeable 
ventilation modules exist for 
animals of various sizes (mice, 
rat, guinea pig). The animals are 
usually connected to the 
ventilator through tracheostomy, 
such as the mouse shown inside 
the orange square. The panels at 
the bottom show the 
a 
b
c 
d e 
f 
The trachea is separated from 
surrounding tissues, and the 
cannula is inserted and fixed 
with surgical silk. 
a 
b
An incision is 
made in the upper 
third of the neck 
Once the cannula is fixed, the 
animal is quickly connected to 
the ventilator. 
Figure 15. Animal preparation for ventilatory mechanics.  
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Table 4. FlexiVent mouse ventilation parameters 
Animal weight About 20 g 
Displaced volume 0.18 mL 
Tidal volume 0.12-0.14 mL 
Tidal volume per weight 6.5-7 mL/Kg 
Minute ventilation  25-30 mL/min 
Respiratory rate 200-250/min 
PEEP 2 cm H2O 
Average inspiratory pressure  6-7 cm H2O 
Peak inspiratory pressure About 11 cmH2O 
 
6.3. Measurement of pulmonary function variables 
Pulmonary function variables were measured under mechanical ventilation by forced oscillation 
technique, using a single-compartment mathematical model as issued by the FlexiVent software 
(FlexiVent 5.2). For data collection, tidal-volume mechanical ventilation was transiently interrupted 
and pressure prime waves ("perturbations") were generated by the ventilator. Pulmonary resistance 
(RL), measured from 20-second "snap-shot" primewaves, was the primary variable analyzed, as an 
indicator of airway responsiveness to increasing MCh doses. Pulmonary elastance and the model's 
coefficient of determination were monitored to discard RL increases due to airway plugging, and for 
overall data quality. Once the anaesthetized animal was connected to the ventilator and the 
ventilation parameters adjusted as appropriate, tidal-volume ventilation was carried out until 
pulmonary function values were stable (this would usually take 1-2 minutes). Then a RL baseline 
value was averaged from a series of several prime waves. After RL baseline reading, the MCh 
nebulization protocol was performed starting with PBS and finishing with the maximum MCh 
concentration (see MCh concentrations on Table 3). For each nebulization, 25 μL of PBS or MCh 
solution was deposited into the nebulizer cup and passed through 20 seconds to the tidal volume-
ventilated animal. After each nebulization was finished, prime waves and data collection were 
performed every 10 seconds for 3-4 minutes. A valid peak RL value was taken as the response RL to 
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each nebulization. The respective MCh doses were stepwise administered every 4 minutes until 
finishing the protocol. The airway responsiveness profile was presented as the curve generated from 
the successive peak RL values obtained after the corresponding MCh doses. Airway 
hyperresponsiveness was considered when RL was significantly higher than baseline RL at 10 
mg/mL MCh or earlier, and significantly higher than control RL for the same MCh dose.  
To avoid artifact data due to the formation of atelectases during mechanical ventilation, a total 
lung capacity (TLC) manoeuvre or “sigh” was administered as necessary. During this manoeuvre, 
the ventilator distends the lungs up to a 300 mmH2O pressure, which usually uncollapses the lung 
parenchyma and/or plugged airways (597). 
 
7. Euthanasia and specimen collection procedures 
7.1. Euthanasia 
Once the lung function data collection protocol was completed, a bolus of 0.2 mL heparin 
(Sodium heparin 1000 IU/mL, MAYNE PHARMA S.L., Madrid, Spain) was i.v. injected to avoid 
post-mortem blood clotting. Then, 0.3 to 0.5 mL of potassium chloride (14.9% w/v, BRAUN, 
Melsungen, Germany) was i.v. administered in the tail to induce cardiac arrest in the deeply 
anaesthetized animal.  
7.2. Bronchoalveolar lavage 
BAL was collected for total and differential leukocyte counts, and to store samples of its fluid 
fraction for further analysis. For this purpose, 1 mL of PBS was introduced into the lungs using a 
syringe connected to the tracheal cannula. The PBS was then slowly retrieved, which allowed for a 
approximate 0.7 mL fluid recovery. This BAL fraction was introduced in a conic polypropylene 
tube (Falcon) and plunged on ice until processing. A second BAL fraction was obtained using a 
three-way stopcock (Discofix® C, Braun) connected to the tracheal cannula, a PBS-filled syringe, 
and a collection syringe.  Four mL of PBS was introduced into the lungs in 1-mL steps, and each 
mL was sequentially recovered and pooled into a clean centrifuge tube. The first BAL fraction was 
centrifuged at 458⋅g for 5 minutes, and its supernatant aliquoted into 2-mL low protein adherence 
tubes (Protein LoBind, Eppendorf Ibérica, Madrid, Spain) and stored at -80 ºC. The cell pellet was 
resuspended and pooled into the second BAL fraction, which was then centrifuged. The supernatant 
was discarded and the cell pellet, comprising the total cells from the first and second BAL fractions, 
was resuspended in 1 mL of PBS. From this suspension, total cell counts were done under the 
microscope using a Neubauer chamber (ZUZI Corp., France), and cell viability was checked by 
tripan blue dye (Gibco, Invitrogen) exclusion. Cell concentration was then adjusted to 400,000 
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viable cells per mL, and cytocentrifuged specimens containing 60,000 cells were prepared for 
differential leukocyte counts as follows: 150 μL of the adjusted cell suspension was placed into each 
of several cytocentrifuge cones (Universal 32, Hettich, Tuttlingen, Germany) mounted on adherent 
microscope slides (SuperFrost® Plus, Menzel-Gläser, Braunschweig, Germany), and centrifuged at 
28⋅g for 6 minutes in the proprietary "cytospin"centrifuge. The slides were then allowed to dry at 
room temperature for 20 minutes, and were fixed in methanol (Panreac, Barcelona, Spain) for 10 
minutes. After fixation, the slides were again dried at room temperature for 20 minutes, and stored 
at -20ºC for later staining. 
7.3. Lungs 
A mid-sagittal incision was done in the abdomen through the skin, subcutaneous tissue, 
muscular plane, and parietal peritoneum, using a scalpel. Once the abdominal cavity was exposed, 
the bowels were separated to expose the inferior vena cava and abdominal aorta on the posterior 
abdominal wall. Then, the diaphragm muscle was cut using blunt scissors, taking care to not 
damage the lungs. After pulmonary collapse by diaphragmatic incision, the chest was opened 
through a mid-sternal line up to the neck tracheotomy. The abdominal cava-aorta bundle was cut 
and the right ventricle was punctured with a syringe and needle to perfuse the pulmonary vascular 
circuit with PBS before lung extraction. After perfusion, the lungs were excised in bloc from the 
thoracic cavity, along with the cannulated tracheobronchial tree and heart. The lungs were then 
inflated at 25 cmH2O standardized pressure by connecting the tracheal cannula to a recirculation 
pump with 4% formaldehyde (Panreac) in PBS for 20 hours, for normalized quantitative 
morphology. After fixation, lung sagittal slices were introduced into histological casettes, immersed 
in 70% ethanol (Panreac) and placed into a carousel tissue processor (STP 120 Spin Tissue 
Processor, Thermo Scientific, Madrid, Spain) overnight, with a paraffin inclusion program detailed 
on Table 5. Once processed, the specimens were blocked in paraffin and cut with a microtome 
(RM2155, Leica Microsystems, Wetzlar, Germany). Four-μm tissue sections were laid onto 
adherent microscopy slides (SuperFrost® Plus, Menzel-Gläser) for subsequent staining procedures. 
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Table 5. Tissue processor program. 
Station Reactive Time Agitation (0/1/2) 
1 Ethanol 70º - 0 
2 Ethanol 70º 1h 1 
3 Ethanol 96º 1h 30min 1 
4 Ethanol 96º 1h 30min 1 
5 Ethanol 100º 1h 1 
6 Ethanol 100º 1h 30min 1 
7 Ethanol 100º 1h 30min 1 
8 Xylene 1h 1 
9 Xylene 1h 1 
10 Xylene 1h 1 
11 Paraffin 3h 1 
12 Paraffin 3h 1 
 
7.4. Skulls 
Heads were sectioned at cerebellomedullary cistern level to separate the skull from the spine, 
and the skin, eyes, brain and lower jaw were excised. The skulls were immersed in formalin and the 
air contained in the nose was purged by introducing formalin through the epipharynx with a blunt 
needle. This procedure eliminated the air trapped in the upper airway to ensure correct fixation of 
the nasal cavity structures (266). The skulls were fixed for 20 hours and then immersed into a 
decalcifying solution (SHANDON TBD-1TM, Thermo Fisher Scientific) for 5 hours. After 
decalcification, frontal slices of the nasal cavity were cut with a scalpel in standardized anatomic 
locations, according to the Young protocol established in rats (266) and later adapted for mice by 
Farraj et al. (263). We processed the samples as per Farraj with minor modifications. A proximal 
cut was done behind the incisisor teeth, middle cut at the first palatal ridge, and distal cut at the 3rd 
palatal ridge (Figure 16). 
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8. Histological staining and specific detection procedures 
Specimens were submitted to a variety of histological stains, immunohistochemistry and nucleic 
acid hybridization procedures for analysis (figrures 17 and 18). Wright-Giemsa staining was done 
for leucocyte differential counts on BAL cytocentrifuged slides. For general histopathological 
assessment, and to identify eosinophils in inflammatory infiltrates in the lungs or nasal sections, 
haematoxylin-eosine staining (H-E) was employed. To identify mucus-producing cells in the 
airways, such as goblet cells, periodic acid-Schiff (PAS) stain was used. Masson trichrome stain 
was performed for the analysis of extracellular matrix deposition. Contractile airway tissue was 
detected by immunohistochemistry using an antibody to alpha smooth muscle actin (α-SMA). In 
adoptive transfer experiments, GFP-expressing cells were localized in the tissues by 
immunohistochemical GFP detection. Where appropriate, in situ hybridization was performed to 
identify Foxp3, Il10, and Tgfb mRNAs in lung cells. 
8.1. Wright-Giemsa 
This technique, first described by Romanowsky in 1902, is broadly used to stain cell smears . It 
is based on eosin and azure colorant-releasing derivates (azure A, B and methylene azure). Eosin 
acts as an anionic cytoplasmatic colorant, staining extracellular components and certain acidophil 
structures, while azure cationic derivates stain basophilic structures, like chromatin.  
Cytocentrifuged BAL samples were retrieved from -20ºC storage, defrosted at room 
temperature for 30 minutes and introduced into acid alcohol (37% hydrochloric acid in 96º ethanol, 
Panreac). They were then stained with Wright solution (Gurr®, VWR, Barcelona, Spain) for 10 
Figure 16. Nasal cavity in mouse. We analyzed 
the nose tissues at three frontal sections: proximal 
at incisisor teeth level, middle at first palatal ridge, 
and distal at third palatal ridge. 
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minutes and washed with distilled water until a change in color was appreciated. After filtration to 
discard precipitates, the samples were stained with commercial Giemsa solution (Merck) for 30 
minutes, and then differentiated into glacial acetic acid (Panreac) to get a regular colored tone. 
Finally, the samples were passed through 96º ethanol (taking care to not to decolor them 
excessively), 100º ethanol and xylene (Panreac), and were mounted with DePex mounting medium 
(Gurr®, VWR) 
 
Figure 17. Especimen collection and analysis procedures. Lung function was evaluated using 
FelxiVent ventilator and then BAL was collected for total and/or differential cell counts. Upper and 
lower airways were collected, formaldehyde fixed and paraffine embebeded. Haematoxylin-eosin (H-
E), PAS, Masson thricrome, α-actin immunohistochemistry (IHC), FISH and/or GFP+ IHC were 
performed as required. 
LUNG FUNCTION (FlexiVent) 
− Histopathology assesment (H-E) 
− Mucous substances (PAS) 
− Subepithelial fibrosis (Masson) 
− MCT (α-actin IHC) 
− mRNA expression (FISH) 
− GFP+ cell detection (GFP IHC) 
Total/differential cell count in BAL 
(Wright-Giemsa) 
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8.2. Haematoxylin-eosin 
Haematoxylin is a vegetable colorant, extracted from the heartwood of the logwood tree 
(Haematoxylum campechianum). When oxidized, haematoxylin acquires a dark purple color. It is 
basic or cationic and therefore is used to stain acidic cellular components, like the nucleus. 
Haematoxylin has a limited capacity to remain in the tissues and must be combined with metallic 
ions (iron salts or aluminum) that act as mordant. Eosin is an acidic fluorescein derivative that gives 
a dark pink color and is used to stain basic cellular components, mostly present in the cytoplasm. 
Four-μm tissue sections were deparaffined by placing them into a heater at 60ºC for 30 minutes 
and immediately immersing them in xylene baths until all paraffin was removed. The samples were 
then rehydrated through 100º ethanol, 96º ethanol, distilled water and tap water with 1 ‰ HCl 
(Merck); the iron contained in tap water favours haematoxylin fixation to the tissues. After 
rehydration, the samples were immersed into Harrys’ Haematoxylin (Panreac) for 5 minutes and 
then washed several times in tap water to attenuate the excess colorant. The samples were then 
immersed into an eosin solution (see appendix) for 5 minutes and then dehydrated in 96º, 100º 
ethanol and xylene, and mounted with DePex mounting medium. 
 
Figure 18. Histological staining techniques. We used several staining techniques to analyze histological 
samples derived from the animals of the study. This figure shows histological sections stained using 
haematoxylin-eosin (A), periodic acid Schiff (B), Masson thricrome (C), immunofluorescence for a-sma 
(D) and GFP (E) and in situ hybridization for Foxp3 (F), Tgfb, and Il10 mRNA. Scale bars: A, B, and C 
50 µm; D, 100 µm; E, 10 µm; and F, 25 µm. 
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8.3. Periodic acid-Schiff (PAS) 
Mucopolysaccharides are the main mucus components and are substances rich in hexoses and 
acetylated or sulfonated acids. The PAS staining technique is based on its ability to break the links 
of the hexose ring and expose aldehyde groups, which are then bound by the Schiff reactive. This 
reactive is a fuchsine derivate that produces leuco-sulfonic acid, a colorless unstable compound, that 
becomes purple-violet when it binds the aldehyde groups and loses its sulphuric acid. Thus, PAS-
positive substances stain from intense pink to violet. 
Four-μm tissue sections were deparaffined and rehydrated as described, except for the use of tap 
water. The samples were then immersed in periodic acid solution (see appendix) for 10 minutes, 
washed in tap water, and placed in Schiff reactive (Merck) in the dark for 30 minutes. After that, the 
slides were immersed in sodium bisulfite (Sigma-Aldrich) for 10 minutes, and washed with tap 
water again. The sections were then placed in Harrys’ haematoxylin for 10 minutes and washed in 
tap water. Finally, the samples were dehydrated and mounted with DePex. 
8.4. Masson’s trichrome 
Collagen fibers are the most abundant component of conjunctive tissues and are derived from 
procollagen secretion by several cell types, such as fibroblasts. The main function of collagen is to 
provide resistance and physical support to tissue structures. There are several types of collagen, 
being I and IV the types mostly found in subepithelial fibrosis and those detected by Masson's 
trichrome staining. This staining technique is based on the use of acid fuchsine to stain conjunctive 
tissue and Weigert’s ferric haematoxylin to stain the cell nuclei. 
Four-μm tissue sections were deparaffined and rehydrated as described, ending in tap water . 
The slides were then immersed in ferric aluminum aqueous solution (Merck) for 20 minutes (ferric 
alum acts as a mordant, favoring subsequent haematoxylin staining), and salt debris was then 
removed by washing the slides in tap water. The samples were then stained with Weigert’s ferric 
haematoxylin (Sigma-Aldrich) for 10 minutes and washed again in tap water until getting a dark-
grey tissue color. Next step was incubation in picric acid (Panreac) for about 6 minutes (time varied 
depending on reactive maturation), to favor acidy for subsequent staining with fuchsine. After 
incubation, the slides were washed in tap water until they became yellow, a color shift attributed to 
the picric acid. The samples were then immersed in Ponceau’s fuchsine (Certistain®, Merck) for 8 
minutes and washed twice with 1% phosphomolybdic acid (Merck) solution in distilled water for 5 
minutes. Collagen was then stained with with aniline blue (Merck) for 12 minutes. The slides were 
finally washed several times in distilled water, dehydrated through 96º and 100º ethanol and xylene, 
and mounted in DePex.  
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8.5. Alpha-smooth muscle actin immunohistochemistry  
Alpha-SMA is the predominant actin isoform in the contractile apparatus of smooth muscle 
cells, and is also present in myofibroblasts. 
Four-μm tissue sections, deparaffined and rehydrated, were subjected to cell membrane 
permeabilization with 0.2 % Triton X-100 (Sigma-Aldrich) in PBS for 20 minutes and then blocked 
with a universal blocking solution (Image-iTTM Signal Enhancer; Molecular Probes, Invitrogen) for 
30 minutes with the aim of reducing tissue autofluorescence. Mouse anti-α-SMA IgG2a monoclonal 
antibody (clone 1A4, Sigma-Aldrich) was used as primary antibody (1:100 dilution), followed by 
Alexa Fluor® 488 labeling kit (Molecular Probes, Invitrogen) as detection system as per 
manufacturer’s instructions, in PBS with 20% goat serum (Vector Labs, Peterborough, UK) and 
0,1% Tween-20 (Sigma-Aldrich) as diluent. Nuclear counterstaining was done with DAPI 
(SelectFXTM Nuclear Labeling Kit, Molecular Probes, Invitrogen). The stained specimens were then 
fixed in 4% paraformaldehyde (Sigma-Aldrich) to favor longer Alexa fluorochrome stability, and 
mounted a permanent medium optimized for fluorescence microscopy (ProLong® Gold, antifade 
reagent; Molecular Probes, Invitrogen). 
8.6. Green fluorescent protein immunohistochemistry 
The native fluorescent signal of GFP and its variants, although appropriate for flow cytometry, 
is usually not reliably detectable in fixed tissue sections. Indirect GFP detection by 
immunohistochemistry allows to overcome this limitation and provides a highly specific, amplified 
signal.  
Four-μm lung sections were deparaffined, rehydrated and permeabilized as described, blocked 
with Mouse-on-Mouse blocking reagent (Vector Labs), and incubated with mouse anti-GFP 
monoclonal antibody JL-8 (Clontech). The primary antibody was followed by a biotinylated horse 
anti-mouse secondary antibody, an avidin-biotin-alkaline phosphatase complex, and development 
with Vector Red chromogen (all from Vector Labs). Cell nuclei were counterstained with methyl 
green solution (Sigma-Aldrich; see appendix for recipe). The specimens were then dehydrated and 
mounted in DePex. 
8.7. Fluorescence In-situ hybridization (FISH)  
The FISH thecnique employs labeled DNA or RNA strands, complementary to a specific DNA or 
RNA squence to be localized in tissue sections. In this work, FISH was performed on lung sections 
using digoxigenin or biotin-labeled DNA probes, followed by fluorescently labeled antibodies to 
detect the hybridized probes. 
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Table 6. Probes for FISH 
Probe Name Sequence (5’ – 3’) 
11 polyT TTTTTTTTTTTTTTTTTTTTTTTTT 
12 Foxp3 positive2 CATAGCTCCCAGCTTCTCCTTTTCCAGCTCCAGCT 
13 TGFB positive1 TCATGTTGGACAACTGCTCCACCTTGGGCTTGCGA 
14 TGFB positive2 ATTCCGTCTCCTTGGTTCAGCCACTGCCGTACAAC 
15 TGFB positive 3 GCTTCCGTTTCACCAGCTCCATGTCGATGGTCTTG 
16 IL10 positive 2 TTGATTTCTGGGCCATGCTTCTCTGCCTGGGGCAT 
17 IL10 positive3 TCTGGCCGACTGGGAAGTGGGTGCAGTTATTGTCT 
18 Foxp3 negative1 accacaatatgcgaccccctttcacctatgccacc 
19 Foxp3 negative2 agctggagctggaaaaggagaagctgggagctatg 
20 Foxp3 negative3 gaggagccagaagagtttctcaagcactgccaagc 
21 TGFB negative1 tcgcaagcccaaggtggagcagttgtccaacatga 
22 TGFB negative2 gttgtacggcagtggctgaaccaaggagacggaat 
23 TGFB negative 3 caagaccatcgacatggagctggtgaaacggaagc 
24 IL10 negative 1 cccctgtgaaaataagagcaaggcagtggagcagg 
25 IL10 negative 2 atgccccaggcagagaagcatggcccagaaatcaa 
26 IL10 negative3 agacaataactgcacccacttcccagtcggccaga 
 
8.7.1. In-situ hybridization design 
Thirty-five-nucleotide probes against Foxp3, Tgfb and Il10 mRNA sequences were designed 
aiming at the same melting temperature (Tm) and GC content. Once the theoretical probes 
sequences were generated using National Center for Biotechnology Information resources (available 
on-line at www.ncbi.nlm.nih.gov) and TIB mol resources (available on-line at www.tib-
molbiol.com), potential intra-probe dimer and hairpin formation, as well as heterodimer formation 
between probes, were checked using Primer3web software (598). No other mRNA homologues 
were found in mouse or rat using a Basic Local Alignment Search Tool (BLAST software, provided 
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online by the National Institutes of Health, USA). One, two and three probes, complementary to 
different sequences, were tested for Foxp3, Il10, and Tgfb mRNAs (Table 6, probes 12 – 17), 
respectively. The probes were labeled by adding a 3’ tail with digoxigenin or biotin-bound 
nucleotides (Roche oligonucleotide tailing kit, Roche Diagnostics). A poli-T probe was used as a 
positive control (Table 6, probe 11) and probes without an annealing sequence were used as 
negative controls (Table 6, probes 18 – 26).  
8.7.2. Fluorescence in situ hybridization protocol 
Lung sections of 7-μm thickness were cut and laid onto silanized slides (Dako, Glostrup, 
Denmark). The sections were kept at 37º C overnight, deparaffined with xylene (10 and 2 minutes, 
twice into each bath), rehydrated through ethanol 100º (twice), 90º, 70º, 50º and water (1 minute 
each), and dried at 37º C for 10 minutes. Proteinase K (Enzo Life Sciemces, Farmingdale, USA) 
pretreatment was applied at 1:30 dilution for 15 min at 37º C, and the slides were then washed twice 
with PBS using gentle agitation for 1 min. The specimens were then acetylated using 0.1 M 
triethanolamine buffer (Sigma-Aldrich) and 0.25% acetic anhidre (Sigma-Aldrich) for 5 min, and 
then washed twice in PBS. After acetylation treatment, the tissues were dehydrated from water 
through 50º, 70º and 100º ethanol (1 min each), and then allowed to dry at room temperature for 10 
min. The samples were then prehybridized with hybridization buffer (Enzo Life Science) at 37º C 
for 20 min and then washed in preheated PBS. The specimens were then immediately covered with 
hybridization buffer containing the probes at 100 ng/mL, had a coverslip (Sigma-Aldrich) applied, 
and were incubated at 37º C for 1 hour. After the hybridization step, the specimens were washed 
with 1x and 0.2x saline-sodium citrate preheated buffers (Sigma-Aldrich) for 10 min, and twice 
with PBS at room temperature. For the detection step, a permeabilizing treatment using 0.2% Triton 
(Sigma-Aldrich) in PBS for 20 min was applied, followed by two PBS washes (5 min each). A 
blocking step was performed with 0,1% Tween-20 (Sigma-Aldrich), 5% bovine serum albumin 
(Sigma-Aldrich) in PBS for 30 min. Sheep anti-digoxigenin (Roche) and goat anti-biotin (Sigma-
Aldrich) were used as primary antibodies (at 1:100 dilution according to manufacturer’s protocol) 
diluted in 2,5% bovine serum albumin and 0,2% Tween-20 in PBS. After a one-hour incubation, the 
slides were washed twice in PBS at room temperature and incubated for 30 min with donkey anti-
sheep and anti-goat fluorescently-labeled secondary antibodies (Alexa 647 and 594 respectively, 
Invitrogen) at 5 μg/μL, in 5% mouse serum (Sigma-Aldrich) and 0,2% Tween-20 in PBS. Two PBS 
washes were done at room temperature followed by a 2-min incubation with DAPI (1:300). The 
samples were then washed three times in PBS, fixed in 4% paraformaldehyde solution (Sigma) for 
15 min and mounted with ProLong® Gold mounting media (Molecular Probes, Invitrogen).  
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8.7.3. FISH quantification 
Hybridized samples were analyzed in a fluorescence microscope and Foxp3+, Il10+ and Tgfb+ 
cells were quantified in at least 10 randomly sampled zones containing inflammatory infiltrates per 
animal. 
8.8. FOXP3 immunostaining on human bronchial biopsies 
Bronchial biopsies were collected in a multicenter fashion, from the following groups of 
subjects: (i) severe asthmatics (n=29); and (ii) control bronchial mucosa group (bronchial biopsies 
from disease-free areas as per endoscopic examination, from subjects undergoing diagnostic 
procedures for focal lung disease such as lung nodule or investigation of hemoptysis; n=5). The 
protocol was approved by the Ethics Review Board of the participating centers, and all subjects 
signed inform consent. The biopsy specimens were provided by: Dr. Vicente Plaza Moral and Dr. 
Alfons Torrego Fernández (Hospital de la Santa Creu i Sant Pau, Barcelona); Dr. Carlos Martínez 
Rivera (Hospital Universitario Germans Trias i Pujol, Badalona-Barcelona); Dr. Antolín López 
Viña (Hospital Universitario Puerta de Hierro, Madrid); Dr. Santiago Bardagí Fons (Hospital de 
Mataró, Mataró-Barcelona); Dr. Francisco Javier González Barcala (Complexo Hospitalario de 
Pontevedra, Pontevedra); Dra. Teresa Bazús González (Hospital Universitario Central de Asturias, 
Oviedo); Dr. Patrick Berger (Université Bordeaux 2, Burdeos, France); and Dr. James G. Martin 
(McGill University, Montreal, Canada). The biopsies were fixed in 4% formaldehyde (10% PBS-
buffered "formalin") for 24 hours (during overnight shipment from collaborating centers as needed), 
and paraffin embedded as described for mouse specimens. For analysis, 4-μm tissue sections were 
deparaffined, passed through an antigen retrieval step (PTLink, Dako), and processed for 
immunostaining in an AutostainerLink 48 (Dako). Mouse anti-human FOXP3 antibody (Abcam) 
was used as primary antibody at 1:100 dilution, followed by Envision Flex Mouse linker, 
Horseradish phosphatase and DAB staining kit (all from Dako) for detection. The tissue sections 
were counterstained with haematoxylin, and mounted in permanent medium. For quantitative 
morphology, the FOXP3+ cell counts were referenced to the biopsy surface area, measured with 
ImageJ software. A surgical tonsil specimen was used as a positive staining control. 
 
9. Quantitative morphology 
Images from lung sections were acquired with an automated fluorescence microscope 
(BX61/BX62, Olympus, Tokyo, Japan) equipped with a digital camera (DP70, Olympus), and using 
10x, 20x and 40x objectives depending on airway size so as to obtain the biggest possible airway 
size within one image. Cross-sectioned airways were analyzed according to established sampling 
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and standardization criteria (599). Airway cell counts and surface areas resulting from extracellular 
matrix and contractile tissue measurements were referenced to the basement membrane perimeter 
squared (PBM2), which is considered a constant airway size reference independently from the airway 
contraction or relaxation status (599). Quantitative measurements in the upper airway were based on 
prior methods (263, 266). Nasal samples in OVA-challenged mice and controls were examined to 
determine the area most sensitive to changes in the amount of PAS-positive epithelial substances, 
which resulted to be the proximal section of the nasal cavity, whereas no differences were observed 
in the middle and distal nasal sections. Within the proximal nasal section, the main differences were 
found in the mid septum, maxiloturbinates, and dorsal wall, which were the areas consequently 
selected for quantitative data acquisition from PAS color extraction. Eosinophils and PAS+ cells 
were counted through the entire length of the nasal epithelium in the proximal sections. Cell counts 
(eosinophils and goblet cells) were normalized by the basement membrane length squared and 
expressed as cells/mm2, while stored mucosubstances, extracellular matrix, and α-SMA+ contractile 
tissue section surface areas were expressed as dimensionless indices.  
Image processing for quantitative morphology was performed with AnalySISD© (Soft Imaging 
System, Olympus) and ImageJ (v.1.43m, National Institutes of Health, USA) software. The digital 
images acquired from the microscope were calibrated using a standard micrometric ruler slide 
(Leica Microsystems). A digital scroll tablet (Trust, Dordrecht, Holland) was used to outline the 
basement membrane for its measurement in intrapulmonary airways and upper airway sections, and 
to define regions of interest for the quantification of airway wall structures. To measure collagen 
deposition and epithelial mucosubstances, the Masson's trichrome blue component and PAS staining 
boundaries were respectively delimited by a colour extraction algorithm and measured as particle 
surface areas. For each cross-sectioned intrapulmonary airway or upper airway section, the particle 
surface area summation was divided by PBM2 or the basement membrane length squared, and the 
result was named “extracellular matrix mass” or “mucoid mass”, respectively. For airway 
contractile tissue quantification, the α-SMA immunofluorescent signal was digitally thresholded and 
extracted, measured as particle surface area summation divided by PBM2 , and named "airway 
contractile tissue mass”. 
 
10. Data analysis 
Statistical analysis was performed using SPSS (version 16.0) software, and graphics were 
gererated using SigmaPlot (version 2000). Data are presented as mean ± standard error of the mean 
(SEM) unless otherwise specified. Group comparisons were analyzed with one-way analysis of 
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variance (ANOVA) followed by Fisher’s least significant difference (LSD) or Games-Howell post-
hoc tests as appropriate. Intra-group MCh reactivity curve analysis was done with ANOVA 
followed by Dunnett post-hoc test (multiple comparisons versus baseline RL). F values of less than 
0.05 were considered significant. 
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1. Pathophysiology of experimental asthma in a murine model of primary airway allergen 
exposure; differences verus i.p. sensitization.  
Experimental asthma modeling in animals has largely been based, since its inception, on 
vaccine-like antigen sensitization, i.e. sensitization based on i.p. or subcutaneous injection of 
allergen with an adjuvant, followed by airway antigen challenge. Such sensitization procedures lead 
to allergic responses in the upper and lower airways after antigen challenge, and airway remodeling 
upon repeated challenge. However, this strategy does not represent human sensitization to airborne 
allergens, and relevant immune pathways, such as those involved in immunoregulation, may be 
skipped in such models. To explore the response to primary allergic sensitization in the airways, we 
compared classical i.p. sensitization (IP model) with primary allergen exposure in the airways in the 
absence of adjuvants (3IN, 10IN and 30IN models as detailed in Methods, Section 2), the latter 
resembling the way in which sensitization to airborne allergens naturally occurs in humans.  
 
1.1. Primary allergen exposure in the upper aiway elicits an attenuated pulmonary 
response with long-term decline. 
In the IP model, the OVA-challenged animals developed frank airway hyperresponsiveness, as 
reflected by a significantly increased RL (p<0,05 versus control group) on the 2.5, 5 and 10 mg/mL 
MCh doses (Figure 19-C and Table S1 in appendix). In the 10IN model, where the time span from 
the first exposure of the immune system to the allergen was similar to the IP model, the OVA-
challenged animals developed and attenuated RL response with borderline significant RL increases 
(p=0,078 at 10 mg/mL MCh) (Figure 19-B and Table S1 in appendix). To profile a timeline for the 
attenuated airway responsiveness observed upon primary allergen exposure in the airways, we 
developed and analyzed the 3IN and 30IN models. In the 3IN model, the RL curve of the OVA-
challenged animals largely overlaid that of the controls (Figure 19-A and Table S1 in appendix). In 
the 30IN model the RL curve was flattened in closeness to the control animals, although the limited 
RL increase reached statistical significance versus control (P <0.05) at 10 mg/mL MCh do to tight 
distribution variability (Figure 19-D and Table S1 in  appendix). These data showed that primary 
allergen exposure of the upper airway induces attenuated airway hyperresponsiveness, which 
reaches a plateau by week 10 after first exposure, and fades if i.n. antigen exposure continues. 
Intranasal vs. intraperitoneal sensitization model 
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Figure 19. Airway responsiveness to MCh. The RL response to MCh challenge was tested upon 
completion of the i.n. instillation protocols. The OVA-challenged animals showed: (A) no RL response in 
the 3IN model; (B) a bordelline significant RL increase in the 10IN model, as opposed to established 
airway hyperresponsiveness in the IP model (C); and (D) declined airway responsiveness in the 30IN 
model. †: P=0,08; *: P<0,05. 
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Figure 20. BAL cell counts. Total BAL cell counts (A) were significantly increased after the OVA 
instillations in all models, with a progressive ramp in the IN models. Differential leukocyte counts are 
shown as confidence intervals of the mean increment versus CTRL for each leukocyte population (B), 
and as population distribution bars (C). In (B), confidence intervals that mutually exclude the counterpart 
mean increment reflect significantly different increments with P<0.05. The differential counts showed 
that, while the inflammatory infiltration was strongly eosinophilic in the IP model, lymphocytes were the 
predominant infiltrating population in the IN models. In these models, the OVA-challenged animals 
showed an attenuated eosinophilic infiltration at 10IN, with a subsequent decline at 30IN. *: P<0.01 
versus their respective control group. †: P<0.05 versus IP, 3IN and 10IN control groups. 
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1.2. Eosinophilic inflammation follows a consistent trend with airway 
hyperresponsiveness in the lung but not in the upper airway. 
Total BAL cell counts were significantly increased in the OVA-challenged mice in all models, 
with a progressive gradient in the IN models (Figure 20-A). Among the control groups, a small but 
significant increase was observed in the 30IN group. In BAL differential counts (Figure 19-B,C and 
tables S2 and S3 in appendix), the eosinophil numbers in the OVA-challenged animals showed a 
trend consistent with the airway responsiveness data. In the IP model, the OVA-challenged animals 
showed strong eosinophilic inflammation in the BAL, whereas the OVA-challenged animals in the 
3IN, 10IN and 30IN models showed attenuated eosinophilic infiltration. These animals in the IN 
models showed, conversely, increased lymphocytic infiltration in the BAL, compared with the IP 
model. 
In lung tissue sections, the OVA-challenged animals showed strong airway inflammation in the 
IP model, and attenuated inflammatory infiltrates in the 10IN and 30IN models. The OVA-
challenged animals were devoid of airway inflammation in the 3IN model, as were control animals 
in all models (Figure 21). Eosinophil numbers in the airway wall, corrected by airway size, showed 
a trend consistent with the BAL eosinophil data in the OVA-challenged animals (Figure 21-E and 
Table S4 in appendix). In nose tissue sections, the OVA-challenged animals showed increased 
eosinophils in the IP, 10IN and 30IN models. Differently from the lungs, the nasal eosinophilic 
inflammatory infiltration increased progressively from the 3IN to the 30IN model, where it reached 
an intensity similar to the IP model (Figure 22 and Table S5 in appendix). Control animals showed a 
baseline presence of eosinophils in the nose, in all models, where the 10IN control group showed a 
higher presence of eosinophils compared with the control groups in the 3IN and 30IN models 
(Figure 22E and Table S5 in appendix). 
 
1.3. Primary antigen airway exposure induces an early mucoid response in the upper and 
lower airways. 
With the aim of studying the mucoid secretory response and goblet cell hyperplasia in the nose 
and lungs, as a feature of tissue remodeling in asthma and allergic rhinitis, tissue sections were 
stained with PAS technique. The number of PAS+ cells and the load of intraepitelially stored mucus 
in the respiratory epithelium were quantitatively assessed in the upper and lower airways. The 
OVA-challenged groups showed a significant increase in stored intraepithelial mucus and goblet 
cell numbers the airways, with the highest values attained in the IP model (Figure 23 and tables S6 
and S7 in appendix). In the IN models, the 3IN OVA animals showed an early increase, limited but 
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Figure 21. Lung inflammatory infiltrates. Tissue sections were stained with H-E. In the IP model, the 
OVA-challenged animals showed strong inflammatory infiltrates with increased eosinophils (A). 3IN 
OVA-exposed mice (B) showed no inflammatory infiltrates in the airways, similarly to the control groups 
in all models. In the 10IN model, the OVA-challenged mice showed attenuated infiltrates with increased 
eosinophisl as well (C), whereas the infiltrates were predominaltly mononuclear in the  30IN model (D). 
Insets show high-magnification detail of the inflammatory infiltrates. *: P<0.01 versus CTRL. Scale bars: 
100 μm in main panels, 20 μm in insets. 
A 
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significant, in both mucus production-related variables. The increased mucous load was more patent 
in the 10IN model, although attenuated in comparison with the IP model, and declined in the 30IN 
model. Regarding the nasal cavity and as stated in the methods section, we found that the proximal 
zone, particularly the septum, was the most sensitive area to changes induced by allergen challenge. 
All OVA exposed groups showed a significant mucoid response in this area of the nasal cavity 
(Figure 24 and tables S8 and S9 in appendix). Such response was already patent at the early stage as 
seen in the 3IN model, showing a greater response than in the lungs. All control groups showed a 
comparable basal mucous production.  
 
Figure 22. 
Subepithelial 
eosinophil 
infiltrates in the 
nose. Four-μm nose 
tissue sections were 
stained with H-E. 
OVA-challeged 
group in the IP 
sensitized model 
showed strong 
eosinophilic 
infiltrates in the 
nose (A). All PBS-
instilled mice 
showed a limited 
baseline eosinophil 
presence, as 
comparably did the 
OVA-challenged 
mice in the 3IN 
model (B). The 
OVA-challenged 
groups in the 10IN 
(C) and 30IN (D) 
models showed 
increased 
eosinophils, without 
differences among 
them (E) or versus 
the OVA challenged 
group in the IP 
model. *: P<0.01 
versus CTRL. †: 
P<0.05 versus 3IN 
and 30IN control 
groups. Scale bars: 
50 μm.  
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1.4. Subepithelial collagen deposition and airway contractile tissue mass increase with 
greater i.n. allergen exposure in the lung.  
To evaluate subepithelial fibrosis as an asthma airway remodeling feature, Masson's trichrome-
stained lung sections were digitally processed to extract and measure the trichrome blue dye 
component, which reflects collagen deposition. The dimensionless index resulting from 
normalization by airway size was termed “extracellular matrix mass” (Figure 25 and Table S10 in 
appendix). In the IN models, the extracellular matrix mass peaked in the 10IN OVA-challenged 
Figure 23. PAS 
staining in lung 
sections. Lung 
tissue sections were 
stained with PAS to 
quantify goblet cell 
number and 
intraephithelial 
mucus load. 
Representative 
airways of OVA-
challenged animals 
in the IP (A), 3IN 
(B), 10IN (C) and 
30IN (D) models are 
shown. Goblet cell 
(E) and mucus load 
(mucoid mass) (F) 
quantification 
yielded comparable 
data. Control groups 
showed no mucous 
response in the 
lungs, while OVA-
challenged groups 
showed a variable 
response. The IP 
model showed a 
strong response. The 
3IN model showed a 
limited response that 
increased in the 
10IN model, and 
declined in the 30IN 
model. *: P<0.01 
versus control 
(CTRL); †: P<0.05 
versus 3IN; ‡: 
P<0.05 versus 3IN, 
10IN and 30IN. 
Scale bars: 100 μm. 
A 
D 
F 
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animals, and was significantly increased in both the 10IN and 30IN models. There were no 
significant increases in the IP nor 3IN OVA-challenged animals. 
 
Figure 24. PAS staining in nose tissue sections. Proximal nose sections were PAS-stained to quantify 
goblet cells and intraephithelial mucus. Control groups showed no differences across the models (3IN 
control group shown in A). The OVA-challenged animals showed significantly increased amounts of both 
goblet cells and epithelial mucous load in the IP (B), 3IN (C), 10IN (D) and 30IN (E) models. Goblet cell 
(F) and mucous load (G) quantification showed comparable trends..*: P<0.01 versus control (CTRL); †: 
P<0.05 versus 3IN; ‡: P<0.05 versus all other OVA-challenged groups. Scale bars: 100 μm. 
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Airway contractile tissue mass was quantified on the basis of α-SMA immunofluorescence and 
digital signal extraction and processing (Figure 26). No differences between controls and OVA-
challenged animals were found in the 3IN and 10IN models. The airway contractile tissue mass 
showed its greatest increase in the OVA-challenged animals of the IP model, and was weakly but 
significantly increased in the 30IN.  
Figure 25. Trichrome 
staining of lung 
sections. Masson's 
trichrome was employed 
to evaluate subepithelial 
fibrosis, quantitatively 
evaluated as extracellular 
matrix mass (ECM) (E). 
Collagen fibers stained 
blue, and ECM masss 
was calculated from 
digital color extraction. 
OVA-challenged animals 
in the IP (A) and 3IN (B) 
models showed a light 
subepithelial collagen 
deposition similar to 
control mice baseline 
(not shown). Conversely, 
ECM was significantly 
increased in the OVA-
challenged animals of the 
10IN and 30IN models 
(C and D). *: P<0.01 
versus controls (CTRL). 
Scale bars: 100 μm. 
 
A B 
C D 
E 
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Figure 26. Alpha-
SMA 
immunofluorescenc
e and airway 
contractile tissue 
mass (MCT) 
quantification. The 
OVA challenged 
animals showed a 
significant increase 
in contractile tissue 
mass (MCT) versus 
control (CTRL) in 
the IP model (A, E). 
Increased MCT was 
absent in the 3IN (B) 
and 10IN (C) 
models, and was 
weak but significant 
in the 30IN model 
(D). *: P<0.01 
versus CTRL. †: 
P<0.01 versus 3IN, 
10IN and 30IN. 
Scale bars: 100 μm 
in A, B and D; 200 
μm in C. 
A B
C D
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1.5. Foxp3, Il10, and Tgfb mRNA levels increase according with antigen tolerance upon 
primary airway exposure, but not in the IP model. 
Due to failure to detect FOXP3 protein by immunohistochemistry on formalin-fixed mouse 
tissues (data not shown), we analyzed Foxp3 mRNA by FISH, and the expressing cells were 
quantified in the inflammatory infiltrates of OVA-challenged animals. To further assess the 
immunoregulatory function, Il10, and Tgfb mRNA was also analyzed by the same method (Figure 
27 and Table S12 in appendix). The OVA-challenged animals of the 3IN model, devoid of 
inflammatory infiltrates, were taken as controls for this purpose. The OVA-challenged animals in 
the IP model showed the greatest numbers of Foxp3 mRNA+ lymphocytes. In the IN models, there 
was a progressive increase in Foxp3-transcribing cells that became significant in the 30IN group, 
but this maximum was 20.3% the IP model mean. Il10 and Tgfb mRNA-expressing cells were 
significantly increased through a joint gradient in the IN models, from the 3IN to the 30IN animals. 
The IP animals showed increased Il10 mRNA-expressing cells, comparably to the 10IN-30IN 
midpoint, and a tendency to similarly increased Tgfb mRNA-expressing cells.  
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Figure 27. FISH in lung 
tissue for Foxp3, Tgfb and 
Il10 mRNA detection. 
Foxp3+ cells were largely 
increased as part of the 
inflammatory infiltrates in 
the OVA challenged 
animals of the IP model (A, 
E). In the IP models, 
Foxp3+ cells increased 
progressively to reach 
significant but limited 
numbers in the 30IN model 
(B, E). For co-localized 
cytokine and Foxp3 mRNA 
analysis, Il10 (C), or Tgfb 
(D) probes were labeled 
with an in infra-red 
emission fluorochrome 
(Alexa Fluor A647) and the 
signal was visualized as red 
pseudocolor, whereas 
Foxp3 (Alexa Fluor A594) 
was colored green. (F-H) 
show an example of Foxp3 
and Il10 mRNA co-
localization in high-
magnification detail (F, 
Foxp3-Alexa Fluor A594 
channel; G, Il10-Alexa 
Fluor A647 channel ; H, 
overlay). The example 
shown is also representative 
of Foxp3+, Tgfb+ cell 
visualization . 
*: P<0.01 versus 3IN; †: 
P<0.05 versus 3IN and 
10IN; ‡: P<0.05 versus 3IN, 
10IN and 30IN. Scale bars: 
30 μm in A, B; 5 μm in C, 
D; 2.5 μm in F-H.  
RESULTS 
 123 
 
2. Role of effector and regulatory T cells in experimental asthma: effector versus regulatory 
arms. 
Classical experimental asthma models, based on i.p. or subcutaneous sensitization to antigen 
with adjuvants, have played a major role to understand the adaptive immune response that underlies 
allergic asthma and the role that effector CD4+ T cells play in it. However, such models may by-
pass T cell-driven regulatory pathways that are present in actual asthma where primary allergen 
exposure occurs in the airways. The results from the IN models presented here show that primary, 
sustained antigen exposure in the airways leads to an overall attenuation of asthma features and to a 
shift from an eosinophilic to a predominantly lymphocytic inflammatory profile, and suggest that 
IL10 and TGFB secreting Tregs may be involved in these effects. On the next section, we aimed at 
demonstrating the role of effector CD4+ T cells and FOXP3+CD4+ Treg cells. For this purpose, we 
performed T cell adoptive transfer experiments in experimental asthma with sole antigen exposure 
in the airways. 
 
2.1. Generation of antigen-specific CD4+T cells 
To study the role of the effector T cells in experimental asthma we generated antigen-specific 
CD4+ T cells in vitro, with forced GFP expression for subsequent tracking in vivo. With the aim of 
to obtain lymphocytes with forced GFP expression, gfp cDNA was subcloned in the MCS of the 
commercial pMSCV expression vector (Figure 28-A,C) between XhoI (5’) and EcorRI (3’) 
restriction sites, resulting in the pMSCV-GFP vector (Figure 28-B). The correct insertion of the gfp 
cDNA was checked by digesting pMSCV-GFP with XhoI and EcoRI restriction enzymes, which 
liberated the gfp cDNA (Figure 28-D). 
 Splenocytes from OVA-sensitized donors were expanded and transduced in vitro with 
pMSCV-GFP virions under OVA stimulation (see section 4 in methods). This resulted in antigen-
specifc CD4+ T cells with forced GFP expression that were purified by cell sorting and used for 
adoptive transfer to unsensiticed recipients. A titration was performed to infer the minimum number 
of effector CD4+ T cells able to induce experimental asthma features. 
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2.2. Adoptive transfer of antigen-specific effector T cells to unsensitized recipients 
induces lung inflammation after 3 i.n. instillations. 
Fourty-eight hours after the first i.n. instillation, the group that received 1x105 OVA-specific 
AcGFP+/CD4+ T cells and were OVA-challenged showed airway hyperresponsiveness, determined 
as per a significant RL increase at [10 mg/mL] MCh compared with PBS-instilled mice (control 1) 
or with mice that received non-activated T cells and were i.n. OVA-instilled (control 2). OVA-
instilled animals that were transferred 0.25x105 or 0.5x105 OVA-specific AcGFP+/CD4+ T cells did 
not show significant RL increases (Figure 29, and Table S13 in appendix). BAL cell counts revealed 
Figure 28. Construction of pMSCV-GFP expression vector. Gfp was amplified from pAcGFP vector by 
PCR (C, column G, 742 bp band) using XhoI and EcoRI sticky end primers, and subcloned into the pMSCV 
expression vector (A and C, column X, 6295 bp band). To verify correct assembly, the resulting pMSCV-
GFP vector (B) was digested with XhoI and EcoRI, which liberated the gfp insert (D, column M, blue 
arrow, 742 bp band) from the plasmid (D, column M, red arrow, 6283 bp band). Vector drafts were 
designed using the New England Biolabs tools (available on www.tools.neb.com). λ: lambda-HindIII 
marker (Roche Diagnostics); G: GFP PCR; X: linearized pMSCV after digestion with XhoI and EcoRI; M: 
modified pMSCV-GFP vector digested with XhoI and ClaI. 
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a significant increase in total 
leukocytes for OVA-challenged 
animals with adoptive transfer of non-
activated T cells versus the PBS-
instilled group with adoptive transfer 
of activated effector T cells (Figure 
30, and Table S14 in appendix). The 
OVA-challenged mice that received 
1x105 OVA-specific AcGFP+/CD4+ T 
cells had a significant increase in total 
BAL leukocytes versus both control 
groups. No significant increase in total 
BAL cells was observed among the 
0.25 x105, 0.5x105 or 1x105 
AcGFP+/OVA animals. Histological 
examination of H-E stained lung 
sections revealed more infiltrating 
cells in the OVA versus PBS-challenged animals (Figure 31). Immunhistochemical GFP staining 
showed GFP+ cells infiltrating peribronchial tissues and alveolar spaces (Figure 32) in all OVA-
challenged groups that received antigen-specific, activated T cells. Histopathological examination 
did not suggest 
any differences in 
airway contractile 
tissue mass, 
subepithelial 
fibrosis or mucous 
production among 
the groups. 
 
Figure 29. Airway responsiveness to MCh after 
adoptive transfer of antigen-specific effector T cells. 
Three experimental groups were respectively transfered 
0.25, 0.5 or 1 x 105 GFP+ effector T cells (Teff), and were 
OVA-challenged. These groups were compared with two 
control groups: recipients of effector T cells, PBS-instilled 
(control 1); and recipients of naive T cells, OVA-instilled 
(control 2). Only the group that received 1 x 105 specific 
GFP+ T cells showed a significant RL increase on 
maximum MCh dose. *: P < 0.05 versus controls 1 and 2. 
Figure 30. BAL cell 
counts after adoptive 
transfer of antigen-
specific effector T 
cells. Total BAL cell 
counts were performed 
in recipients of effector 
T cells (Teff) or naive 
T cells (N/A T cells), 
challenged with OVA 
or PBS, as indicated. *: 
P<0.05 versus control 
group 1 (recipients of 
1x105 effector T cells, 
PBS-instilled); 
†: P<0.05 versus 
control group 2 
(recipients of 1x105 
naive T cells, OVA-
challenged). 
Adoptive transfer models 
 126 
 
2.3. Generation of antigen-specific Treg cells 
To study the role of antigen-specifc Treg cells in a mouse model of asthma with ongoing 
disease, we generated antigen-specific Treg cells in vitro, with stable FOXP3 expression, by means 
of retroviral gene transduction. These cells co-expressed GFP for subsequent tracking in the 
recipient animals. For this purposes we used a bicistronic vector with two open reading frames 
separated by an IRES sequence, with one common promoter that drives co-expression of the two 
subcloned cDNAs. Due to our preferred use of the AcGFP1 GFP variant, the bicistronic expression 
vector pRetroX-IRES-ZsGreen (Figure 33-A), as commercially provided, was amplified to 
eliminate the ZsGreen cDNA encoding ZsGreen GFP variant (Figure 33-C, and methods section). 
To track the transduced cells, a cDNA encoding AcGfp1 and puromycin resistance ("puro") (Figure 
33-D) was subcloned in place of ZsGreen, resulting in a construct that we term pRetroX-IRES-GFP 
A B C 
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Figure 31. Histopathological analysis of lung tissue sections, adoptive T cell transfer 
experiments. Four-μm lung tissue sections were stained with H-E. OVA exposed mice that received 
105 activated GFP expressing T cells (A) and mice instilled with PBS that received 105 non-activated 
T cells (B), showed no inflammation after 3 PBS or OVA i.n. instillations, respectively. The 
predominant leukocytes present in the air spaces were alveolar macrophages (A and B insets). 
Animals that were recipients of of 2.5 x 104 (C), 5.0 x 104 (D) or 1 x 105 (E) activated, GFP 
expressing, T cells, and were OVA-challenged, showed progressive mononuclear and eosinophilic 
airway inflammatory infiltrates ranging from quasi-normality (inset C) to unequivocal inflammation 
(inset E), respectively. Scale bars: 500 μm in main panels, 20 μm in insets.
D 
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vector herein (Figure 33-E). The Foxp3 cDNA was then amplified (Figure 33-E) and subcloned into 
the MCS of the pRetroX-IRES-GFP construct (Figure 33-F), resulting in the pRetroFOXP3-IRES-
GFP vector (Figure 33-B). 
 
To verify the performance of the pRetroFOXP3-IRES-GFP vector, we checked GFP expression 
in tranfected Phoenix packaging cells by flow cytometry. After transfection, the Puromycin resistant 
cells expressed GFP (Figure 34-A,B). We then expanded pRetroFOXP3-IRES-GFP transfected and 
puromycin-selected Phoenix cells to produce retroviruses. The retroviral supernatants were tested 
by transducing NIH3T3 cells, which properly expressed GFP (Figure 34-C,D). As an additional 
check point, transduced NIH3T3 cells were checked for GFP and FOXP3 expression by Western 
Blot (Figure 34-E). 
Figure 32. Tracking of adoptively transferred T cells by GFP detection on lung tissue sections. 
Four-μm lung sections were immunostained using JL-8 monoclonal antibody to GFP. (A) Recipients of 
naive, non-transduced T cells, OVA-challenged. (B) Recipients of 1x105 activated GFP+ T cells, PBS-
instilled. (C-D) Recipients of 0.25 x 105, 0.5 x 105 and 1 x 105 activated GFP+ T cells, OVA-challenged, 
respectively. The GFP signal is seen as a red cytoplasmic signal. A progressive presence of GFP+ cells 
can be observed in (C-E, insets). Scale bars: 500 μm in main panels, 20 μm in insets. 
A B C 
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To generate Treg cells, splecnocytes from HDM-sensitized donors were expanded in vitro and 
transduced with pRetroFOXP3-IRES-GFP under HDM stimulation (see section 4 in methods). This 
resulted in antigen-specifc Treg cells with forced FOXP3 and GFP expression. The transduced cells 
were checked for GFP, FOXP3 and CD25 expression by flow cytometry (Figure 35-C, D). Also, 
CD25+ FOXP3+ Treg cells were found among total CD4+ lymphocyte population (Figure 35-E). 
Moreover, GFP+ cells are also CD25+, which in turn implies FOXP3 expression. GFP+ lymphocytes 
Figura 33. Construction of the pRetroFOXP3-IRES-GFP expression vector. pRetroX-IRES-GFP 
bicistronic vector (A) was modified to obtain pRetroFOXP3-IRES-GFP (B), which drives co-expression of 
FOXP3 and GFP. ZsGreen was removed by PCR using primers with XhoI sticky ends (C, red arrow, 5252 
bp band). The GFP-Puro fragment was amplified from pMSCV-GFP using XhoI sticky end primers (D, red 
arrow, 1855 bp band) and subcloned into the XhoI site. The resulting pRetroX-IRES-GFP vector had a 7107 
bp length (E, column X). Foxp3 cDNA was amplified using NotI and ClaI sticky end primers (E, column F, 
1290 bp) and subcloned into the pRetroX-IRES-GFP MCS. To verify correct assembly, the pRetroFOXP3-
IRES-GFP was digested with NotI and ClaI, which liberated the Foxp3 insert (F, blue arrow, 1290 bp band) 
from the plasmid (F, red arrow, 7107 bp band). W: pRetroX-IRES-XhoI PCR lane; λ: lambda-HindIII 
marker; G: GFP-Puro PCR lane; XIV: DNA molecular weigh marker XIV; X: linearized pRetroX-IRES-
GFP; F (lane in E): Foxp3 PCR lane; M: pRetroFOXP3-IRES-GFP digested with XhoI and ClaI. 
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were purified by cell sorting (Figure 35-A,B) and used for adoptive transfer to HDM-sensiticed 
recipients with allergic disease ongoing.  
 
Figure 34. Verification of expression vector competence. Transfected Phoenix cells were selected with 
puromycin, and the resistant cells checked for GFP expression by flow citometry (A, B: example of 
Phoenix cell cultures transfected with pRetroFOXP3-IRES-GFP, after Puromycin selection). Viral 
supernatants were titrated on NIH3T3 cells (C, D: example of NIH3T3 cells transduced with 
pRetroFOXP3-IRES-GFP viruses, where almost 97% of cells were successfully trasduced). Additionally, 
Foxp3 and GFP expression was checked by Western blot assay (E) on two pools of NIH3T3 cells after 
transduction with pRetroFOXP3-IRES-GFP viruses (second and third gel columns). In the first column, a 
non-transduced pool of NIH3T3 cells was run. Alpha-tubulin was used as a positive control for all 
cellular pools. In the flow cytometry histograms, blue lines represent non-transduced controls and green 
lines represent transduced populations. 
B
C D
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2.4. Adoptively transferred, antigen-specific Treg cells attenuate airway inflammation 
and hyperresponsiveness in an HDM-induced experimental asthma model. 
To test the effect of Treg cells on ongoing disease, we conducted pilot adoptive transfer 
experiments on a murine model of experimental asthma induced by primary HDM exposure in the 
airways. For this purpose, the animals received i.n. HDM instillations under the same regime and 
protocol duration as the 30IN model. Upon reaching 28 HDM instillations, the mice (n=4) showed 
Figure 35. T cell transduction with pRetroFOXP3-IRES-GFP viruses. Following in vitro retroviral 
infection, T cells were checked for GFP expression. (A) GFP signal in the cultured splenocyte population. 
(B) Forward/side scatter distribution of the GFP signal (green) gated in the R1 region, consistent with a 
FSC/SSC profile of activated T cells. GFP+ cells were CD25+ (C) and, among CD4+ cells (D), there was a 
subpopulation expressing FOXP3. Most Foxp3+ cells were also CD25+ (E). 
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airway hyperresponsiveness, reflected as a significant RL increase on the 5 and 10-mg/mL MCh 
doses, compared with the PBS-instilled animals of the 30IN model (n=10), which acted as a control 
group (figura 36 and Table S15 in appendix). The HDM-challenged animals also showed a 
significant increase in lung airway contractile tissue mass (Figure 37 and Table S16 in appendix), 
and total BAL cell counts (Figure 38-E and Table S17 in appendix). On histopathological 
examination, they showed inflammatory lung infiltrates comprising mononuclear cells and 
eosinophils (Figure 38-A,B), and mucus overproduction in the airway epithelium. 
 
To explore the immunoregulatory capacity of Treg cells, we injected 7.5x104 in vitro-induced 
Treg cells (see methods) to HDM-challenged mice (n=4) on day 31 of the i.n. instillation protocol 
and continued the protocol up to completion on day 37 (28 HDM instillations). These animals 
showed attenuated responsiveness to MCh (figura 36 and Table S15 in appendix). Histopathological 
examination of lung sections showed decreased inflammatory cell infiltration and attenuated 
mucous production in the Treg cell recipients (Figure 38A-B). Immunohistochemical GFP detection 
on lung tissue sections revealed GFP+ Treg cells infiltrating peri-bronchiolar trafficking zones 
(Figure 38C-D). The Treg cell recipients also showed a tendency to a decrease in total BAL cell 
counts, with borderline statistical significance (Figure 38E and Table S17 in appendix). No airway 
contractile tissue mass reduction was found versus the HDM-challenged animals that did not receive 
Treg cells (Figure 37 and Table S16). 
Figure 36. RL responsiveness to 
MCh after adoptive transfer of 
Treg cells. Airway responsiveness to 
MCh challenge was tested in HDM-
instilled animals, in comparison with 
PBS-instilled animals (control group 
of the 30IN model), and HDM-
instilled animals that received 
adoptively transferred Treg cells. For 
the comparison between the HDM-
instilled groups, the MCh dosing was 
further extended to 20 mg/mL.  
*: P<0.05, HDM versus PBS;  
†: P=0.005 HDM+Treg versus PBS; 
‡: P=0.08 HDM versus HDM+Treg. 
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3. FOXP3+ cells infiltrate the bronchial mucosa of subjects with severe asthma. 
FOXP3+ cells were detected in variable numbers in the bronchial biopsies from subjects with severe 
asthma, and were virtually absent in control subjects (Figure 39 and Tables 7, 8 and S18). The 
FOXP3+ cells had lymphocyte morphology and mainly localized in the lamina propria connective 
tissue under the respiratory epithelium, often as part of inflammatory infiltrates.  
A 
C 
Figure 37. Airway 
contractile tissue mass 
(MCT) in the Treg 
adoptive transfer model. 
Animals instilled with 
HDM (A), and animals 
instilled with HDM that 
received 75000 GFP+ Treg 
cells (B), showed both a 
significant increase in MCT 
compared with the control 
animals of the 30IN model 
(C) *: P<0.01 versus the 
PBS challenged group of 
the 30IN model. Scale bars: 
100 μm. 
B
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Figure 38. Airway inflammatory cell infiltrates and GFP+ Treg cell tracking. Four-μm lung tissue 
sections were stained with H-E (A, B) or were immunostained for GFP antibody (C, D, red cytoplasmic 
signal). Untreated HDM-challenged mice (A) presented mononuclear and eosinophilic inflammatory 
infiltrates. In the Treg recipients (B), the infiltrates appeared somewhat less dense. As for GFP detection, no 
signal was observed in untreated animals (C). In the Treg recipients (D), GFP+ Treg cells were found 
infiltrating the conective tissues that bridge the airways with accompanying vessels, which provide 
leukocyte trafficking pathways. (E) Total BAL cell counts. *: P<0.01 versus 30IN control group (HDM-, 
Treg-). Scale bars: 500 μm in A, B; 200 μm in C, D; 20 μm in insets. 
A 
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Figura 39. FOXP3+ cells in human bronchial biopsies. Four-μm thick tissue sections of human tonsil (A) 
and bronchial biopsies (B – E) were immunostained to detect FOXP3. The tonsil was used as a positive 
staining control, where FOXP3+ cells are densely distributed in the interfollicular T cell zone (A). Bronchial 
biopsies from control subjects were virtually devoid of FOXP3+ cells (B,  F), whereas most biopsies from 
asthmatics showed a number of lymphoid FOXP3+ cells infiltrating the subepithelial connective tissue (C – 
F).  *: P<0.01 versus control group (CTRL). Scale bars: 200 μm in (A); 100 μm in (B, C); 50 μm in (D); 2.5 
μm in (E). 
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Table 7. Subject clinical data 
 
Age 
Mean ± SEM 
[range] 
Gender 
Female:Male 
Atopy 
Yes:No 
FEV1, 
(predictive value, %) 
Mean ± SEM 
FEV1/FVC 
(ratio, %) 
Mean ± SEM 
Controls 
61.00 ± 3.72 
[16] 
1:4 2:3 85.50 ± 1.5 83.50 ± 11.5 
Severe 
Asthma 
56.28 ± 2.24 
[37] 
23:6 22:7 67.20 ± 4.54 63.12 ± 2.23 
SEM: standard error of the mean 
FEV1: forced expiratory volume in 1 second 
FVC: forced vital capacity 
 
 
 
Table 8. Indications for bronchoscopy in control subjects 
 
Subject number Indication for bronchoscopy 
1 Lung nodule 
2 Bronchoscopy after lung transplantation 
3 Middle lobe endobronchial atelectasis 
4 Lung infiltrate (X-ray) 
5 Lung infiltrate (X-ray) 
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Animal models of experimental asthma allow for the study of biological disease mechanisms 
with a scope and depth not possible on human subjects. Many hypotheses generated from clinical 
observation in patients can be explored using experimental models, and the data from such models 
can often be translated to the human setting. Animal models play as well a crucial role in the 
preclinical development of new drugs by the pharmaceutical industry. There is a variety of 
publications in the literature where different animal species have been used to model asthma (55, 
117, 133, 154, 164, 204, 208, 600). The animal most often employed is the mouse, due to its low 
cost and easy handling, but also due to the similarities seen between murine experimental asthma 
and actual human asthma. In fact, it is possible to reproduce human asthma features in the mouse, 
such as: the adaptive immune response against allergens, orchestrated by effector CD4+ T cells with 
a Th2 activation phenotype; airway inflammatory infiltration involving lymphocytes, eosinophils 
and mast cells; structural airway wall alterations reflecting airway remodeling; and airway 
hyperresponsiveness leading to airflow obstruction upon nonspecific airway challenge. The latter is 
considered the functional correlate of airway inflammation and remodeling, and is a cardinal human 
asthma feature (149, 160, 601, 602). However, animal models have limitations to be considered 
when interpreting the data in the human disease translation context. In most studies reported on 
animal asthma models, the experimental disease was induced by allergic sensitization through one 
or more i.p. or subcutaneous injections containing the allergen and an adjuvant, then followed by 
airway antigen challenges. Therefore, such models involve a vaccine-like sensitization stage 
followed by secondary airway antigen exposure, an approach that does not truly represent how 
airway allergic disease is acquired in humans. Such an approach, devoid of any involvement of the 
respiratory epithelia during primary antigen exposure, may indeed skip relevant immunoregulatory 
pathways involved in the mechanisms of tolerance and allergic responses.  
In the work presented in this thesis, we aimed at studying the role of immune regulation 
employing experimental asthma models based on primary antigen exposure in the airways, in the 
absence of prior subcutaneous or i.p. sensitization, to better represent the natural acquisition and 
development of airway allergic disease to perennial airborne allergens through models 
encompassing all immunological pathways involved in the disease, both effector and regulatory. For 
this purpose, the animals were airway-exposed to antigen or control through continued protocols, 
without a defined distinction between a sensitization phase and secondary exposure. Because OVA 
has been generally used as an allergen to model asthma in animals (55, 133, 164, 200-202, 263, 
603-607), and with the purpose of referencing our data from primary airway antigen exposure 
modeling to a classical i.p.-sensitization model (600), we adhered to the use of OVA in our i.n. 
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instillation models despite the limitation and certain criticism that OVA is not an actual airborne 
allergen related to human airway disease (608). We chose i.n. instillation as the procedure for 
airway allergen exposure based on previous studies by us (600), and others who reported that 
antigens administered by i.n. instillation reach the intrathoracic airways and are deposited into the 
lungs (151, 200). Other approaches for airway allergen exposure have been less used and present 
practical inconveniences or limited lung deposition. Antigen delivery through orotracheal intubation 
or tracheotomy requires general anesthesia, and surgery in the latter case. Such methods are 
controversial as a repeated procedure on the same animal due to the invasive intervention required. 
Another approach is the exposure of awake animals to allergen nebulized into a chamber, which 
results in poor deposition in the airways and facilitates bowel allergen exposure, partly indirectly 
through skin deposition and licking, which may induce immune tolerance. In fact, the inhalation of 
aerosolized OVA in an exposure chamber has been used as a model of antigen tolerance induction 
(609, 610). Conversely, i.n. OVA instillations lead to IgE-mediated airway inflammation by week 5 
after primary exposure in the A/J mouse (263). In order to profile the timeline of the immune 
response and associated experimental disease driven by i.n. instillation, we developed the 3IN, 10IN 
and 30IN models. The 3IN model was aimed at providing a minimum or no-response reference, 
within an early time window where an adaptive immune response leading to IgE-mediated airway 
inflammation could not yet be developed. It is widely accepted that the time elapsed from the first 
contact of the immune system with an immunizing antigen to the attainment of a primary adaptive 
immune response is about 7 days (611). Therefore, the response if any observed in the 3IN model 
shall be attributable to the innate immune system. The 10IN model cutoff was chosen as the time 
point where the time elapsed from the first contact with the antigen was equivalent to the time span 
of the comparator model, the IP model, from the first i.p. injection for sensitization to the last i.n. 
challenge. Finally, the results obtained in the in 10IN model led us to develop the 30IN model, to 
represent extended chronicity and analyze whether the experimental asthma features elicited in the 
10IN model would worsen, plateau or decline.  
We chose RL responsiveness to MCh, an in vivo lung function output sensitive to airway 
hyperresponsiveness, as the primary outcome to evaluate the development of experimental disease 
through the 3IN, 10IN and 30IN models. The inhalation of nebulized MCh, an acetylcholine-
analogue cholinergic agent (68), stimulates muscarinic receptors in the airway smooth muscle and 
induces smooth muscle contraction, which in turn increases RL. In animals with experimental 
asthma, RL increases significantly through progressive MCh doses in comparison with control 
animals. Testing RL responsiveness to MCh under mechanical ventilation in experimantal animals 
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serves indeed as a close analogue to spirometric testing of airway hyperresponsiveness in humans. 
In the experiments presented in this thesis, the OVA-challenged animals of the IP model showed a 
steep, significant RL increase versus the control group, i.e. frank airway hyperresponsiveness, 
consistent with the established features of this immunization-driven model. In the 3IN model, the RL 
response profile of the OVA-challenged mice closely followed that of the control group, an 
expected outcome in the absence of an adaptive immune response and dependent IgE and effector T 
cell-driven inflammatory mechanisms. In the 10IN model, the OVA-challenged animals yielded 
reduced RL increases in comparison with the frank hyperresponsiveness seen in the IP model. The 
RL response was in this case limited to borderline statistical significance versus the control group. 
Thus we interpreted this result as an attenuation but not complete blunting of airway 
hyperresponsiveness, attributable to regulatory mechanisms only elicited by primary antigen 
exposure in the airways. Such regulatory mechanisms likely arose from “natural” exposure to 
airborne antigen, in close interplay with the effector pathways driving airway inflammation and 
hyperresponsiveness, and were bypassed in the classical IP model. In view of the 10IN model data, 
we enquired whether the attenuated airway response would fully develop into consolidated airway 
hyperresponsiveness should airway antigen challenge continue for a prolongued period. This was 
tested in the 30IN model where, conversely, the RL response in the OVA-challenged animals 
declined and closely approached the control group such as in the 3IN model. In summary, primary 
allergen exposure in the airways led to limited, borderline airway hyperresponsiveness that declined 
upon sustained airway antigen challenge. Control groups showed RL increments, significant versus 
intra-group baseline RL at the highest MCh doses, which reflects physiologic airway reactivity to 
inhaled cholinergic agonist as also seen in clinical MCh testing on healthy subjects. 
Airway inflammation was evaluated by total and differential BAL cell counts, and 
histopathological examination of lung tissue sections with quantitative morphology to determine the 
numbers of eosinophils infiltrating the airway wall. All OVA-challenged groups had significantly 
increased BAL total cell counts versus their respective control groups. Control groups were 
homogeneous across the IP, 3IN and 10IN models, whereas the 30IN control groups showed a 
modest but significant increase in total BAL cells, attributable to nonspecific leukocyte recruitment 
through a 70-day long i.n. instillation regime. Such BAL cell increase in the 30IN control group was 
due to lymphocyte influx, as shown by the differential counts. Although without an impact on total 
BAL cells, the control group of the IP model showed increased eosinophils compared with the IN 
control groups, attributable to background systemic Th2 activity. The OVA-challenged group in the 
IP model showed robust eosinophilic inflammation consistent with previous reports (55, 154, 164, 
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600), reflected in the BAL differential counts and quantitative morphology data. The IN models 
showed attenuated eosinophil infiltration in the OVA-challenged animals, with a trend paralleling 
the RL response, best reflected in the airway wall counts as per quantitative morphology. It is 
noteworthy that the 3IN model showed a limited but significant eosinophil influx in the airways. 
Such eosinophil increment is unlikely to have occurred through IL5 released by activated Th2 cells 
or IgE-mediated mastocyte degranulation. Innate immune system pathways, perhaps involving 
alternative mastocyte activation, may have accounted for the eosinophil response in the 3IN model 
(612). Contrary to the attenuation of eosinophilic infiltration, the IN models showed a relevant 
increase of lymphocytres in the airways, quantitatively demonstrated in the BAL differential counts 
and consistently observed on examination of lung tissue sections. In summary, primary antigen 
exposure in the airways elicited attenuated airway inflammation and hyperresponsiveness, and 
shifted cell infiltrates from eosinophilic to a predominantly lymphocytic pattern. 
Airway mucus production was analyzed by goblet cell counts and PAS color extraction 
(mucoid mass), with both approaches yielding equivalent results. All OVA-challenged groups 
showed significantly increased mucus production versus their respective control groups. In the 3IN 
model, the OVA-challenged group showed a considerable increment of mucoid mass in the lungs, 
regardless the brief i.n. instillation period. Goblet cell hyperplasia and mucus overproduction are 
characteristic changes of the lower and upper airways in asthma and allergic rhinitis, respectively. 
In asthma, the degree of mucus secretion contributes to disease severity and its substrate, goblet cell 
hyperplasia, is considered an airway remodeling feature (49, 51, 52, 54, 60, 613-615). The 
mechanisms that induce these changes in asthma are poorly understood, but animal models have 
pointed at cytokines such as IL9 and IL13 as implicated (53-55). The involvement of IL13, a major 
cytokine produced by activated Th2 lymphocytes, links the adaptive immune response to mucus 
hyper-production. However, the presence of significant goblet cell hyperplasia and mucus 
overproduction in the airways of OVA-challenged mice in the 3IN model suggest that this early 
response, which occurred ahead of the necessary time to mount an adaptive immune response, may 
be driven by in innate immunity mechanisms during the process of allergic disease induction. In the 
nasal mucosa, OVA exposure induced goblet cell hyperplasia and increased mucoid mass, the 
greater the longer exposure in the IN models. The nasal septum region was the most sensitive to 
such changes. Overall, the data suggest that the mucoid response to antigen exposure is initiated 
before the specific adaptive immune response develops, an idea that links the innate immune system 
with the early induction of one of the components of airway remodeling, as is mucus 
overproduction. The mucoid response in the nose seems indeed independent from lower airway 
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eosinophil infiltration and the overall lung response, because the IN models showed a progressive 
increase in mucus production, particularly reflected in the mucoid mass measurements, despite the 
tendency to a decline of eosinophilic infiltration and goblet cell hyperplasia in the lungs. Therefore, 
the mucosal responses to allergen exposure may be differentially regulated in the upper airway and 
the intrapulmonary airways. 
Subepithelial fibrosis is a relevant feature of airway remodeling in asthma. We measured 
collagen deposition in the lungs by Masson's trichrome staining and digital color extraction analysis. 
The OVA-challenged mice in the 10IN and 30IN models showed significantly increased collagen 
deposition in the lamina propria of the intrapulmonary airways. Conversely, there was no significant 
increase in the IP and 3IN models. In both cases, the absence of subepithelial fibrosis is attributable 
to the short airway antigen exposure, particularly in the IP model. Since prolonged airway challenge 
of sensitized animals led to increased collagen deposition in a prior IP model (600), the data suggest 
that subepithelial fibrosis is associated with chronicity and may be driven by the adaptive immune 
response.  
Increased airway smooth muscle, at the expense of both hyperplasia and hypertrophy, is 
considered central to the mechanism of airway hyperresponsiveness and airflow obstruction (26, 27, 
61). The smooth muscle increment also correlates with disease severity (561, 616). The increased 
thickness of the airway smooth muscle layer is in fact the airway remodeling feature on which most 
attention has been focused, and for which the largest data body has been generated. Mechanisms 
proposed for the growth of airway smooth muscle in asthma include: (i) in situ proliferation, at least 
in part induced by the proximity of mastocytes (62) or by direct T cell contact (133, 561); (ii) the 
migration and differentiation of fibroblasts or dedifferentiated smooth muscle cells (65, 617); and 
the recruitment and differentiation of fibrocytes, a circulating, bone marrow-derived progenitor cell 
(618, 619). Changes in myocyte contractile properties may also contribute to the mechanism of 
airway hyperresponsiveness (66). In addition, airway smooth muscle cells have the capacity to 
switch between a contractile and a secretory phenotype, and may release inflammatory mediators 
such as IL6, IL8 and granulocyte macrophage colony-stimulting factor (620, 621). In this work, we 
analysed airway smooth muscle remodeling in response to primary airway allergen exposure in the 
IN models, versus the IP model. We employed α-SMA detection, the most extensively used 
procedure to label airway smooth muscle since the commercially available 1A1 monoclonal 
antibody shows excellent performance on tissue sections under virtually any type of fixation 
including formalin, on virtually any vertebrate species including rodents, horse and human. Because 
myofibroblasts may also express α-SMA, the more inclusive term "airway contractile tissue mass" 
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was coined (595) to refer to α-SMA-based detection of the airway contractile apparatus, which 
largely coincides with histologically defined airway smooth muscle bundles. The analysis of airway 
contractile tissue mass in the IP model demonstrated a large increments of airway contractile tissue 
mass regardless the shortness of the airway challenge period, whereas the IN models showed 
attenuated growth that reached statistical significance in the 30IN model only. In these models, 
there was therefore a dissociation between the trend of airway hyperresponsiveness and that of the 
airway contractile tissue growth.  
Another objective in the series of experiments presented here was to study an integrated rhinitis and 
asthma model. In human disease there is strong evidence for a connection between rhinitis and 
asthma. Allergic rhinitis is in fact considered a risk factor to develop asthma, and vice versa (622-
624). This epidemiological relationship is probably a consequence of subjacent mechanisms linking 
upper and lower airway inflammation in the context of a global airway involvement in the immune 
responses. However, there are few or no works that have integrated the study of the upper and lower 
airways within the same experimental disease model. The establishment of an integrated model as 
described here may provide a useful tool for the study of the mechanisms of allergic sensitization 
and immune regulation, and has the potential to shed light on aspects such as the increase in asthma 
prevalence and the validation of new therapeutic or preventive strategies. To study the model 
response in terms of allergic rhinitis, we analyzed sections comprising the nasal cavity and 
paranasal sinuses, of which only the nasal mucosa was sensitive to changes, particularly in the 
septal region. The OVA-exposed group of the IP model showed strong eosinophilic inflammatory 
infiltration. In the IN models, there was a gradient of eosinophil infiltration from non-significant in 
the 3IN model to maximum in the 30IN model. Therefore, the intensity of eosinophilic 
inflammation in the nose, a surrogate measure of allergic rhinitis in this study, was associated with 
the length of i.n. antigen exposure. Such progressive increase of eosinophilic inflammation in the 
nasal mucosa, paralleled by stepwise increasing mucoid mass, sharply contrasted with the trend of 
both eosinophilic inflammation and mucus load in the lungs, which were downregulated after 
plateauing in the 10IN model. Thus, the data generated from modeling primary allergen exposure in 
the airways suggest that the features of allergic rhinitis, which increase according to allergen 
exposure, are not responsive to regulatory mechanisms elicited in the lung. Interestingly, the nasal 
mucosa showed a baseline presence of eosinophils in all control groups, not seen in the 
intrapulmonary airways. Such eosinophil baseline fluctuated and peaked at the 10IN control group, 
to return to bottom line in the 30IN model. Although there is no direct explanation for this, we 
speculate that the baseline presence of eosinophils in the nasal mucosa is relevant to its 
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physiological functions, and is responsive to non-specific stimuli in a regulated fashion. The nose is 
in fact an organ subjected to intense sampling of antigens and non-protein chemicals, and our data 
support that core immune system decisions on responsiveness or tolerance may occur at this level. 
The differences seen between the IP and IN models also strengthen the idea that the primary site of 
antigen exposure plays a fundamental role in determining the choice of a subsequent immune 
response. Upon i.p. sensitization, the direct entry of a foreing antigen into a body cavity definitely 
escapes immunoregulatory pathways that reside in the mucosal systems, yet the responses arising 
from primary exposure on a mucosal system, such as the respiratory tract, seem regionally 
regulated. The latter is reflected in our data by the different response patterns elicited in the nasal 
mucosa versus intrapulmonary airways, in the IN models. The 3IN, 10IN and 30IN model series 
may be interpreted as an allergic disease history where rhinitis and asthma develop concomitantly, 
yet events leading to progressive inflammation and mucus production in the nose activate regulatory 
pathways that limit the peak intensity of the asthma features (at 10IN versus the IP model), and 
eventually downregulate intrapulmonary airway inflammation and mucus load upon continuing 
allergen exposure. Our data are therefore consistent with the epidemiological association between 
allergic rhinitis and asthma, yet challenge the simplistic theory that encloses both disorders together 
under the "one airway, one disease" concept (238, 241). The relationship between both disorders is 
in fact subjected to a great variability of natural disease history in humans. Inhaled exposure to 
airborne antigens may lead to allergic inflammation in the whole respiratory tract, with a varying 
sequence of the clinical rhinitis and asthma manifestations in naturally acquired human disease, yet 
our data are consistent with differentially regulated responses in the nose and lungs rather than a 
physiopathologically homogeneous airway.  
Given the data suggesting that immunoregulatory mechanisms acted in the intrapulmonary 
airways to attenuate experimental asthma in the IN models, and the time sequence of the events 
observed, we hypothesized an involvement of Treg cells. We therefore aimed at demonstrating the 
presence of Treg-mediated immune regulation in the lungs, trigered upon primary airway allergen 
exposure. Due to the diversity of regulatory T cell subpopulations under ongoing description, and 
the absence of a definite marker or panel of markers to identify such cells, we abode with the 
FOXP3 transcription factor and IL10 and TGFB cytokines, as best defined markers (397, 411, 433, 
482) suitable for in situ detection on fixed tissue sections. Because of limitations of commercially 
available antibodies to detect these targets on formalin-fixed mouse tissues, we analyzed the 
expression of Foxp3, Il10 and Tgfb mRNA by FISH and we limited the technique to the OVA-
challenged groups of the four models. The 3IN OVA group, devoid of signs of an established 
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adaptive immune response, acted as a comparator for the 10IN and 30IN OVA groups, and we 
analyzed the presence of transcripts in the lymphoid cells of the inflammatory infiltrates. We found 
that, in the lungs of the IN models, the numbers of Foxp3, Il10 and Tgfb mRNA+ lymphoid cells 
increased progressively as the experimental asthma features declined. That is, there was a 
progressive presence of lymphoid cells with signs of Treg activity that correlated with the 
development of a tolerant state. Interestingly, the OVA animals of the IP model, which showed the 
strongest airway hyperresponsiveness and inflammatory infiltration, showed an outstanding high 
level of Foxp3 mRNA+ cells, not accompanied by concordant levels of Il10 and Tgfb transcription. 
This suggests that, in the OVA animals of the IP model, there is a reactive induction of Foxp3+ cells 
although most of them may not be functional. Whether a post-transcriptional impairment of FOXP3 
translation or functionality underlies this finding, and why those lymphoid cells still transcribing 
Il10 and/or Tgfb do not effectively bring down the experimental asthma features as in the IN 
models, remain open questions.  
In summary, the data from the IN model series versus the IP model show that primary antigen 
exposure in the airways leads to allergic rhinitis that progresses through the antigen exposure 
period, and attenuated asthma that declines on continuing antigen challenge. The modulation of the 
asthma features is associated with increasing numbers of lymphoid cells expressing Foxp3, Il10 and 
Tgfb transcripts in the lung inflammatory infiltrates, which suggests the establishment of a Treg-
driven immunoregulatory setting in the lungs. The diverging findings in the IP model suggest that 
the interaction of the antigen with the airway mucosa is essential for the development of an effective 
immunoregulatory arm. The activation of Treg cells may be driven by signals of the innate immune 
system and the effector arm of the adaptive immune response and, in the case of i.p. sensitization, 
the failure to mount effective immune regulation may be caused by events occurring beyond Foxp3 
transcription. Finally, the differing trends of inflammation, goblet cell hyperplasia and mucoid mass 
in the nasal mucosa versus intrapulmonary airways suggest that, whereas the initiation of effector 
immune pathways may be coupled in both territories together, the overall immune response may be 
subjected to differential regulation in the nose and the lungs. The data are consistent with a 
biological basis for the epidemiological association between allergic rhinitis and asthma, but the 
"one airway, one disease" postulate may be an invalid simplification. 
The data presented so far on experimental asthma induced by primary antigen exposure in the 
airways are consistent with the presence of an immunoregulatory arm, operated by Treg 
subpopulations other than the effector T cells driving the effector arm of the adaptive immune 
response that leads to the allergic manifestations. Antigen-specific, effector CD4+ T cells had been 
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previously shown to be necessary and sufficient to drive airway inflammation and remodeling 
(133). To further demonstrate that FOXP3-expressing T cells may drive immune regulation in an 
experimental asthma setting, versus the induction of asthma features by effector CD4+ T cells, we 
performed two series of adoptive transfer experiments. In the first of such series, antigen-specific 
effector CD4+ T cells were generated by in vitro activation coupled with retroviral gene 
transduction, and transferred to naive mice as previously done in the rat (133). Coupling in vitro T 
cell activation with gene transduction by oncoretroviral vectors had previously been shown to select 
antigen-specific T cells, because only such cells enter cell cycle as a result of activation by antigen 
in the presence of antigen-presenting cells, and oncoretrovirus-derived gene transfer vectors can 
only transduce cells undergoing proliferation (625). This principle was successfully employed as a 
tool to select effector, antigen-specific CD4+ T cells for adoptive transfer in the rat, on the basis of 
GFP gene transduction and subsequent cytometric sorting of GFP+ cells (133). In the experiments 
presented here, we aimed at titrating the minimum necessary number of antigen-specific CD4+ T 
cells to induce airway hyperresponsiveness and inflammation, upon adoptive transfer to naive mice. 
The recipient mice were i.n.-challenged three times only within a short time window after cell 
transfer, to prevent any overlap of a host adaptive immune response. In this titration series, 105 
effector, antigen-specific CD4+ T cells sufficed to induce airway hyperresponsiveness, significantly 
increased BAL cell counts and apparent airway inflammation on histopathological examination of 
lung tissue sections. Although with no effect on RL, eosinophil recruitment to the airways could be 
appreciated starting at 2.5⋅104 cell transfer, and the transferred cells could be tracked to the airways 
on the basis of their GFP expression. Therefore, following a single i.v. tail injection containing as 
few as 25,000 effector, antigen-specific CD4+ T cells, some of the cells are able to migrate to the 
airways upon antigen challenge and initiate airway inflammation. It is unlikely that the readily 
observed presence in the lungs of such few transferred cells is the result of random distribution in 
the entire organism. The data are rather consistent with addressed recruitment, and suggest that 
staggering small amounts of effector CD4+ T cells may drive airway inflammation and remodeling, 
and subsequent disease manifestations, in actual asthma. This fact may also have implications for 
therapeutic strategies based on T cell engineering for asthma or other inflammatory conditions, 
since T cells are a difficult-to-transduce population and the generation of autologous, viable 
engineered cells may not be feasible in large numbers. Our data suggest that quite limited numbers 
of engineered cells may successfully target the diseased organ and induce clinically relevant effects. 
In the second series of adoptive transfer experiments we aimed at testing the effect of transfered 
Treg cells on experimental asthma induced by primary airway antigen exposure, upon established 
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disease. Prior studies in murine models showed that Treg cells are involved in the induction of 
tolerance during sensitization or prior to airway challenge on sensitized animals (592-594), but did 
not test the therapeutic potential of Treg cells to revert established airway disease. The data 
presented here are from pilot experiments where experimental asthma was first induced through 
repeated i.n. antigen exposure, and the animals received Treg cell transfer at a point where airway 
hyperresponsiveness and inflammation were already patent. Following cell transfer, the animals 
received a further course of i.n. antigen instillations to test the effect of the transferred cells under 
ongoing allergen exposure, such as in naturally acquired disease would occur. In these experiments, 
standardized HDM extract was used instead of OVA to employ an actual airborne allergen, already 
tested in previous reports (596, 626, 627). Due to the exploratory nature of these pilot experiments, 
and in keeping with the "3R" principle (Replacement, Reduction, Refinement) (628, 629), we 
employed the PBS-instilled group of the 30IN model as a control for the HDM-induced asthma. 
HDM-challenged animals showed airway hyperresponsiveness, inflammation and remodeling as 
reported by others (192), at a time point where OVA-challenged animals showed a decline of 
experimental asthma features in the IN experiment series. Variability due to the molecular structure 
of each particular allergen, which may determine factors such as its interaction with innate immune 
system pattern recognition receptors (630), may have contributed to the lack of data consistency 
between OVA and HDM as experimental inhaled allergens. The cause of such mismatch is 
nevertheless unclear in the absence of a timeline data set for HDM exposure, to demonstrate 
whether a similar but out-of-phase immunoregulatory trend would exist. Treg cells were generated 
by in vitro activation with antigen coupled with retroviral gene transduction as for the CD4+ effector 
T cells, employing for this purpose a gene transfer vector encoding Foxp3 and gfp. It has been 
previously demonstrated that forced expression of FOXP3 reverts the effector phenotype and turns 
the CD4+ T cells into functional IL-10-producing Treg cells (411). It is noteworthy that the Treg 
cells generated through this process are antigen-specific. Under the experimental design employed 
in these exploratory experiments, Treg cell transfer led to a modest reduction of the inflammatory 
infiltrates seen on tissue sections, without achieving a significant impact on BAL cell counts. 
However, Treg cell transfer did result in a significant attenuation of airway hyperresponsiveness, 
and the transferred cells reached the lungs as demonstrated by GFP detection. The soundness of the 
experiments may have been limited by the small group size, and an insufficiently strong 
experimental intervention. Viable Treg cells generated from retroviral gene transduction under in 
vitro antigen stimulation are a hard-to-obtain cell population, which limited Treg cell dosing to one 
single administration of 75,000 cells, aimed at ameliorating established disease. Considering these 
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limitations and valuing the data as preliminary, the outcome suggests that Treg cells have the 
potential to attenuate or revert established asthma if transferred in sufficient, but not necessarily 
large, numbers. These adoptive transfer experiments support that the limitation and further 
attenuation of asthma features observed through the 3IN, 10IN and 30IN model series were at least 
in part driven by the increasing numbers of endogenous lymphoid cells expressing FOXP3 and 
producing IL10 and TGFB cytokines. It remains unknown whether such endogenous Treg cells 
where thymus-derived nTreg cells recruited to the sites of inflammation or, more plausibly, post-
thymic iTreg cells, which have been shown to regulate Th2-driven inflammation at mucosal sites 
(631).  
Although a challenging goal, data from experimental disease models should ultimately be 
translated to human disease and clinical significance. In the asthma field, data on Treg cell 
populations are limited and inconsistent (632). Most of the scarce clinical Treg cell studies done on 
asthma have reported decreased numbers in peripheral blood in comparison with control subjects 
(633-635) and, in BAL fluid, Treg cells have been found to be either decreased (588) or increased 
(636). The predominance of studies showing decreased Treg cell numbers, along with reports 
suggesting impaired responsiveness to chemotactic stimuli (637, 638), suggested a Treg cell 
deficiency in asthma, a hypothesis provided with a straightforward rationale anyhow. As for Treg 
cell functionality, no direct data have been contributed for asthma, but a report showing that Treg 
cells from peripheral blood of atopic subjects have a decreased capacity to suppress effector CD4+ T 
cell proliferation in vitro (639) suggests that Treg cell function may be impaired in at least some 
asthmatics. However, out of the previous studies on the role of Treg cells in asthma, evidence from 
direct lung sampling is lacking almost completely. Two studies on Treg cells in BAL fluid, a 
sampling procedure not necessarily representing the status of the airway wall, yielded inconsistent 
data (588, 636), and no work has been reported on tissue specimens. The difficulty and complex 
logistics involved in obtaining bronchial biopsies for asthma research may explain the lack of direct 
Treg cell data in the airway wall. To contribute data filling this gap, and to translate our results from 
experimental asthma modeling to the clinical setting, we performed FOXP3 immunostaining on 
bronchial biopsies from severe asthmatics and control subjects on specimens from a multicenter 
biobank specialized in bronchial biopsy for asthma research, that we have developed. We found that 
FOXP3+ cells were virtually absent in control biopsies, whereas the specimens from asthmatics 
revealed a significant influx of FOXP3+ mononuclear cells in subepithelial location. The increased 
presence of FOXP3+ cells in bronchial biopsies from subjects with severe asthma suggests a 
relevant role of Treg cell-mediated immunoregulation, and is consistent with our data from the 
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animal models. Our experimental and clinical data may together turn the faulty Treg hypothesis into 
the possibility that Treg cells are reactively increased in asthma, in response to chronic airway 
inflammation. Whether such Treg cells are fully competent or not remains unknown at this point. 
The failure to physiologically resolve airway inflammation in asthma results from complex, 
multifactorial causes, not necessarily involving a deficiency in Treg cell recruitment or function. It 
is plausible that Treg cells may play a physiological role in bridging the downregulation of 
inflammation with the activation of tissue repair pathways. Because of the cytokine secretion profile 
of Treg cells, particularly the production of TGFB, a reactive increase of competent Treg cells in the 
airway wall might contribute to airway remodeling, particularly subepithelial fibrosis.  
Overall, we conclude from the work presented in this thesis that primary airway exposure to 
allergen elicits Treg cell-mediated immunoregulatory mechanisms that may attenuate asthma 
features such as airway hyperresponsiveness, inflammation, mucous metaplasia, mucus 
hypersecretion and airway contractile tissue increment, whereas subepithelial fibrosis may be 
favoured as a result of increased TGFB production. Classical models where experimental asthma is 
induced by i.p. sensitization fail to reflect such immunoregulatory component of asthma, and may 
mostly represent the effector arm of the disease. Our findings on Foxp3-expressing cells in the IN 
versus IP models also suggest that mucosal contact during primary antigen exposure may be crucial 
to prime subsequent Treg cell cytokine production and functionality. Therefore, experimental 
asthma models based on primary airway antigen exposure may provide a tool for the joint analysis 
of effector and immunoregulatory pathways, and a closer representation of the overall immune 
response in human asthma. Our approach on integrated rhinitis and asthma modeling yielded data 
suggesting that the immune response may be subjected to complex, differential regulation, and 
highlights the importance of analyzing the upper and lower airways. Finally, our analysis on 
FOXP3-expressing cells on human bronchial biopsies suggests that, consistently with the 
experimental asthma data, Treg cells are actively involved in the physiopathology of asthma. 
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I. Primary airway antigen exposure and continued challenge, in comparison with i.p. 
sensitization followed by airway antigen challenge, induces experimental asthma with 
attenuation and subsequent downregulation of airway hyperresponsiveness, eosinophilic 
inflammation, mucous metaplasia and mucus hypersecretion, and modulates the increase of 
airway contractile tissue mass. On the contrary, subepithelial fibrosis increases progressively 
and the cellular inflammatory infiltrates turn predominantly lymphocytic. 
II. On primary airway antigen exposure, goblet cell hypertrophy and hyperplasia are significant, 
both in the nose and intrapulmonary airways, within an early time window insufficient for the 
development of an adaptive immune response. Such early mucous response may result from 
mechanisms of innate immunity. 
III. In the nose, both primary airway antigen exposure and i.p. sensitization lead to allergic 
rhinitis with eosinophilic inflammatory infiltration, goblet cell hyperplasia and increased 
mucus production. Contrary to the manifestations of experimental asthma, primary airway 
antigen exposure followed by continued challenge leads to a progessive intensity of rhinitis 
over time. 
IV. Upon primary airway antigen exposure followed by continued challenge, the attenuation of 
most experimental asthma features, the progression of subepithelial fibrosis and the shift to 
predominantly lymphocytic infiltrates are concomintant with a progressive presence of 
Foxp3, Il10 and Tgfb mRNA-expressing lymphoid cells in the inflammatory infiltrates. 
Intraperitoneal sensitization leads to outstanding numbers of Foxp3 mRNA+ cells in the 
inflammatory infiltrates, not correlated with concordant Il10 or Tgfb transcription. 
V. Adoptively transferred, antigen-specific effector CD4+ T cells drive airway 
hyperresponsiveness and inflammation upon antigen challenge. Scarce numbers of such cells 
are able to migrate to the airways and elicit the aforementioned effects.  
VI. Adoptively transferred, antigen-specific CD4+ T cells with forced FOXP3 expression act as 
Treg cells in vivo and downregulate airway hyperresponsiveness and inflammation on 
established experimental asthma. Scarce numbers of such cells are able to migrate to the 
airways and elicit the aforementioned effects.  
VII. FOXP3+ lymphoid cells are significantly increased in bronchial biopsies of severe asthmatics 
versus control subjects. 
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I. Supplementary Methods 
1. Periodic acid 
For experiments described here, we used a 0.5% (weight-volume) periodic acid (Sigma-
Aldrich) solution in distilled water. 
 
2. Eosin 
We used a 7‰ eosin (Merck) solution in distilled water. 
 
3. PBS 
137 mM Sodium chloride (Sigma-Aldrich) 
2.68 mM Potassium chloride (Sigma-Aldrich) 
10.15 mM Sodium Phosphate dibasic (Sigma-Aldrich) 
1.76 mM Potassium phosphate (Sigma-Aldrich) 
 
PBS was prepared and filtered through 0.22 μm filter (Millex® GV, Millipore, Carrigtwohill, 
Ireland) to sterilize and avoid precipitates 
 
4. Flow cytometry buffer 
Solution made of 3% FBS and 0.09% sodic azide in PBS. Solution is sterilized through 0.22 
μm filter (Millipore) and store at 4ºC before use. 
 
5. Luria-Bertani (LB) culture medium 
5.1. LBA agar 
1%  Bacto triptona (Conda-Pronadisa, Madrid, Spain) 
0,5% Yeast extract (Conda-Pronadisa) 
0,5% Sodium chloride (Sigma-Aldrich) 
1,5% Agar (Conda-Pronadisa) 
70 µg/mL Ampicilin (Sigma-Aldrich) 
5.2. LB liquid 
1%  Bacto triptona (Conda-Pronadisa) 
0,5% Yeast extract (Conda-Pronadisa) 
0,5% Sodium chloride (Sigma-Aldrich) 
 
6. PCR reactions 
Typical PCR volume reactions were performed as follows: 
 
Volume (μL) Component 
1  Template 
1  dNTPs 
10 Buffer reaction (5x) 
2  Primer forward 
2 Primer reverse 
0.5 Pol Taq 
33.5 H2O 
50 Total 
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Primer solutions were at 0.01 mM. 
We used one cycle of initial denaturing (95ºC for 5 min) to separate template DNA strands 
followed by 30 cycles of denaturing, annealing and elongation stages. The last cycle was final 
elongation. Therefore, a typical PCR reaction cycle was: 
 
Nº cycles Temperature (ºC) Time 
1 95 5 min 
95 30 s 
Ta 30 s 30 
72 Et 
1 72 5 min 
 
Where Ta: annealing temperature (depending on primers); Et: elongation time (we used 1 
minute per 1000 base length elongation. 
 
7. Lipofectamine transfection protocol 
100.000 Phoenix cells were cultured with DMEM medium (Gibco, Invitrogen), 5% foetal 
bovine serum (FBS) (Gibco) and without antibiotics in a 24-well plate (Corning) until reaching 
approximately 95% confluence. Plasmidic DNA was linealized by digestion and purified before 
each transfection experiment to facilitate cell DNA integration. Lipofectamine (2 μL) was diluted 
into 50 μL DMEN and incubated at RT for 5 minutes. Lipofectamine solution was then mixed with 
50 μL of DMEN containing 0.8 μg of lineal plasmidic DNA and incubated for 20 minutes at RT. 
Each well was incubated with this transfection solution for 4 hours and then changed with fresh 
medium. Then after 24 hours of transfection, each well was trypsinized (trypsine, Gibco) and 
cultured into a 10 cm culture plate (Gibco) with fresh medium. The following day, cells were 
cultured with DMEM, 5% FBS, 1% Penicillin-Streptomycin-Glutamine (PSG), all from Gibco 
(Invitrogen), and using 2 µg/mL Puromycin (Sigma-Aldrich) was used as a selective medium for 
successfully transfected cells. Cell culture was maintained until cell colonies were visible. The plate 
was then trypsinized and expanded, obtaining a transfected pool cell population.  
 
8. Retrovirus titration 
NIH3T3 cells (200.000) were seeded on 6-well plates and cultured with DMEM 5% FBS for 48 
hours. Representative wells were counted for the average of cells in each well. Virus supernatant, 
0.5 μl, 5 μl, 50 μl and 500 μl of were added to the wells in duplicate, using 6 μg/ml polybrene in 
each well. Cells were incubated with virus suspension for 24 hours and then replaced by fresh 
DMEM 10% FBS 1% PSG. After 48 hours, transduced cultures were collected and analyzed using 
cytometry (FacsScalibur) with Scell Quest software. Virus stock titer was calculated according to 
take the following: TU/mL = nº cells x (% of GFP positive cells/100)/ mL of virus used, where TU is 
the transforming unit and thenumber of cells refers to the amount of cells at the beginning of the 
culture. 
 
9. Western blot assay for FOXP3 expression 
NIH3T3 cells were cultured and transduced as previously described: cells were cultured in six-
well plates with DMEM containing 10% FBS and 1% PSG at 37ºC ambient air, supplemented with 
5% CO2 as normal culture conditions. Additionally, medium was supplemented with 6 µg/mL 
polybrene during pRetroFOXP3-IRES-GFP viral transduction in a 1:1 cell-virus ratio. Cell cultures 
were lysed for 30 minutes in 0.3 mL of 1% Triton X-100 lysis buffer (20 mM Tris-HCl, pH 7.5; 150 
mM NaCl; and 1% Triton X-100) containing 5 μg/mL lupeptin, 50 mM phenyl-methylsulfonyl 
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fluoride, and 7.2 trypsin inhibitor units for aprotinin. After centrifugation at 14000 g for 10 min, 50 
μg of the protein contained in the supernatant was resuspeneded in Laemmli’s buffer (4% SDS, 20 
glicerol, 10% 2-mercaptoethanol, 0.004% bromophenol blue, Tris-HCl 0.125 M) and loaded in 10% 
polyacrilamide SDS-PAGE and running at 200V for 40 minutes. Β-mercaptoethanol and SDS give 
negative charge to proteins according to the mass, so they can migrate to the anode. Samples were 
transferred to a PVDF membrane (Millipore) running at 70V for 1 hour. Membranes were blocked 
with blocking buffer (3% BSA and 0.05% Tween-20) overnight at 4ºC. Once blocked, membranes 
were incubated for 2 hours with primary antibodies against Foxp3 (eBioscience, Rat monoclonal, 
1:5000), GFP (Abcam, Rabbit monoclonal, 1:10000) and α-tubulin (Sigma, mouse monoclonal, 
1:2000) followed by horseradish peroxidase-conjugated goat anti-rat IgG, donkey anti-rabbit IgG or 
goat anti-mouse IgG (1:2000; Santa Cruz Biotechnology, Santa Cruz, USA) and detected using 
LumiPico® ECL kit (ShineGene, Shanghai, China) according to manufacturer’s instructions.  
 
10. Lymphocite stimulation culture media 
 
DMEM/10%CF/1%PSG 
Aminoácidos no esenciales ......2% 
Β-mercapto etanol ....................100μM 
IL2............................................100 U/mL 
HDM ........................................8 ng/mL 
IL4............................................10 ng/mL 
Anti-IL12..................................250 ng/mL 
 
11. Methyl green solution 
For nucleus counterstaining 0.5% methyl green solution in 0.1M sodium acetate buffer at pH 4 
was used. 
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II. Data tables 
Table S1. RL responsiveness to MCh. IP and IN OVA models. 
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Table S2. Total BAL cell counts. IP and IN OVA models. 
 
Model Group cells/mL  (x105) 
 
 CTRL 1.264 ± 0.226 
 
*P=0.002 
**P=0.001 
IP 
OVA 13.313 ± 2.811 
***P=0.009 
 
 CTRL 1.331 ± 0.137 
 3IN 
OVA 3.569 ± 0.408 *P<0.001 
 
 CTRL 1.288 ± 0.150 
 10IN 
OVA 6.456 ± 0.703 *P<0.001 
†P=0.002 
†† P=0.002 CTRL 2.560 ± 0.383 
††† P=0.003 30IN 
OVA 16.970 ± 2.784 *P<0.001 
 
Data are mean ± standard error of the mean. IP, 3IN, 10IN, 30IN, CTRL and OVA as described.  
*: versus CTRL; **: versus 3IN OVA group; ***: versus 10IN OVA group. †: versus IP CTRL. ††: 
versus 3IN CTRL. †††: versus 10N CTRL. 
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Table S3. Differential BAL leukocyte counts. 
 
MONOCITES Mean [95% CI] P Mean ∆ [95% CI] 
CTRL 95.82 ± 1.11 
IP 
OVA 24.22 ± 2.34 
<0.001 -71.60 [-77.47, -65.74] 
CTRL 95.20 ± 1.91 
3IN 
OVA 55.00 ± 2.58 
<0.001 -40.20 [-47.27, -33.14] 
CTRL 95.56 ± 1.33 
10IN 
OVA 47.44 ± 3.46 
<0.001 -48.13 [-56.07, -40.18] 
CTRL 80.13 ± 4.80 
30IN 
OVA 53.63 ± 2.80 
<0.001 -26.50 [-38.38, -14.62] 
EOSINOPHILS Mean [95% CI] P Mean ∆ [95% CI] 
CTRL 2.43 ± 0.77 
IP 
OVA 67.19 ± 2.55 
<0.001 64.76 [58.64, 70.88] 
CTRL 0.20 ± 0.20 
3IN 
OVA 2.44 ± 0.49 
0.002 2.24 [1.04, 3.43] 
CTRL 0.66 ± 0.25 
10IN 
OVA 13.31 ± 1.74 
<0.001 12.66 [8.88, 16.44] 
CTRL 0.23 ± 0.07 
30IN 
OVA 5.38 ± 0.69 
<0.001 5.15 [3.69, 6.61] 
LYMPHOCYTES Mean [95% CI] P Mean ∆ [95% CI] 
CTRL 1.68 ± 0.90 
IP 
OVA 8.53 ± 1.59 
0.003 6.85 [2.82, 10.89] 
CTRL 4.55 ± 1.68 
3IN 
OVA 42.38 ± 2.33 
<0.001 37.83 [31.50, 44.16] 
CTRL 3.72 ± 1.12 
10IN 
OVA 38.50 ± 3.79 
<0.001 34.78 [26.30, 43,27] 
CTRL 19.60 ± 4.78 
30IN 
OVA 40.95 ± 2.33 
0.001 21.35 [9.87, 32.83] 
NEUTROPHILS Mean [95% CI] P Mean ∆ [95% CI] 
CTRL 0.07 ± 0.05 
IP 
OVA 0.06 ± 0.06 
>0.05 - 
CTRL 0.05 ± 0.05 
3IN 
OVA 0.19 ± 0.10 
>0.05 - 
CTRL 0.06 ± 0.04 
10IN 
OVA 0.75 ± 0.30 
0.041 0.69 [0.03, 1.34] 
CTRL 0.05 ± 0.05 
30IN 
OVA 0.05 ± 0.03 
>0.05 - 
 
Data are mean ± standard error of the mean. IP, 3IN, 10IN, 30IN, CTRL and OVA as described. 
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Table S4. Airway eosinophils in lung sections. 
 
Model Group eosinophils/mm2 
CTRL 2.42 ± 0.66  
IP 
OVA 24.55 ± 3.82 *P<0.001 
CTRL 0.2 ± 0.07  
3IN 
OVA 0.66 ± 0.19 *P=0.036 
CTRL 0,55 ± 0,07  
10IN 
OVA 11.77 ± 1.36 *P<0.001 
CTRL 0 ± 0  
30IN 
OVA 5.1 ± 0.96 *P<0.001 
 
Data are mean ± standard error of the mean. IP, 3IN, 10IN, 30IN, CTRL and OVA as described.  
*: versus CTRL; **: dfference versus 10IN OVA group. 
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Table S5. Eosinophilic infiltration in nasal mucosa. 
 
Model Group EOSINOPHILS/mm2 x 10-9 
CTRL 10.78 ± 1.354  
IP 
OVA 54.452 ± 8.994 *P=0.001 
CTRL 3.530 ± 0.969  
3IN 
OVA 4.392 ± 0.419 *P=0.427 
 †P<0.001 
CTRL 17.055 ± 3.260
††P=0.011 10IN 
OVA 36.997 ± 5.097 *P=0.005 
CTRL 7.00 ± 1.71  
30IN 
OVA 47.43 ± 17.97 *P<0.001 
 
Data are mean ± standard error of the mean. IP, 3IN, 10IN, 30IN, CTRL and OVA as described.  
*: versus CTRL. †: versus 3IN CTRL. ††: versus 30IN CTRL. 
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Table S6. Quantitative morphology for lung goblet cells. 
 
Model Group Goblet cells/mm2 
 
 CTRL 0.45 ± 0.4 
 
*P<0.001 
†P<0.001 
‡P=0.022 
IP 
OVA 66.34 ± 10.89
§P<0.001 
  
 CTRL 0 ± 0 
 3IN 
OVA 3.84 ± 1.36 *P=0.014 
  
 CTRL 0 ± 0 
 
*P=0.003 
†P=0.04 
10IN 
OVA 38.88 ± 10.93
§P=0.125 
 
 CTRL 0 ± 0 
 
*P<0.001 
30IN 
OVA 21.85 ± 4.78 
†P<0.019 
 
Data are mean ± standard error of the mean. IP, 3IN, 10IN, 30IN, CTRL and OVA as described.  
*: versus CTRL; †: versus 3IN; ‡: versus 10IN; §: versus 30IN. CTRL groups showed no significant 
differences among them. 
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Table S7. Quantitative morphology for mucoid mass  
in intrapulmonary airways. 
 
Model Group Mucoid mass (dimensionless) 
  
  CTRL 0 ± 0 
 
*P=0.001 
†P<0.001 
‡P=0.03 
IP 
OVA 4591.01 ± 930 
§P<0.005 
  
  CTRL 0 ± 0 
 3IN 
OVA 76.71 ± 27.26 *P=0.014 
  
  CTRL 0 ± 0 
  
*P=0.02 
10IN 
OVA 1804.44 ± 687.24 
†P=0.025 
  
  CTRL 0 ± 0 
  
*P=0.001 
30IN 
OVA 1539.43 ± 391.97 
†P=0.004 
 
Data are mean ± standard error of the mean. IP, 3IN, 10IN, 30IN, CTRL and OVA as described.  
*: versus CTRL; †: versus 3IN; ‡: versus 10IN; §: versus 30IN. CTRL groups showed no significant 
differences among them. 
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Table S8. Quantitative morphology for goblet cells in nasal mucosa. 
 
Model Group Goblet cells/mm2 
 
 CTRL 11.934 ± 1.269 
 
*P<0.001 
IP 
OVA 32.377 ± 2.105 
†P=0.073 
  
 CTRL 10.4 ± 3.022 
 3IN 
OVA 24.858 ± 2.678 *P=0.004 
  
 CTRL 16.024 ± 1.846 
 
*P=0.001 
10IN 
OVA 33.354 ± 3.586 
†P=0.044 
 
 CTRL 11.29 ± 1.45 
 
*P=0.001 
30IN 
OVA 36.37 ± 2.36 
†P=0.006 
 
Data are mean ± standard error of the mean. IP, 3IN, 10IN, 30IN, CTRL and OVA as described.  
*: versus CTRL; †: versus 3IN. CTRL groups showed no significant differences among them. 
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Table S9. Quantitative morphology for mucoid mass in nasal epithelium. 
 
Model Group Mucoid mass (dimensionless) 
 
 CTRL 168.12 ± 54.83 
 
*P<0.001 
IP 
OVA 1138.68 ± 163.25 
†P=0.004 
  
 CTRL 173.04 ± 64.71 
 3IN 
OVA 450.45 ± 56.15 *P=0.007 
  
 CTRL 351.8 ± 109.15 
 
*P=0.005 
10IN 
OVA 975.94 ± 153.86 
†P=0.025 
 
 CTRL 302.69 ± 94.3 
 
*P<0.001 
†P<0.001 
‡P<0.001 
30IN 
OVA 2431.65 ± 163.47 
§ P<0.001 
 
Data are mean ± standard error of the mean. IP, 3IN, 10IN, 30IN, CTRL and OVA as described.  
*: versus CTRL; †: versus 3IN; ‡: versus 10IN; §: versus IP. CTRL groups showed no significant 
differences among them. 
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Table S10. Quantitative morphology for subepithelial collagen deposition in intrapulmonary 
airways. 
 
Model Group ECM mass (dimensionless) 
CTRL 0.1043 ± 0.02  
IP 
OVA 0.1218 ± 0.03 *P=0.658 
CTRL 0.0838 ± 0.01   
3IN 
OVA 0.1118 ± 0.03 *P=0.462 
CTRL 0.0657 ± 0.02   
10IN 
OVA 0.232 ± 0.06 *P=0.015 
CTRL 0.0772 ± 0.03   
30IN 
OVA 0.2075 ± 0.03 *P=0.004 
 
Data are mean ± standard error of the mean. IP, 3IN, 10IN, 30IN, CTRL and OVA as described.  
*: versus CTRL. 
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Table S11. Quantitative morphology for airway contractile tissue mass (MCT). 
 
Model Group MCT (dimensionless) 
 
 CTRL 0.807 ± 0.05 
 
*P<0.001 
†P<0.001 
‡P<0.001 
IP 
OVA 1.2694 ± 0.07 
§ P=0.001 
  
 CTRL 0.6491 ± 0.06 
 3IN 
OVA 0.8391 ± 0.07 *P=0.053 
  
 CTRL 0.7999 ± 0.14 
 10IN 
OVA 0.8954 ± 0.05 *P=0.537 
  
 CTRL 0.7935 ± 0.04 
 
*P<0.001 
30IN 
OVA 0.8391 ± 0.07 
†P=0.038 
 
Data are mean ± standard error of the mean. IP, 3IN, 10IN, 30IN, CTRL and OVA as described.  
*: versus CTRL; †: versus 3IN; ‡: versus 10IN; §: versus 30IN. CTRL groups showed no significant 
differences among them. 
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Table S12. Foxp3, Tgfb and Il10 mRNA-expressing cells in lung inflammatory infiltrates. 
 
Model Group Foxp3+ cells Il10+ cells Tgfb+ cells 
*P<0.001 
†P<0.001 IP OVA 66.74 ± 2.32 
 ‡P<0.001 
12.59 ± 1.49 *P=0.002 †P=0.072 17.57 ± 3.50 *P=0.128 
    
   3IN OVA 0.71 ± 0.22 
 
2.47 ± 0.19 
 
7.03 ± 0.39 
 
 
 10IN OVA 1.32 ± 0.39 
  
8.11 ± 0.92 *P=0.032 13.71 ± 1.11 *P=0.048 
*P=0.001 
†P=0.003 30IN OVA 13.53 ± 1.10 *P<0.001 †P<0.001 17.40 ± 2.51
§P=0.057 
21.82 ± 7.96 *P=0.044 
 
Messenger RNA-expressing cells in lung inflammatory infiltrates of OVA-challenged animals were 
counted. Data are mean ± standard error of the mean. IP, 3IN, 10IN, 30IN, CTRL and OVA as 
described; n=3 for each condition. *: versus 3IN; †: vesus 10IN; ‡: versus 30IN. §: versus IP. 
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Table S13. RL responsiveness to MCh. Effector T cell adoptive transfer model. 
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Table S14. Total BAL cell counts. Effector T cell adoptive transfer model. 
 
Challenge Adoptive transfer cells/mL (x103) 
PBS 1x10
5 Activated 
GFP+Teff cells 295.83 ±  56.80  
1x105 untransduced 
unactivated T cells 460.00  ±  42.85 *P<0.05 
0.25x105  Activated 
GFP+Teff cells 490.00 ±  81.77  *P<0.05 
0.5x105 Activated 
GFP+Teff cells 460.00 ±  62.14 *P<0.05  
*P<0.05 
OVA 
1x105 Activated 
GFP+Teff cells 551.67  ±  104.63 †P<0.05 
 
Data are mean ± standard error of the mean. T cell transfer and i.n. instillations as indicated.  
*: versus Control 1 (recipients of 0.25x105 activated T cells, PBS-instilled); †: versus Control 2 
(recipients of 0.25x105 naive T cells, OVA-challenged). 
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 Table S15. RL responsiveness to MCh. Treg cell adoptive transfer model. 
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Table S16. Quantitative morphology for airway contractile tissue mass (MCT). Treg cell 
adoptive transfer model. 
 
Challenge Adoptive transfer α-SMA (dimensionless) 
PBS None 0.7935 ± 0.04   
 *P<0.001 
None 1.6859 ± 0.12 
†P=0.309 
HDM 
7.5x104 GFP+ 
Treg cells 1.8531 ± 0.09  *P<0.001 
 
 
Data are mean ± standard error of the mean. Treg cell transfer and i.n. instillations as indicated.  
*: versus control group. †: versus HDM challenge mice that received adoptive transfer of Treg cells. 
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Table S17. Total BAL cell counts. Treg cell adoptive transfer model. 
 
Challenge Adoptive transfer cells/mL (x10
-3) 
PBS None 256.00 ± 38295.63  
 *P<0.001 
None 1493.33 ± 502.07 
†P=0.458 
HDM 
7.5x104 GFP+ 
Treg cells 1253.33 ± 215.28 *P=0.002 
 
Data are mean ± standard error of the mean. Treg cell transfer and i.n. instillations as indicated.  
*: versus control group. †: versus HDM challenged mice that received adoptive transfer of Treg 
cells. 
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Table S18. FOXP3 immunostaining on human bronchial biopsies 
 
Group FOXP3+ (cels/mm2) T-student 
SEVERE 
ASTHMA 18.08 ± 4.49 *P<0.001 
CONTROL 0.91 ± 0.70  
 
Data are mean ± standard error of the mean.* vs control 
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III. Summary 
 
Castellano 
El asma afecta aproximadamente a unos 300 millones de personas en todo el mundo. Su 
prevalencia se ha incrementado, especialmente en los países industrializados, habiendo llegado a 
doblarse en solamente una década en la Unión Europea. A pesar de los desarrollos terapéuticos ya 
alcanzados, aproximadamente un 10% de los asmáticos sufren enfermedad grave refractaria a la 
terapia máxima disponible. El asma es una enfermedad compleja caracterizada principalmente por 
la inflamación crónica de la vía aérea junto con cambios estructurales, conocidos mediante el 
término “remodelación”, que subyacen a las manifestaciones clínicas y gravedad de la enfermedad, 
especialmente al deterioro irreversible de función pulmonar que existe en algunos asmáticos. La 
remodelación de vías respiratorias en el asma ocurre en asociación a la inflamación crónica, resulta 
en anormalidades estructurales permanentes en su pared, y afecta vías respiratorias de todas las 
categorías en cuanto a localización y tamaño. Se entiende actualmente que la remodelación de las 
vías respiratorias forma parte del sustrato fisiopatológico de la hiperreactividad bronquial y la 
obstrucción al flujo aéreo, y puede comenzar en una fase temprana de la enfermedad, previa a la 
aparición de síntomas. Los cambios estructurales descritos como parte de la remodelación de vías 
respiratorias son: (i) engrosamiento del epitelio respiratorio, junto con hiperplasia e hipertrofia de 
células caliciformes; (ii) aumento del tamaño y número de glándulas mucosas que se traduce, junto 
con los cambios en las células caliciformes, en la hipersecreción de moco a la luz de la vía aérea, 
participando de forma especial en la obstrucción al flujo aéreo de instauración súbita en el contexto 
de crisis, y contribuyendo al desarrollo de atelectasias; (iii) hiperplasia de células caliciformes, 
asociada a la hipersecrección de moco; (iv) fibrosis subepitelial, debida a un depósito excesivo de 
matriz extracelular en la capa de tejido conjuntivo que subyace al epitelio bronquial; (v) 
angiogénesis bronquial y permeabilidad vascular alterada, que facilita la formación de edema; y (vi) 
aumento de la masa de músculo liso bronquial y bronquiolar, debido a la combinación de 
hiperplasia e hipertrofia de las células musculares lisas, más una probable contribución de células 
progenitoras circulantes que son reclutadas y se diferencian a miofibroblasto y célula muscular lisa. 
De entre estos cambios, el más estudiado es la remodelación del músculo liso, que se considera de 
importancia central en el mecanismo de la hiperreactividad bronquial y obstrucción al flujo aéreo. 
Los modelos animales de enfermedad experimental permiten el estudio de mecanismos 
biológicos de enfermedad con un detalle y profundidad no posible en sujetos humanos. Los modelos 
animales de asma experimental han contribuido a una mejor comprensión y tratamiento de la 
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enfermedad en humanos. La especie más ampliamente utilizada para modelar asma experimental es 
el ratón, tanto por reproducir la mayoría de los rasgos patológicos de la enfermedad humana como 
por su bajo coste y fácil manejo. La fisiopatología del asma ha sido ampliamente estudiada en 
modelos de asma experimental basados en sensibilización intraperitoneal a antígenos junto con 
coadyuvantes seguido de provocación con el antígeno en la vía aérea. Este procedimiento reproduce 
con intensidad la mayoría de signos de la enfermedad asmática, tales como la hiperreactividad 
bronquial y remodelación de vías respiratorias, a través de una respuesta alérgica tipo Th2 con 
elevados niveles de IgE. Sin embargo, esta estrategia experimental no representa el modo real en el 
que los humanos desarrollan asma y rinitis alérgica por sensibilización y exposición a 
aeroalérgenos, y puede haber diferencias relevantes en los mecanismos biológicos subyacentes. De 
hecho, el contacto directo de la mucosa del tracto respiratorio con el antígeno alergénico es con gran 
probabilidad esencial para la función del sistema inmunitario innato, e interacciones a este nivel 
pueden determinar la subsiguiente respuesta inmunitaria, en términos de ataque o tolerancia. Es 
altamente probable que los modelos de asma alérgica experimental que se basan en sensibilización 
intraperitoneal se salten un paso crucial para entender la fisiopatología del asma. Por tanto, modelos 
animales basados en exposición primaria al antígeno en la vía aérea, sin sensibilización 
intraperitoneal tipo "vacuna", pueden tener el potencial de reflejar de un modo más integral el 
desarrollo del asma alérgica, por involucrar las vías inmunorreguladoras que los modelos basados 
en sensibilización intraperitoneal pueden fallan en reflejar. En dichas vías inmunorreguladoras, 
pueden estar implicadas células T con función reguladora (células Treg). Desde la descripción en 
2003 del factor de transcripción FOXP3 como responsable del fenotipo regulador de células T 
CD4+, han sido descritos diversos tipos de células T con fenotipo regulador. Auque en la actualidad 
es generalmente aceptado que no todas las células con fenotipo regulador expresan FOXP3, la 
detección de este marcador continúa siendo un instrumento de gran utilidad en el estudio de la 
función inmunoreguladora vehiculada por células T CD4+.  
A todo esto hay que añadir que la vía aérea superior ha sido extensamente ignorada en los 
modelos animales de asma experimental. Recientemente, se ha desarrollado la teoría de la “vía 
aérea única”, que postula que el asma y la rinitis son dos manifestaciones diferentes de una misma 
enfermedad, en dos partes de una vía aérea común. Aunque esta teoría es criticada de ser 
excesivamente simplista, existe evidencia de una asociación entre rinitis alérgica y asma, y de una 
relación biológica e inmunológica entre la mucosa de la vía aérea superior, y la de las vías 
respiratorias intrapulmonares.  
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Por todo ello, en el presente trabajo de tesis doctoral nos propusimos desarrollar un modelo 
integrado de rinitis alérgica y asma basado en exposición primaria antigénica en vía respiratoria, y 
estudiar en este modelo la existencia de mecanismos de inmunorregulación acoplados a la respuesta 
efectora generadora del asma, y la posible implicación de las células Treg en el desarrollo de la 
enfermedad. Adicionalmente, para añadir valor traslacional básico-clínico a los datos obtenidos en 
los modelos animales, realizamos análisis en biopsias bronquiales humanas. 
Para explorar la respuesta a la sensibilización alérgica en la vía aérea, desarrollamos modelos de 
exposición primaria a OVA en vía aérea mediante instilación intranasal repetida en régimen lunes-
miércoles-viernes, en ausencia de adyuvantes inmunológicos, con recogida de datos y estudio en 
tres puntos de tiempo diferentes: (i) un punto  temprano exploratorio de enfermedad mínima o 
incipiente (tres instilaciones, denominado modelo 3IN); (ii) un punto de intervalo de tiempo desde 
la primera exposición antigénica equivalente a un modelo clásico de sensibilización intraperitoneal 
(10 instilaciones, denominado modelo 10IN, que fue comparado con el modelo de sensibilización 
intraperitoneal -IP-); y (iii) un modelo prolongado para explorar si el grado de enfermedad reflejado 
en el modelo 10IN se reforzaría, alcanzaría un plateau o se atenuaría si la exposición antigénica 
intranasal se extendiese (30 instilaciones, modelo 30IN). En el modelo de sensibilización 
intraperitoneal, los animales mostraron, tras tres broncoprovocaciones intranasales: hiperreactividad 
bronquial a metacolina, infiltración leucocitaria de predominio eosinófilo en lavado broncoalveolar, 
infiltración inflamatoria asimismo eosinófila de vías respiratorias mostrada en secciones de tejido 
pulmonar y nasal, incremento de la presencia de sustancias mucosas en vías aéreas superior en 
inferiores, incremento de la masa de músculo liso en vías respiratorias intrapulmonares; y un 
aumento notable de células con expresión de mRNA de Foxp3 con aumento limitado de células con 
expresión de mRNA de Il10 y Tgfb. 
En los modelos de exposición antigénica primaria en vía respiratoria, la reactividad de vías 
respiratorias a metacolina resultó atenuada en el modelo 10IN respecto al modelo IP, y declinó en el 
modelo 30IN. Los tres modelos de exposición antigénica primaria en vía aérea presentan un 
aumento de células totales en lavado broncoalveolar con predominancia de linfocitos. Los modelos 
10IN y 30IN mostraron infiltración inflamatoria pulmonar con presencia de eosinófilos, pero 
atenuada respecto al modelo IP, y con un viraje del recuento diferencial hacia predominio 
linfocitario. Sin embargo el infiltrado inflamatorio en la mucosa nasal fue comparable al modelo IP, 
excepto en el modelo de 3IN, en el que no se apreció un aumento respecto al grupo control. En lo 
que respecta a la producción de sustancias mucosas, los intranasales mostraron un aumento 
progresivo de la respuesta mucoide en el epitelio nasal, desde las 3 instilaciones hasta las 30, siendo 
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este último modelo comparable a lo obtenido en el modelo IP. Por el contrario, la respuesta mucoide 
en pulmón, aunque aumentada respecto a los grupos control tras 3, 10 y 30 instilaciones, resultó 
atenuada respecto al modelo IP. En lo que concierne a la deposición de matriz extracelular, tras 3 
instilaciones intranasales no se apreciaron diferencias significativas respecto al grupo control ni al 
modelo IP; sin embargo, sí se apreció fibrosis subepitelial tras 10 y 30 instilaciones intranasales, lo 
que sugiere que la fibrosis subepitelial es un fenómeno progresivo con la duración de la 
enfermedad. La masa de músculo liso solo resultó incrementada pero de forma atenuada en el 
modelo 30IN, de forma concomitante a la atenuación observada en la hiperreactividad bronquial. La 
obtención de una respuesta alérgica con máximo atenuado y subsiguiente declive en los modelos 
intranasales, en comparación con el modelo de sensibilización intraperitoneal como comparador de 
capacidad de respuesta máxima, sugiere que la exposición primaria antigénica en vía respiratoria, tal 
como ocurre en la adquisición natural de enfermedad humana, activan mecanismos 
inmunoreguladores. La evidencia de este brazo inmunoregulador, reflejado en la atenuación de la 
inflamación e hiperreactividad de vías respiratorias, nos condujo a explorar un posible papel de 
células Treg. Debido a dificultades técnicas para la detección de proteína FOXP3 en tejido de ratón 
fijado con formalina, analizamos la expresión de mRNA de Foxp3 en estos modelos, junto con la 
expresión de mRNA de Il10 y Tgfb, dos citoquinas directamente relacionadas con la función de las 
células T reguladoras. Estos análisis, realizados mediante hibridación in situ sobre secciones de 
tejido pulmonar, condujeron a la detección en los infiltrados inflamatorios de un aumento 
progresivo de la cantidad de células que expresaban Foxp3, Il10 y Tgfb hasta alcanzar sus máximos 
niveles en el modelo 30IN. La cantidad de células con expresión de Il10 y Tgfb fue comparable a lo 
observado en el modelo de sensibilización intraperitoneal. Sin embargo, la cantidad de células con 
expresión de Foxp3 en el modelo IP fue desproporcionadamente elevada, sugiriendo la presencia de 
células Foxp3+ sin funcionalidad inmunoreguladora. 
Estos datos mostraron que la exposición primaria a antígeno en la vía aérea y en ausencia de 
sensibilización intraperitoneal o adyuvantes induce rinitis alérgica que progresa durante el período 
de exposición al antígeno, y asma experimental atenuada que se modula como resultado de la 
exposición continuada. Esta modulación está asociada con un aumento de los números de células 
linfoides que expresan Foxp3, Il10 y Tgfb en los infiltrados inflamatorios pulmonares, lo que 
sugiere mecanismos de inmunorregulación activa que los modelos basados en sensibilización 
intraperitoneal fallan en reflejar. Los resultados obtenidos en esta primera parte del trabajo de 
investigación doctoral mostraron que la exposición primaria y continuada a antígeno en las vías 
respiratorias induce la activación de un brazo inmunoregulador que resulta en la atenuación de los 
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rasgos del asma alérgica experimental, pero no de la rinitis alérgica, sugiriendo además un papel 
importante de células Treg productoras de IL10 y TGFB. Este conjunto de datos fue asimismo 
consistente con la hipótesis de que la interacción del alérgeno con la mucosa de la vía respiratoria en 
el momento de la exposición antigénica primaria es crucial, mediante la probable participación del 
sistema inmunitario innato, para definir el perfil de respuesta subsiguiente a cargo del sistema 
inmunitario adaptativo. Así pues, en la siguiente parte del trabajo nos propusimos demostrar el 
papel de células T efectoras CD4+ y células T reguladoras CD4+ en el asma experimental. 
Para estudiar el papel de las células T CD4+ efectoras y reguladoras, realizamos experimentos 
de transferencia adoptiva en dos modelos de exposición antigénica en vía aérea. Con la finalidad de 
realizar seguimiento in vivo de las células transferidas, procedimos a su modificación genética para 
inducir la expresión permanente de una variante de proteína verde fluorescente (GFP). La expansión 
clonal de células T activadas representa el ciclo celular más rápido conocido entre las células de 
organismos pluricelulares. Dada la necesidad de conseguir la modificación genética permanente de 
las células diana y su progenie, nos decantamos por la transducción retroviral empleando vectores 
de tipo onco-retroviral que, tras su retrotranscripción, se integran de forma permanente en el 
genoma de las células transducidas, y con ello el cDNA de interés subclonado en el vector. Para 
ello, estos vectores aprovechan la ausencia de envoltura nuclear durante la mitosis (metafase y 
anafase) para integrarse en el genoma celular y originar expresión constitutiva. Esta característica, 
combinada con la estimulación in vitro de células T efectoras antígeno-específicas obtenidas de 
donantes sensibilizados a un determinado antígeno, resulta en un método eficaz para la transducción 
de células T efectoras antígeno-específicas, dado que el tipo de vector de transferencia génica 
empleado solamente transduce células en ciclo celular activo, y únicamente las células T CD4+ 
antígeno-específicas entran en ciclo celular cuando una población de esplenocitos de un animal 
sensibilizado se expone al antígeno in vitro. 
Tras el diseño y construcción del vector retroviral de transferencia génica para inducir 
expresión permanente de GFP, al que hemos denominado pMSCV-GFP por derivarse de un Murine 
Stem Cell Virus, procedimos a generar mediante transducción y separar por citometría de flujo 
células T CD4+GFP+ efectoras, con las cuales realizamos un modelo de asma experimental basado 
en transferencia adoptiva de estas células a animales receptores singénicos no sensibilizados, y 
posterior instilación intranasal del antígeno (OVA) en los animales receptores. En este modelo, nos 
propusimos titular el número mínimo de células T CD4+ antígeno-específicas efectoras necesario 
para inducir hiperreactividad e inflamación de vías respiratorias, bajo la hipótesis de que muy 
pequeñas cantidades de estas células serían suficientes. Los ratones receptores fueron instilados dos 
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veces con OVA antes de la transferencia adoptiva y tres veces después (5 instilaciones intranasales), 
en forma de un modelo breve para prevenir posible solapamiento con una respuesta inmunitaria 
adaptativa que el huésped podría desarrollar. Realizamos series de titulación, que mostraron que la 
transferencia adoptiva de 105 células T efectoras CD4+ OVA-específicas es suficiente para inducir 
hiperreactividad a metacolina, incremento de células totales en el lavado broncoalveolar e 
inflamación de la vía aérea evidente en el análisis histopatológico del tejido pulmonar, donde se 
detectaron células GFP+. Estos datos indicaron que pequeños números de células T CD4+ efectoras 
antígeno-específicas tienen la capacidad de migrar a las vías respiratorias y dirigir la inflamación en 
una respuesta inmunitaria adaptativa alérgica.  
En el segundo modelo de transferencia adoptiva, nos propusimos comprobar el efecto de la 
transferencia de células Treg en un modelo de asma experimental con enfermedad establecida, 
inducido en este caso por exposición primaria en vía aérea a extracto estandarizado de ácaros del 
polvo (house dust mite, en adelante HDM). Para las finalidades de este experimento se generaron 
células T CD4+ reguladoras in vitro mediante transducción retroviral de una manera similar a la 
obtención de células T  CD4+ efectoras descrita anteriormente, pero a partir de donantes 
sensibilizados a HDM. En este caso se construyó un vector retroviral bicistrónico que contiene las 
secuencias de Foxp3 y gfp separadas por una secuencia interna de entrada ribosomal (un internal 
ribosome entry site, en adelante IRES), vector al que denominamos pRetroFOXP3-IRES-GFP. Este 
vector induce la expresión simultánea de FOXP3 y GFP en las células transducidas, de forma que la 
detección de GFP permite la identificación de células FOXP3+. La expresión forzada de FOXP3 
generada de este modo en células T CD4+ activadas induce función reguladora en estas células, es 
decir, genera células Treg. Además, las células Treg así generadas son antígeno-específicas. Los 
animales receptores fueron instilados con HDM un total de 28 veces a lo largo de 40 días de 
duración del modelo. En el grupo receptor de transferencia adoptiva, 75.000 células Treg fueron 
inyectadas en la vena de la cola antes de la finalización de las instilaciones intranasales (en la 
instilación 24, día 31). En este experimento piloto (n=4 por grupo), la transferencia adoptiva de 
solamente estas 75.000 células Treg generadas in vitro provocó una modesta reducción en los 
infiltrados inflamatorios en tejido pulmonar, sin modificar significativamente los recuentos de 
células totales en lavado broncoalveolar, y se observó asimismo una atenuación de la 
hiperreactividad de vías respiratorias, demostrándose mediante detección de GFP que las células 
transferidas estaban presentes en los infiltrados inflamatorios en las vías respiratorias 
intrapulmonares. 
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Como último objetivo y con un enfoque traslacional, nos propusimos explorar la aplicabilidad 
de los datos obtenidos en los modelos animales a la enfermedad humana. Los datos sobre células 
Treg en el asma humana están en una fase muy incipiente y los resultados en este sentido son 
limitados e inconsistentes. La totalidad de los escasos trabajos realizados sobre células Treg en el 
asma humana se han centrado en la detección de dichas células en sangre periférica o lavado 
broncoalveolar, pero hasta la fecha no existen estudios sobre tejido pulmonar. Teniendo en cuenta 
esta carencia, nos propusimos estudiar la presencia de células FOXP3+ mediante 
inmunohistoquímica en biopsias bronquiales de pacientes con asma grave y compararlos con sujetos 
control. Hemos hallado que las células FOXP3+ están prácticamente ausentes en biopsias de sujetos 
control. Por el contrario, las biopsias de pacientes con asma grave mostraron una presencia 
significativa de células FOXP3+ infiltrando principalmente zonas de tejido conectivo laxo 
subepitelial. Este aumento de células FOXP3+ en biopsias bronquiales de pacientes con asma grave 
sugiere un papel de la inmunorregulación mediada por células Treg, y es además consistente con los 
datos derivados de modelos animales. Nuestro conjunto de datos generados a partir de asma 
experimental e investigación clínica sugiere que las células Treg están aumentadas en la pared de las 
vías respiratorias en el asma, probablemente de forma reactiva a la inflamación crónica que subyace 
a la enfermedad. Si las células FOXP3+ observadas en las biopsias bronquiales humanas son 
funcionalmente competentes como células Treg o no, es desconocido en este punto y, por tanto, se 
necesitan nuevos estudios que las caractericen de forma más extensa en sujetos asmáticos. El fallo 
en resolver la inflamación crónica de las vías respiratorias en el asma tiene con toda probabilidad 
una causa compleja multifactorial, y no necesariamente implica una deficiencia en la función o 
reclutamiento de células Treg. 
De los resultados obtenidos en el presente trabajo de tesis doctoral se puede concluir que:  
- La exposición primaria en la vía aérea y la provocación continuada con antígeno, a diferencia 
de la sensibilización intraperitoneal seguida de provocación intranasal, induce asma experimental 
atenuada con disminución de la hiperreacitividad de vías respiratorias, la hipersecreción de moco y 
ligero aumento de la masa de músculo liso. Por el contrario, la fibrosis subepitelial aumenta 
progresivamente y los infiltrados inflamatorios giran hacia un predominio linfocitario. 
- Tras la exposición primaria a antígeno en la vía aérea, se produce una hipertrofia e hiperplasia 
de células caliciformes, tanto en vía aérea superior como vías respiratorias inferiores, en un espacio 
de tiempo insuficiente para el desarrollo de una respuesta inmunitaria adaptativa. Esta respuesta 
mucosa temprana podría ser el resultado de la acción de mecanismos del sistema inmunitario innato. 
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- En la mucosa nasal, tanto la exposición primaria a antígeno en vía aérea como la 
sensibilización intraperitoneal previa, inducen rinitis alérgica con infiltración eosinofílica, 
hiperplasia de células caliciformes y aumento de la producción de moco. Al contrario de las 
manifestaciones del asma experimental, la exposición primaria a antígeno en la vía aérea seguida de 
provocación continuada provoca un aumento progresivo de la intensidad de la rinitis alérgica con el 
tiempo. 
- Tras la exposición primaria a antígeno en la vía aérea seguida de provocación intranasal 
continuada, la atenuación de la mayor parte de las características del asma experimental, la 
progresión de la fibrosis subepitelial y el viraje hacia infiltrados predominantemente linfocitarios 
están asociados con una progresiva presencia en el infiltrado inflamatorio de células que expresan 
mRNA de Foxp3, Il10 y Tgfb. La sensibilización intraperitoneal tiene como consecuencia un 
aumento anormal de células que expresan mRNA de Foxp3 en el infiltrado inflamatorio, pero que 
no se correlaciona con un aumento concordante en la transcripción de Il10 y Tgfb. 
- Células T CD4+ efectoras antígeno-específicas dirigen el reclutamiento de células 
inflamatorias y la hiperreactividad de vías respiratorias tras la provocación antigénica. Estas células, 
en escasa cantidad, son capaces de migrar a las vías respiratorias y provocar los efectos 
mencionados. 
- Células T efectoras CD4+ antígeno-específicas con expresión forzada de FOXP3 actúan como 
células Treg in vivo y modulan la hiperreactividad e inflamación de las vías respiratorias en modelos 
animales con asma experimental establecida. Estas células, en escaso número, son capaces de 
migrar a las vías respiratorias y provocar los efectos mencionados. 
- Existe un aumento significativo en la presencia de linfocitos FOXP3+ en biopsias bronquiales 
de pacientes con asma grave en comparación con sujetos control. Dicho aumento puede reflejar un 
incremento de células Treg reactivo a la inflamación crónica. 
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Galego 
A asma afecta a uns 300 millóns de persoas en todo o mundo. A sua prevalencia incrementouse, 
especialmente nos países industrializados, chegando a duplicarse en tan só unha década na Unión 
Europea. A pesares dos desarroios terapéuticos xa acadados, aproximadamente un 10% dos 
asmáticos sofren enfermidade grave refractaria á terapia máxima dispoñible. A asma é unha 
enfermidade complexa caracterizada principalmente pola inflamación crónica da vía aérea xunto 
con cambios estructurais, coñecidos mediante o término “remodelación”, que subxace ás 
manifestacións clínicas e gravidade da enfermidade, especialmente ó deterioro irreversible da 
función pulmonar que se encontra nalgúns asmáticos. A remodelación das vías respiratorias na asma 
ocorre en asociación á inflamación crónica, resulta en anormalidades estructurais permanentes na 
súa parede, e afecta vías respiratorias de tódalas categorías en canto a localización e tamaño. 
Enténdese actualmente que a remodelación das vías respiratorias forma parte do sustrato 
fisiopatolóxico da hiperreactividade bronquial e a obstrución ó fluxo aéreo, e pode empezar cedo na 
enfermidade, previo á aparición de síntomas. Os cambios estructuráis descritos como parte da 
remodelación de vías respiratorias son: (i) engrosamento do epitelio respiratorio, xunto con 
hiperplasia e hipertrofia de células caliciformes; (ii) aumento do tamaño e número das glándulas 
mucosas que se traduce, xunto cos cambios nas células caliciformes, na hipersecreción de moco á 
luz da vía aérea, participando de xeito especial na obstrucción ó fluxo aéreo de instauración súbita 
no contexto de crise, e contribuíndo ó desarroio de atelectasias; (iii) hiperplasia de células 
caliciformes, asociada á hipersecrección de moco (iv) fibrose subepitelial, debida a un depósito 
excesivo de matriz extracelular na capa de tecido conxuntivo que subxace ó epitelio bronquial; (v) 
anxioxénese bronquial e permeabilidade vascular alterada, que facilita a formación de edema; e (vi) 
aumento da masa de músculo liso bronquial e bronquiolar, por mor da combinación de hiperplasia e 
hipertrofia das células musculares lisas, máis unha probable contribución de células proxenitoras 
circulantes que son reclutadas e que se diferencian a miofibroblasto e célula muscular lisa. De entre 
estes cambios, o máis estudado é a remodelación do músculo liso, que se considera de importancia 
central no mecanismo da hiperreactividade bronquial e a obstrución ó fluxo aéreo. 
Os modelos animáis de enfermidade experimental permiten o estudo de mecanismos biolóxicos 
de enfermidade cun detalle e profundidade non posible en suxeitos humanos. Os modelos animáis 
de asma experimental contribuíron a unha mellor comprensión e tratamento da enfermidade en 
humanos. A especie máis amplamente usada para modela-la asma experimental é o rato, tanto por 
reproducires a maioría dos rasgos patolóxicos da enfermidade humana como polo seu baixo coste e 
fácil manexo. A fisiopatoloxía da asma foi amplamente estudada en modelos de asma experimental 
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basadosen sensibilización intraperitoneal a antíxenos xunto con adxuvantes seguido de provocación 
co antíxeno na vía aérea. Este procedemento reproduce con intensidade a maioría dos signos da 
enfermidade asmática, tales como a hiperreactividade bronquial e remodelación de vías 
respiratorias, a través dunha resposta alérxica tipo Th2 con elevados niveis de IgE. Sen embargo, 
esta estratexia experimental non representa o xeito real no que os humanos desarroian asma e rinitis 
alérxica por sensibilización e exposición ós aero-alérxenos, e poden existir diferenzas relevantes nos 
mecanismos biolóxicos subxacentes. De feito, o contacto directo da mucosa do tracto respiratorio co 
antíxeno alerxénico é, cunha grande posibilidade, esencial para a función do sistema inmunitario 
innato, e interaccións a este nivel poden determinar a conseguinte resposta inmunitaria, en termos 
de ataque ou tolerancia. É altamente probable que os modelos de asma alérxica experimental 
basados en sensibilización intraperitoneal salten un paso crucial para entenderes a fisiopatoloxía da 
asma. Polo tanto, modelos animáis basados en exposición primaria a antíxeno na vía aérea, sen 
sensibilización intraperitoneal tipo “vacina”, poden te-lo potencial de reflexar dun modo máis 
integral o desarroio da asma alérxica, por mor de involucra-las vías inmunorreguladoras que os 
modelos basados en sensibilización intraperitoneal poden errar en reflexar. En ditas vías 
inmunorreguladoras, poden estar implicadas células T con función reguladora (células Treg). Dende 
a descrición no 2003 do factor de transcrición FOXP3 como responsábel do fenotipo regulador de 
células T CD4+, teñen sido descritos diversos tipos de células T con fenotipo regulador. Aínda que 
na actualidade é xeralmente aceptado que non tódalas células con fenotipo regulador expresan 
FOXP3, a detección deste marcador continúa sendo un instrumento de gran utilidade no estudo da 
función inmunorreguladora levada a cabo por células T CD4+. 
A todo isto hai que engadir que a vía aérea superior foi extensamente ignorada nos modelos 
animáis de asma experimental. Recentemente, desenvolveuse a teoría da “vía aérea única”, que 
postula que a asma e a rinitis son dúas manifestacións diferentes dunha misma enfermidade, en dúas 
partes dunha vía aérea común. Aínda que esta teoría é criticada por seres excesivamente simplista, 
existe evidencia dunha asociación entre rinitis alérxica e asma, e dunha relación biolóxica e 
inmunolóxica entre a mucosa da vía aérea superior, e a de vías respiratorias intrapulmonares. 
Por todo elo, no presente traballo de tese doutoral propuxémonos desenvolver un modelo 
integrado de rinitis alérxica e asma basado en exposición primaria antixénica en vía respiratoria, e 
estudar neste modelo a existencia de mecanismos de inmunorregulación acoplados á resposta 
efectora xeradora da asma, e á posible implicación das células Treg no desenvolvemento da 
enfermidade. Adicionalmente, para engadir un valor traslacional básico-clínico ós datos obtidos nos 
modelos animáis, realizamod análises en biopsias bronquiais humanas. 
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Para explora-la resposta á sensibilización alérxica na vía aérea, desenvolvemos modelos de 
exposición primaria a OVA na vía aérea mediante instilación intranasal repetida en réxime lunes-
mércores-venres, en ausencia de adxuvantes inmunolóxicos, con recollida e datos e estudo en tres 
puntos de tempo diferentes: (i) un punto temperán exploratorio de enfermidade mínima ou 
incipiente (tres instilacións, denominado modelo 3IN); (ii) un punto de intervalo de tempo dende a 
primeira exposición antixénica equivalente a un modelo clásico de sensibilización intraperitoneal 
(10 instilacións, denominado modelo 10 IN, que foi comparado co modelo de sensibilización 
intraperitoneal -IP-); e (iii) un modelo prolongado para explorar se o grado de enfermidade 
reflectido no modelo 10IN reforzaríase, alcanzaría un plateau ou atenuaríase se a exposición 
antixénica intranasal se extendese (30 instilacións, modelo 30IN). No modelo de sensibilización 
intraperitoneal, os animáis amosaron, tras tres bronco-provocacións intranasáis: hiperreactividade 
bronquial a metacolina, infiltración leucocitaria de predominio eosinófilo en lavado bronco-
alveolar, infiltración inflamatoria eosinófila de vías respiratorias detectada en seccións de tecido 
pulmonar e nasal, incremento da presenza de sustancias mucosas en vías aéreas superiores e 
inferiores, incremento da masa de músculo liso en vías respiratorias intrapulmonares; e un aumento 
notábel de células con expresión de mRNA de Foxp3 con aumento limitado de células con 
expresión de mRNA de Il10 e Tfgb. 
Nos modelos de exposición antixénica primaria en vía respiratoria, a reactividade de vías 
respiratorias a metacolina resultou atenuada no modelo 10IN respecto do modelo IP, e disminuíu do 
modelo 30IN. Os tres modelos de exposición antixénimca primaria na vía aérea presentan un 
aumento de células totais en lavado bronco-alveolar con predominancia de linfocitos. Os modelos 
10IN e 30IN amosaron infiltrado inflamatorio pulmonar con presenza de eosinófilos, pero atenuado 
respecto do modelo IP, e cunha viraxe do reconto diferencial a predominio linfocitario. Sen 
embargo, o infiltrado inflamatorio na mucosa nasal foi comparable ó do modelo IP, excepto no 
modelo 3IN, no que non se apreciou un aumento respecto do grupo control. No que respecta á 
producción de sustancias mucosas, os intranasáis amosaron un aumento progresivo da resposta 
mucoide no epitelio nasal, dende as 3 instilacións ate as 30, sendo neste último modelo comparable 
ó obtido no modelo IP. Pola contra, a resposta mucoide no pulmón, aínda que aumentada respecto 
dos gruops control tras 3, 10 e 30 instilacións, resultou atenuada respecto do modelo IP. No 
concernete á deposición de matriz extracelular, tras 3 instilacións intranasáis non se apreciaron 
diferenzas significativas respecto do grupo control nin do modelo IP; sen embargo, sí se apreciou 
fibrose subepitelial tras 10 e 30 instilacións intranasáis, o que suxire que a fibrose subepitelial é un 
fenómeno progresivo coa duración da enfermidade. A masa de músculo liso resultou incrementada, 
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pero de forma atenuada, no modelo 30IN, de forma concomitante á atenuación observada na 
hiperreactividade bronquial. A obtención dunha resposta alérxica con máximo atenuado e 
subseguinte declive nos modelos intranasáis, en comparación co modelo de sensibilización 
intraperitoneal como comparador de capacidade de resposta máxima, suxire que a exposición 
primaria antixénica en vía respiratoria, tal e coma ocorre na adquisición natural de enfermidade 
humana, activan mecanismos inmunorreguladores. A evidencia deste brazo inmunorregulador, 
reflectido na atenuación da inflamación e da hiperreactividade de vías respiratorias, conduciunos a 
explorar un posible papel de células Treg. Debido a dificultades técnicas para a detección de 
proteína FOXP3 en tecido de rato fixado con formalina, analizamos a expresión de mRNA de 
Foxp3 nestes modeloes, xunto coa expresión de mRNA de Il10 e Tgfb, dúas citocinas directamente 
relacionadas coa función das células Treg. Estas análises, realizadas mediante hibridación in situ 
sobre seccións de tecido pulmonar, leváronnos á deteccion nos infilitrados inflamatorios dun 
aumento progresisvo na cantidade de células que expresavan Foxp3, Il10 e Tgfb hasta acadares os 
seus máximos niveis no modelo 30IN. A cantidade de células con expresión de Il10 e Tgfb foi 
comparable ó observado no modelo de sensibilización intraperitoneal. Sen embargo, a cantidade de 
células con expresión de Foxp3 no modelo IP foi desproporcinadamente elevada, suxerindo a 
presenza de células Foxp3 sen funcionalidade inmunorreguladora. 
Estes datos amosaron que a exposición primaria a antíxeno na vía aérea en ausencia de 
sensibilización intraperitoneal ou adxuvantes induce rinitis alérxica que progresa durante o periodo 
de exposición ó antíxeno, e asma experimental atenuada que se modula como resultado da 
exposición continuada. Esta modulación está asociada cun aumento dos números de células 
linfoides qeu expresan Foxp3, Il10 e Tgfb nos infiltrados inflamatorios pulmonares, o que suxire 
mecansimos de inmunorregulación activa que os modelos basados en sensibilización intraperitoneal 
erran en reflectir. Os resultados obtidos nesta primeira parte do traballo de investigación doutoral 
amosaron que a exposición primaria e continuada a antíxeno nas vías respiratorias induce a 
activación dun brazo inmunorregulador que resulta na atenuación dos rasgos da asma alérxica 
experimental, pero non da rinitis alérxica, suxerindo ademáis un papel importante de células Treg 
productoras de IL10 e TGFB. Este conxunto de datos foi tamén consistente coa hipótese de que a 
interacción do alérxeno coa mucosa da vía respiratoria no momento da exposición antixénica 
primaria é crucial, mediante a probable participación do sistema inmunitario innato, para defini-lo 
perfil de resposta subseguinte a cargo do sistema inmunitario adaptativo. Así pois, na seguinte parte 
do traballo propuxémonos demostra-lo papel de células T efectoras CD4+ e células T reguladoras 
CD4+ na asma experimental. 
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Para estuda-lo papel das células T CD4+ efectoras e reguladoras, realizamos experimentos de 
transferencia adoptiva nos modelos de exposición antixénica na vía aérea. Coa finalidade de realizar 
seguimento in vivo das células transferidas, procedemos á súa modificación xenética para introducir 
a expresión permantente dunha variante de proteína verde fluorescente (GFP). A expansión clonal 
de células T activadas representa o ciclo celular máis rápido coñecido entre as células de 
organismos pluricelulares. Dada a necesidade de conseguires a modificación xenética permantente 
das células diana e da súa proxenie, decantámonos pola transducción retroviral usando vectores de 
tipo retroviral que, trala súa retrotranscripción, intégranse de modo permanente no xenoma das 
células transducidas, e con elo o cDNA de interese subclonado no vector. Para elo, estes vectores 
aproveitan a ausencia de envoltura nuclear durante a mitose (metafase e anafase) para integrarse no 
xenoma celular e orixinar expresión constitutiva. Esta característica, combinada coa estimulación in 
vitro de células T efectoras antíxeno-específicas obtidas de donantes sensibilizados a un 
determinado antíxeno, resulta nun método eficaz para a transducción de células T efectoras 
antíxeno-específicas, dado que o tipo de vector de transferencia xénica usado soamente transduce 
células en ciclo celular activo, e únicamente as células T CD4+ antíxeno-específicas entran en ciclo 
celular cando a poboación de esplenocitos dun animal sensibilizado exponse ó antíxeno in vitro. 
Tralo deseño e construcción do vector retroviral de transferencia xénica para inducir expresión 
permantente de GFP, ó que denominamos como pMSCV-GFP por derivarse dun Murine Stem Cell 
Virus, procedemos a xerar mediante transduccón e separación por citometría de fluxo células T 
CD4+GFP+ efectoras, coas que realizamos un modelo de asma experimental basado en transferencia 
adoptiva destas células a animáis receptores sinxénicos non sensibilizados, e posterior instilación 
intranasal do antíxeno (OVA) nos animáis receptores. Neste modelo, propuxémonos titular o 
número mínimo de células T CD4+ antíxeno específicas efectoras necesario para inducir 
hiperreactividade e inflamación de vías respiratorias, baixo a hipótese de que cantidades moi 
pequenas destas células sería suficientes. Os ratos receptores foron instilados dúas veces con OVA 
antes da transferencia adoptiva e tres veces tras ela (5 instilacións intranasáis), en forma dun modelo 
curto para previr un posible solapamento coa desposta inmunitaria adaptativa que o hóspede podería 
desenvolver. Realizamos series de titulación, que amosaron que a transferencia adoptiva de 105 
células T efectoras CD4+ OVA-específicas é abondo para inducir hiperreactividade bronquial a 
metacolina, incremento de células totais no lavado bronco-alveolar e inflamación da vía aérea 
evidente na análise histopatolóxica do tecido pulmonar, onde se detectaron células GFP+. Estes 
datos indicaron que pequenos números de células efectoras T CD4+ antíxeno-específicas teñen a 
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capacidade de migrar ás vías respiratorias e dirixir a inflamación nunha resposta inmunitaria 
adaptativa alérxica. 
No segundo modelo de transferencia adoptiva, propuxémonos comproba-lo efecto da 
transferencia de células Treg nun modelo de asma experimental con enfermidade establecida, 
inducido neste caso por exposición primaria na vía aérea a extracto estandarizado de ácaros de po 
(house dust mite, en adiante HDM). Para as finalidades deste experimento xeráronse células T 
reguladoras CD4+ in vitro mediante transducción retroviral dun xeito similar á obtención de células 
T efectoras CD4+ descrita anteriormete, pero a partires de dontantes sensibilizados a HDM. Neste 
caso construíuse un vector retroviral bicistrónico que contén as secuencias de Foxp3 e gfp separadas 
por unha secuencia interna de entrada ribosomal (un internal ribosomal entry site, en adiante IRES), 
vector ó que nomeamos pRetroFOXP3-IRES-GFP. Este vector induce a expresión simultánea de 
FOXP3 e GFP nas células transducidas, de xeito que a detección de GFP permite a identificación de 
células FOXP3+. A expresión forzada de FOXP3 xerada deste modo en células T CD4+ activadas 
induce función reguladora nestas células, é dicir, xera células Treg. Ademáis, as células Treg 
xeradas deste xeito son antíxeno-específicas. Os animáis receptores foron instilados con HDM un 
totla de 28 veces ó largo de 40 días de duración do modelo. No grupo receptor de transferencia 
adoptiva, 75.000 células Treg foron inxectadas na vena da cola antes da finalización das instilacións 
intranasáis (na instilación 24, día 31). Neste experimento piloto (n=4 por grupo), a transferencia 
adoptiva de tan só estas 75.000 células Treg xeradas in vitro provocou unha modesta redución nos 
infiltrados inflamatorios en tecido pulmonar, sen modificar significativamente os recontos de 
células totáis no lavado bronco-alveolar, e observouse tamén unha atenuación da hiperreactividade 
de vías respiratorias, probándose mediante detección de GFP que as células transferidas estaban 
presentes nos infiltrados inflamatorios nas vías respiratorias intrapulmonares. 
Como derradeiro obxectivo e cun efoque traslacional, propuxémonos explora-la aplicabilidade 
dos datos obtidos nos modelos animáis á enfermidade humana. Os datos sobre células Treg na asma 
humana están nunha fase moi inicial e os resultados neste sentido son limitados e inconsistentes. A 
totalidade dos escasos traballos realizados sobre células Treg na asma humana centráronse na 
detección destas células en sangue periférica ou lavado bronco-alveolar, pero ata o de agora non 
existen estudos sobre tecido pulmonar. Tendo en conta esta carencia, propuxémonos estuda-la 
presenza de células FOXP3+ mediante inmunohistoquímica en biopsias bronquiais de doentes con 
asma grave e comparalos con suxeitos control. Atopamos que as células reguladoras CD4+ están 
prácticamente ausentes en biopsias de suxeitos control. Pola contra, as biopsias de doentes con asma 
grave amosaron una presenza significativa de células FOXP3+ infiltrando principalmente zonas de 
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tecido conectivo laxo subepitelial. Este aumentde células FOXP3+ en biopsias bronquiais de 
pacientes con asma grave suxire un papel da inmunorregulación mediada pro células Treg, e é 
ademáis consistente cos datos derivados de modelos animáis. O noso conxunto de datos xerados a 
partires de asma experimental e investigación clínica suxire que as células Treg están aumentadas 
na parede das vías respiratorias na asma, probablemente de forma reactiva á inflamación crónica 
que subxace á enfermidade. Se as células FOXP3+ observadas nas biopsias bronquiais humanas son 
funcionalmente competentes como células Treg ou non, é desconocido neste punto e, polo tanto, son 
necesarios novos estudos que as caractericen de xeito máis extenso en suxeitos asmáticos. O erro en 
resolve-la inflamación crónica das vías respiratorias na asma ten con toda probabilidade una causa 
complexa multifactorial, en non implica necesariamente unha diferencia na función ou reclutamento 
de células Terg. 
Dos resultados obtidos no presente traballo de tese doutora pódese concluír que:  
- A exposición primaria na vía aérea e a provocación continuada con antíxeno, a diferenza da 
sensibilización intraperitoneal seguida de provocación intranasal, induce asma experimental 
atenuada con disminución da hiperreactividade das vías respiratorias, hipersecreción de moco e 
lixeiro aumento da masa de músculo liso. Pola contra, a fibrose subepitelial aumenta 
progresivamente e os infiltrados inflamatorios xiran cara un predominio linfocitario. 
- Trala exposición primaria a antíxeno na vía aérea, prodúcese unha hipertrofia e hiperplasia de 
células caliciformes, tanto en vía aérea superior coma vías aéreas respiratorias inferiores, nun 
estpacio de tempo insuficiente para o desenvolvemento dunha resposta inmunitaria adaptativa. Esta 
resposta mucosa temperá podería se-lo resultado da acción de mecanismos do sistema inmune 
innato. 
- Na mucosa nasal, tanto a exposición primaria a antíxeno na vía aérea coma a sensibilización 
intraperitoneal previa, inducen rinitis alérxica con infiltración eosinofílica, hiperplasia de células 
caliciformes e aumento da produción de moco. Ó contrario das manifestacións da asma 
experimental, a exposición primaria a antíxeno na vía aérea seguido de provocación continuada 
provoca un aumento progresivo da intensidade da rinitis alérxica co tempo. 
- Trala exposición primara a antíxenon na vía aérea seguida de provocación intranasal 
continuada, a atenuación da maior parte das características da asma experimental, a progresión da 
fibrose subepitelial e a viraxe cara infiltrados predominantemente linfocitarios están asociados 
cunha progresiva presenza no infiltrado inflamatorio de células que expresan mRNA de Foxp3, Il10 
e Tgfb. A sensibilización intraperitoneal ten coma consecuencia un aumento anómalo de células que 
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expresan mRNA de Foxp3 no infiltrado inflamatorio, pero que non se correlaciona cun aumento 
concordante na transcripción de Il10 e Tgfb. 
- Células T CD4+ efectoras antíxeno-específicas dirixen o reclutamento de células inflamatorias 
e a hiperreactividade de vías respiratorias trala provocación antixénica. Estas células, nesta 
cantidade, son capaces de migrar ás vías respiratorias e provoca-los efectos mencionados. 
-Células T efectoras CD4+ antíxeno-específicas con expresión forzada de FOXP3 actúan como 
células Treg in vivo e modulan a hiperreactividade e inflamación de vías respiratorias en modelos 
animáis con asma experimental establecida. Estas células, en escaso número, son capaces de migrar 
ás vías respiratorias e provoca-los efectos mencionados. 
- Existe un aumento significativo na presenza de linfocitos FOXP3+ en biopsias bronquiais de 
pacientes con asma grave en comparación con suxeitos control. Este aumento pode reflectir un 
incremento de células Treg reacivo á inflamación crónica. 
